[go: up one dir, main page]

WO2007051810A2 - Pharmaceutical use of substituted amides - Google Patents

Pharmaceutical use of substituted amides Download PDF

Info

Publication number
WO2007051810A2
WO2007051810A2 PCT/EP2006/068015 EP2006068015W WO2007051810A2 WO 2007051810 A2 WO2007051810 A2 WO 2007051810A2 EP 2006068015 W EP2006068015 W EP 2006068015W WO 2007051810 A2 WO2007051810 A2 WO 2007051810A2
Authority
WO
WIPO (PCT)
Prior art keywords
carbonyl
benzyl
aza
methyl
bicyclo
Prior art date
Application number
PCT/EP2006/068015
Other languages
French (fr)
Other versions
WO2007051810A3 (en
Inventor
Henrik Sune Andersen
Anker Steen JØRGENSEN
John Paul Kilburn
Gita Camilla Tejlgaard Kampen
Søren EBDRUP
Original Assignee
Transtech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma filed Critical Transtech Pharma
Priority to EP06819214A priority Critical patent/EP1948190A2/en
Priority to AU2006310518A priority patent/AU2006310518A1/en
Priority to US12/092,230 priority patent/US20090124598A1/en
Priority to EA200801243A priority patent/EA200801243A1/en
Priority to JP2008537121A priority patent/JP2009514818A/en
Priority to CA002627306A priority patent/CA2627306A1/en
Publication of WO2007051810A2 publication Critical patent/WO2007051810A2/en
Publication of WO2007051810A3 publication Critical patent/WO2007051810A3/en
Priority to IL191035A priority patent/IL191035A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to use of substituted amides and pharmaceutical compositions comprising the same for treating disorders where it is desirable to modulate the ac- tivity of 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 ⁇ HSD1 ).
  • the present invention also relates to novel substituted amides, to their use in therapy, to pharmaceutical compositions comprising the same, to the use of said compounds in the manufacture of medicaments, and to therapeutic methods comprising the administration of the compounds.
  • the present compounds modulate the activity of 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 ⁇ HSD1 ) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
  • the metabolic syndrome is a major global health problem. In the US, the prevalence in the adult population is currently estimated to be approximately 25%, and it continues to increase both in the US and worldwide.
  • the metabolic syndrome is characterised by a combination of insulin resistance, dyslipidemia, obesity and hypertension leading to increased morbidity and mortality of cardiovascular diseases. People with the metabolic syndrome are at increased risk of developing frank type 2 diabetes, the prevalence of which is equally escalating. [0003] In type 2 diabetes, obesity and dyslipidemia are also highly prevalent and around 70% of people with type 2 diabetes additionally have hypertension once again leading to increased mortality of cardiovascular diseases.
  • 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 ⁇ HSD1 ) catalyses the local generation of active glucocorticoid in several tissues and organs including predominantly the liver and adipose tissue, but also e.g., skeletal muscle, bone, pancreas, endothelium, ocular tissue and certain parts of the central nervous system.
  • 1 1 ⁇ HSD1 serves as a local regulator of glucocorticoid actions in the tissues and organs where it is expressed (Tannin et al., J.
  • 1 1 ⁇ HSD1 The role of 1 1 ⁇ HSD1 in the metabolic syndrome and type 2 diabetes is supported by several lines of evidence.
  • treatment with the non-specific 1 1 ⁇ HSD1 inhibitor car- benoxolone improves insulin sensitivity in lean healthy volunteers and people with type 2 diabetes.
  • 1 1 ⁇ HSD1 knock-out mice are resistant to insulin resistance induced by obesity and stress. Additionally, the knock-out mice present with an anti-atherogenic lipid profile of decreased VLDL triglycerides and increased HDL-cholesterol.
  • mice that overexpress 1 1 ⁇ HSD1 in adipocytes develop insulin resistance, hyperlipidemia and vis- ceral obesity, a phenotype that resembles the human metabolic syndrome (Andrews et al., J. Clin. Endocrinol. Metab., 88, 285 (2003); Walker et al., J. Clin. Endocrinol. Metab., 80, 3155 (1995); Morton et al., J. Biol. Chem., 276, 41293 (2001 ); Kotelevtsev et al., Proc. Natl. Acad.
  • 1 1 ⁇ HSD1 promotes the features of the metabolic syndrome by increasing hepatic expression of the rate-limiting enzymes in gluconeogenesis, namely phosphoenolpyuvate carboxykinase and glucose-6-phosphatase, promoting the differentiation of preadipocytes into adipocytes thus facilitating obesity, directly and indirectly stimulat- ing hepatic VLDL secretion, decreasing hepatic LDL uptake and increasing vessel contractility (Kotelevtsev et al., Proc. Natl. Acad. ScL USA, 94, 14924 (1997); Morton et al., J. Biol. Chem.
  • WO 01/90090, WO 01/90091 , WO 01/90092, WO 01/90093, and WO 01/90094 dis- closes various thiazol-sulfonamides as inhibitors of the human 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 enzyme, and further states that said compounds may be useful in treating diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders and depression.
  • substituted amides that modulate the activity of 1 1 ⁇ HSD1 lead- ing to altered intracellular concentrations of active glucocorticoid.
  • the present compounds inhibit the activity of 1 1 ⁇ HSD1 leading to decreased intracellular concentrations of active glucocorticoid.
  • the present compounds can be used to treat disorders where a decreased level of active intracellular glucocorticoid is desirable, such as e.g., the metabolic syndrome, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glu- cose (IFG), dyslipidemia, obesity, hypertension, diabetic late complications, cardiovascular diseases, arteriosclerosis, atherosclerosis, myopathy, muscle wasting, osteoporosis, neurodegenerative and psychiatric disorders, and adverse effects of treatment or therapy with glucocorticoid receptor agonists.
  • One object of the present invention is to provide compounds, pharmaceutical compositions and use of compounds that modulate the activity of 1 1 ⁇ HSD1.
  • halo includes fluorine, chlorine, bromine, and iodine.
  • trihalomethyl includes trifluoromethyl, trichloromethyl, tribromomethyl, and triiodomethyl.
  • trihalomethoxy includes trifluorometoxy, trichlorometoxy, tribromometoxy, and triiodometoxy.
  • alkyl includes CrC 8 straight chain saturated and methylene aliphatic hydrocarbon groups and C 3 -C 8 branched saturated hydrocarbon groups having the specified number of carbon atoms.
  • this definition includes methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, isopropyl (i-Pr), isobutyl (i-Bu), te/t-butyl (f-Bu), sec-butyl (s- Bu), isopentyl, and neopentyl.
  • alkenyl includes C 2 -C 6 straight chain unsaturated aliphatic hydrocarbon groups and branched C 3 -C 6 unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • this definition includes ethenyl, propenyl, butenyl, pentenyl, hexenyl, methylpropenyl, and methylbutenyl.
  • alkynyl includes C 2 -C 6 straight chain unsaturated aliphatic hydrocarbon groups and C 4 -C 6 branched unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • this definition includes ethynyl, propynyl, butynyl, pentynyl, hexynyl, and methylbutynyl.
  • saturated or partially saturated monocyclic, bicyclic, or tricyclic ring system represents but is not limited to aziridinyl, azepanyl, azocanyl, pyrrolinyl, pyrrolidinyl, 2- imidazolinyl, imidazolidinyl, 2-pyrazolinyl, morpholinyl, piperidinyl, thiomorpholinyl, piperaz- inyl, phthalimide, 1 ,2,3,4-tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydro-isoquinolinyl, 1 ,2,3,4- tetrahydro-quinoxalinyl, indolinyl, 1 , 6-aza-bicyclo[3.2.1 ]octane, 2-aza-bicyclo[4.1 .1 ]octane, 2-aza-bicyclo[3.2.1]octanyl, 7-aza-bicyclo
  • saturated or partially saturated ring represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooc- tenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, and tetrahydropyranyl.
  • saturated or partially saturated aromatic ring represents cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, and pyrimid- inyl.
  • cycloalkyl represents a saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[3.2.1 ]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, and adamantyl).
  • cycloalkylalkyl represents a cycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms or substituted alkyl group as defined above (e.g., cyclopropylmethyl, cyclobutylethyl, and adamantylmethyl).
  • cycloalkenyl represents a partially saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms (e.g., cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl).
  • cycloalkylcarbonyl represents a cycloalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., cyclopropylcarbonyl and cyclohexylcarbonyl).
  • cycloalkylalkylcarbonyl represents a cycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms or substituted alkyl group as defined above (e.g., cyclohexylmethylcarbonyl and cycloheptylethylcarbonyl).
  • hetcycloalkylalkyl represents a hetcycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., tetrahydro- furanylmethyl, tetrahydropyranylethyl, and tertahydrothiopyranylmethyl).
  • hetcycloalkylcarbonyl represents a hetcycloalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., 1 - piperidin-4-yl-carbonyl and 1 -(1 ,2,3,4-tetrahydro-isoquinolin-6-yl)carbonyl).
  • alkyloxy represents an alkyl group having the indicated number of carbon atoms attached through an oxygen bridge (e.g., methoxy, ethoxy, propyloxy, allyloxy, and cyclohexyloxy).
  • alkyloxyalkyl represents an alkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., methyloxymethyl).
  • aryl includes a carbocyclic aromatic ring that is monocyclic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, and biphenylenyl.
  • Aryl also includes the partially hydrogenated derivatives of the carbocyclic aromatic enumerated above. Examples of partially hydrogenated de- rivatives include 1 ,2,3,4-tetrahydronaphthyl and 1 ,4-dihydronaphthyl.
  • heteroaryl includes pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1 - imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazol-1 -yl, 1 ,2,3-triazol-2- yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thio- phenyl (2-thiophenyl, 3-thiophenyl, 4-thiophenyl, 5-thiophenyl), furany
  • arylalkyl represents an aryl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., benzyl, phenylethyl, 3- phenylpropyl, 1 -naphtylmethyl, and 2-(1 -naphtyl)ethyl).
  • hetarylalkyl or “hetaralkyl” represents a hetaryl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, and 1 - methyl-1 -(2-pyrimidyl)ethyl).
  • aryloxyhetaryl represents an aryloxy group as defined above attached through a hetaryl group (e.g., 2-phenoxy-pyridyl).
  • aryloxy represents an aryl group as defined above attached through an oxygen bridge (e.g., phenoxy and naphthyloxy).
  • hetaryloxy represents a hetaryl group as defined above attached through an oxygen bridge (e.g., 2-pyridyloxy).
  • arylalkyloxy represents an arylalkyl group as defined above attached through an oxygen bridge (e.g., phenethyloxy and naphthylmethyloxy).
  • hetarylalkyloxy represents a hetarylalkyl group as defined above attached through an oxygen bridge (e.g., 2-pyridylmethyloxy).
  • alkyloxycarbonyl represents an alkyloxy group as defined above attached through a carbonyl group (e.g., methylformiat and ethylformiat).
  • aryloxycarbonyl represents an aryloxy group as defined above attached through a carbonyl group (e.g., phenylformiat and 2-thiazolylformiat).
  • arylalkyloxycarbonyl represents an "arylalkyloxy” group as defined above attached through a carbonyl group (e.g., benzylformiat and phenyletylformiat).
  • alkylthio represents an alkyl group having the indicated number of carbon atoms attached through a sulphur bridge (e.g., methylthio and ethylthio).
  • arylthio represents an aryl group as defined above attached through a sulphur bridge (e.g., benzenthiol and naphthylthiol).
  • hetarylthio represents a hetaryl group as defined above attached through a sulphur bridge (e.g., pyridine-2-thiol and thiazole-2-thiol).
  • arylthioalkyl represents an arylthio group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., methylsulfanyl benzene, and ethylsulfanyl naphthalene).
  • hetarylthioalkyl represents a hetarylthio group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 2-methylsulfanyl- pyridine and 1 -ethylsulfanyl-isoquinoline).
  • hetaryloxyaryl represents a hetaryloxy group as defined above attached through an aryl group as defined above (e.g., 1 -phenoxy-isoquinolyl and 2-phenoxypyridyl).
  • hetaryloxyhetaryl represents a hetaryloxy group as defined above attached through a hetaryl group as defined above (e.g., 1 -(2-pyridyloxy-isoquinoline) and 2- (imidazol-2-yloxy-pyridine)).
  • aryloxyalkyl represents an aryloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., phenoxymethyl and naphthyloxyethyl).
  • aryloxyaryl represents an aryloxy group as defined above attached through an aryl group as defined above (e.g., 1 -phenoxy-naphthalene and phenyloxyphenyl).
  • arylalkyloxyalkyl represents an arylalkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., ethoxy- methyl-benzene and 2-methoxymethyl-naphthalene).
  • hetaryloxyalkyl represents a hetaryloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 2- pyridyloxymethyl and 2-quinolyloxyethyl).
  • hetarylalkyloxyalkyl represents a hetarylalkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., A- methoxymethyl-pyrimidine and 2-methoxymethyl-quinoline).
  • alkylcarbonyl represents an alkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., octylcarbonyl, pen- tylcarbonyl, and 3-hexenylcarbonyl).
  • arylcarbonyl represents an aryl group as defined above attached through a carbonyl group (e.g., benzoyl).
  • hetarylcarbonyl represents a hetaryl group as defined above attached through a carbonyl group (e.g., 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, and oxa- zolylcarbonyl).
  • carbonylalkyl represents a carbonyl group attached through an alkyl group having the indicated number of carbon atoms (e.g., acetyl).
  • alkylcarbonylalkyl represents an alkylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., propane- one and 4,4-dimethyl-pentan-2-one).
  • arylcarbonylalkyl represents a arylcarbonyl group as defined above at- tached through an alkyl group having the indicated number of carbon atoms (e.g., 1 -phenyl- propan-1 -one and 1 -(3-chloro-phenyl)-2-methyl-butan-1 -one).
  • hetarylcarbonylalkyl represents a hetarylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 1 - pyridin-2-yl-propan-1 -one and 1 -(1 -H-imidazol-2-yl)-propan-1 -one).
  • arylalkylcarbonyl represents an arylalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., phenylpro- pylcarbonyl and phenylethylcarbonyl).
  • hetarylalkylcarbonyl represents a hetarylalkyl group as defined above wherein the alkyl group is in turn attached through a carbonyl (e.g., imidazolylpentylcar- bonyl).
  • alkylcarbonylamino represents an "alkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group (e.g., methylcarbonylamino, cyclopentylcarbonyl-aminomethyl, and methylcarbonylaminophenyl).
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • alkylcarbonylaminoalkyl represents an "alkylcarbonylamino” group attached through an alkyl group having the indicated number of carbon atoms (e.g.N-propyl- acetamide and N-butyl-propionamide).
  • arylalkylcarbonylamino represents an "arylalkylcarbonyl” group as defined above attached through an amino group (e.g., phenylacetamide and 3-phenyl-propionamide).
  • arylalkylcarbonylaminoalkyl represents an "arylalkylcarbonylamino” group attached through an alkyl group having the indicated number of carbon atoms (e.g., N-ethyl- phenylacetamide and N-butyl-3-phenyl-propionamide).
  • arylcarbonylamino represents an "arylcarbonyl” group as defined above attached through an amino group (e.g., benzamide and naphthalene-1 -carboxylic acid amide).
  • arylcarbonylaminoalkyl represents an "arylcarbonylamino” group attached through an alkyl group having the indicated number of carbon atoms (e.g., N-propyl- benzamide and N-butyl-naphthalene-1 -carboxylic acid amide).
  • alkylcarboxy represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., heptylcarboxy, cyclopropyl- carboxy, and 3-pentenylcarboxy).
  • arylcarboxy represents an arylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., benzoic acid).
  • alkylcarboxyalkyl represents an alkylcarboxy group as defined above wherein the oxygen is attached via an alkyl bridge (e.g., heptylcarboxymethyl, propylcarboxy te/t-butyl, and 3-pentylcarboxyethyl).
  • arylalkylcarboxy represents an arylalkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., benzylcarboxy and phenylpropylcarboxy).
  • arylalkylcarboxyalkyl represents an arylalkylcarboxy group as defined above wherein the carboxy group is in turn attached through an alkyl group having the indicated number of carbon atoms (e.g., benzylcarboxymethyl and phenylpropylcarboxypropyl).
  • hetarylcarboxy represents a hetarylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., pyridine-2-carboxylic acid).
  • hetarylalkylcarboxy represents a hetarylalkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., (1 -H-imidazol- 2-yl)-acetic acid and 3-pyrimidin-2-yl-propionic acid).
  • an oxygen bridge e.g., (1 -H-imidazol- 2-yl)-acetic acid and 3-pyrimidin-2-yl-propionic acid.
  • m oxygen atoms
  • Certain of the above defined terms may occur more than once in the structural formu- lae, and upon such occurrence each term shall be defined independently of the other.
  • optionally substituted as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified.
  • treatment or “treating” is defined as the management and care of a patient for the purpose of combating or alleviating the disease, condition, or disorder, and the term includes the administration of the active compound to prevent or delay the onset of the symptoms or complications; alleviating (both temporary and permanent) the symptoms or complications; and/or eliminating the disease, condition, or disorder.
  • treatment or “treating” includes prevention and/or prophylaxis of the disease, condition, or disorder.
  • pharmaceutically acceptable is defined as being suitable for administration to humans without adverse events.
  • prodrug is defined as a chemically modified form of the active drug, said prodrug being administered to the patient and subsequently being converted to the active drug. Techniques for development of prodrugs are well known in the art.
  • the present invention provides a novel substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the compound is of formula I:
  • R 2 is selected from H, d-C 6 alkyl, and C 3 -C 6 cycloalkyl;
  • Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O) n ;
  • Ring A is substituted with 0-3 groups selected from d-C 8 alkyl, halo, OH, oxo, cyano, Ci-C 6 alkyloxy, Ci-CealkyloxyCi-Cealkyl or d-C 6 alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R 18 ;
  • R 5 is selected from H, d-C 6 alkyl, C 3 -C 6 cycloalkyl, halo, OH, and cyano;
  • R 6 and R 7 are independently selected from H, d-C 6 alkyl, F, trihalomethyl, and triha- lomethoxy;
  • R 6 and R 7 together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, d-C 6 alkyl, oxo, and d-C 6 alkyloxy;
  • R 8 is selected from d-C 8 alkyl, C 2 -C 8 alkenyl, aryl, hetaryl, arylCi-C 6 alkyl, hetaryl- Ci-C 6 alkyl, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C 6 alkyl, hetary- loxyCi-C 6 alkyl, arylCi-CealkyloxyCi-Cealkyl, and hetarylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R 19 ;
  • R 9 is selected from d-C 8 alkyl, C 2 -C 8 alkenyl, aryl, hetaryl, arylCrC 6 alkyl, hetaryl- Ci-C 6 alkyl, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyCi-C 6 alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R 20 ;
  • R 10 and R 11 are independently selected from H, d-C 8 alkyl, C 3 -Ci 0 cycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C 6 alkyl, and hetarylCi-C 6 alkyl, wherein each of the alkyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 21 ;
  • R 10 and R 11 together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O) m , wherein this ring is substituted with 0-3 groups selected from Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl, hydroxy, oxo, COOH, Ci-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-C 6 alkyloxyCi-C 6 alkyl, Ci-C 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C 6 alkylcarbonyl,
  • R 12 is selected from OH, d-C 8 alkyl, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, Ci-C 8 alkyloxy, aryl, arylCi-C 6 alkyl, hetaryl, hetarylCi-C 6 alkyl, aryloxy, hetary- loxy, and NR 13 R 14 ;
  • R 13 and R 14 are independently selected from H, C r C 8 alkyl, C 3 -Ci ocycloalkyl, aryl, hetaryl, arylCi-C 6 alkyl, and hetarylCi-C 6 alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 22 ;
  • R 13 and R 14 together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring con- sisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O) m , wherein this ring is substituted with 0-3 groups selected from Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl, OH, oxo, Ci-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-C 6 alkyloxyCi-C 6 alkyl, d-C 6 alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, aryld-Cealkylcarbonyl, he
  • R 15 is selected from H, d-C 6 alkyl, and C 3 -C 6 cycloalkyl;
  • R 18 is selected from halo, OH, oxo, COOH, cyano d-C 6 alkyloxy, C 3 -Ci 0 cyclo- alkyloxy, aryloxy, hetaryloxy, hetarylthio and arylCi-C 6 alkyloxy;
  • R 22 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy,
  • R 23 and R 24 are independently selected from H, C r C 8 alkyl, and arylCi-C 6 alkyl;
  • m is selected from 0, 1 , and 2;
  • n is selected from 1 and 2;
  • Y is selected from O and S;
  • the present invention provides the novel substituted amides of formula I, wherein:
  • R 2 is Ci-C 4 alkyl
  • Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O) m ;
  • Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, OH, oxo, cyano, Ci-C 4 alkyloxy, Ci-C 4 alkyloxyCi-C 4 alkyl or Ci-C 4 alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R 18 ;
  • R 5 is H
  • R 6 and R 7 are independently selected from H and C r C 4 alkyl; and,
  • n 2
  • the present invention provides the novel substituted amides of formula I, wherein:
  • R 2 is Ci-C 4 alkyl;
  • Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O) n ;
  • Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, OH, oxo, cyano, d-C 4 alkyloxy, d-dalkyloxyd-dalkyl or Ci-C 4 alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R 18 ;
  • R 5 is H
  • R 6 and R 7 are independently selected from H and d-C 4 alkyl; and,
  • n 2
  • the present invention provides the novel substituted amides of formula I, wherein:
  • R 2 is selected from H, C r C 4 alkyl and C 3 -C 6 cycloalkyl;
  • Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O) m ;
  • Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, OH, oxo, cyano, Ci-C 4 alkyloxy, Ci-C 4 alkyloxyCi-C 4 alkyl or Ci-C 4 alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R 18 ;
  • R 5 is H
  • R 6 and R 7 are independently selected from H and C r C 4 alkyl; and,
  • n 2
  • the present invention provides the novel substituted amides of formula I, wherein:
  • R 2 is Ci-C 4 alkyl.
  • the present invention provides the novel substituted amides of formula I ovel use of compounds of formula I, wherein:
  • R 8 is selected from d-C 6 alkyl, C 2 -C 6 alkenyl, aryl, hetaryl, arylC r C 4 alkyl, hetarylCrC 4 alkyl, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCi-C 4 alkyl, and hetaryloxyCi-C 4 alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R 19 ;
  • R 9 is selected from d-C 6 alkyl, C 2 -C 6 alkenyl, aryl, hetaryl, arylC r C 4 alkyl, hetarylCrdalkyl, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C 4 alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R 20 ; [00144] R 10 and R 11 are independently selected from H, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R
  • R 10 and R 11 together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-2 groups selected from d-C 8 alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, and Ci-C 6 alkylcarbonyl ;
  • R 12 is selected from OH, CrC 4 alkyl, C 3 -C 6 cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, CrC 4 alkyloxy, aryl, arylCi-C 4 alkyl, hetaryl, hetarylCi-C 4 alkyl, aryloxy, and hetaryloxy;
  • n 2
  • the present invention provides the novel substituted amide or prodrug thereof of formula Ia:
  • the present invention provides the novel substituted amide or prodrug thereof of formula Ib:
  • the present invention provides the novel substituted amide or prodrug thereof of formula Ic:
  • the present invention provides the novel substituted amide or prodrug thereof of formula Id:
  • the present invention provides the novel substituted amide or prodrug thereof of formula Ie:
  • the present invention provides the novel substituted amide formula I, wherein:
  • the present invention provides the novel substituted amide formula I, wherein R 1 and R 2 , together with the nitrogen to which they are attached, are:
  • the present invention provides the novel substituted amide of formula I, wherein Ring A is selected from:
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein Ring A is selected from:
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hy- droxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hy- droxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
  • Ring A is substituted with 0-2 R 25 ; and, R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and d-C 6 alkyloxy.
  • the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is azepane.
  • the present invention provides the novel compounds of formula I, wherein the substituted amide or a prodrug thereof is of the selected from the group: N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- acetamide
  • Morpholine-4-carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
  • Morpholine-4-carboxylic acid [4-(6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-benzyl]- methyl-amide
  • Morpholine-4-carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide
  • Morpholine-4-carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
  • the present invention provides the novel compounds of formula I, wherein the substituted amide or a prodrug thereof is the selected from the group : [4-(1 -Amino-cyclopropyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)- methanone
  • Morpholine-4-carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
  • Morpholine-4-carboxylic acid [4-(3-hydroxy-adamantan-1 -yl-carbamoyl)-benzyl]- methyl-amide
  • Morpholine-4-carboxylic acid [4-(3-fluoro-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide
  • Morpholine-4-carboxylic acid [4-(4-aza-tricyclo[4.3.1 .1 * 3,8 * ]-undecane-4-carbonyl)- benzyl]-methyl-amide
  • the present invention provides for the novel use of a substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the substituted amide or a prodrug thereof is of formula I:
  • R 2 is selected from H, d-C 6 alkyl, and C 3 -C 6 cycloalkyl;
  • Ring A is substituted with 0-3 groups selected from d-C 8 alkyl, halo, OH, oxo, cyano, Ci-C 6 alkyloxy, Ci-C 6 alkyloxyCi-C 6 alkyl or Ci-C 6 alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R 18 ;
  • R 5 is selected from H, d-C 6 alkyl, C 3 -C 6 cycloalkyl, halo, OH, and cyano;
  • R 6 and R 7 are independently selected from H, d-C 6 alkyl, F, trihalomethyl, and triha- lomethoxy;
  • R 6 and R 7 together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, d-C 6 alkyl, oxo, and d-C 6 alkyloxy;
  • R 8 is selected from d-C 8 alkyl, C 2 -C 8 alkenyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl, C 3 -Ci 0 cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C 6 alkyl, hetary- loxyCi-C 6 alkyl, arylCi-CealkyloxyCi-Cealkyl, and hetarylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R 19 ;
  • R 9 is selected from d-C 8 alkyl, C 2 -C 8 alkenyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl, C 3 -Ci 0 cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C 6 alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R 20 ;
  • R 10 and R 11 are independently selected from H, C r C 8 alkyl, C 3 -Ci 0 cycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C 6 alkyl, and hetarylCi-C 6 alkyl, wherein each of the alkyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 21 ; [00200] alternatively, R 10 and R 11 , together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-3 groups se- lected from d-C 8
  • R 12 is selected from OH, d-C 8 alkyl, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C 8 alkyloxy, aryl, aryld-C 6 alkyl, hetaryl, hetaryld-C 6 alkyl, aryloxy, hetary- loxy, and NR 13 R 14 ;
  • R 13 and R 14 are independently selected from H, d-C 8 alkyl, C 3 -Ci ocycloalkyl, aryl, hetaryl, arylCi-C 6 alkyl, and hetarylCi-C 6 alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 22 ;
  • R 13 and R 14 together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-3 groups selected from Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl, OH, oxo, d-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, d-Cealkyloxyd-Cealkyl, d-C 6 alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C 6 alkylcarbonyl, hetarylcarbonyl,
  • R 15 is selected from H, d-C 6 alkyl, and C 3 -C 6 cycloalkyl;
  • R 22 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy, NR 23 R 24 , methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
  • R 23 and R 24 are independently selected from H, d-C 8 alkyl, and arylCi-C 6 alkyl;
  • m is selected from 0, 1 , and 2;
  • n is selected from 1 and 2;
  • Y is selected from O and S;
  • R 2 is selected from H, d-C 6 alkyl, and C 3 -C 6 cycloalkyl;
  • Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O) n ;
  • Ring A is substituted with 0-3 groups selected from d-C 8 alkyl, halo, OH, oxo, cyano, d-C 6 alkyloxy, d-Cealkyloxyd-Cealkylene or d-C 6 alkylcarbonyl, wherein each al- kyl/alkylene group is substituted with 0-3 R 18 ;
  • R 5 is selected from H, d-C 6 alkyl, C 3 -C 6 cycloalkyl, halo, OH, and cyano;
  • R 6 and R 7 are independently selected from H, d-C 6 alkyl, F, trihalomethyl, and triha- lomethoxy;
  • R 6 and R 7 together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, d-C 6 alkyl, oxo, and d-C 6 alkyloxy;
  • R 8 is selected from d-C 8 alkyl, C 2 -C 8 alkenyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCrC 6 alkylene, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C 6 alkylene, hetaryloxyCi-C 6 alkylene, arylCi-CealkyloxyCi-Cealkylene, and hetaryl- Ci-CealkyloxyCi-Cealkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloal- kyl, and hetcycloalkyl groups are independently substituted with 0-3 R 19 ;
  • R 9 is selected from d-C 8 alkyl, C 2 -C 8 alkenyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C 6 alkylene, and arylCi-CealkyloxyCi-Cealkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R 20 ; [00225] R 10 and R 11 are independently selected from H, CrC 8 alkyl, C 3 -Ci 0 cycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C 6 alky
  • R 10 and R 11 together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O) m , wherein this ring is substituted with 0-3 groups se- lected from d-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, hydroxy, oxo, COOH, Ci-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-C 6 alkyloxyCi-C 6 alkylene, Ci-C 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrC 6 alky
  • R 12 is selected from OH, d-C 8 alkyl, C 3 -Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, Ci-C 8 alkyloxy, aryl, arylCi-C 6 alkylene, hetaryl, hetarylCi-C 6 alkylene, aryloxy, hetaryloxy, and NR 13 R 14 ;
  • R 13 and R 14 are independently selected from H, C r C 8 alkyl, C 3 -Ci ocycloalkyl, aryl, hetaryl, arylCi-C 6 alkylene, and hetarylCi-C 6 alkylene, wherein each of the alkyl/alkylene, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 22 ;
  • R 13 and R 14 together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O) n , wherein this ring is substituted with 0-3 groups selected from Ci-C 8 alkyl, aryl, hetaryl, arylCi-C 6 alkylene, hetarylCi-C 6 alkylene, OH, oxo, Ci-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, Ci-C 6 alkyloxyCi-C 6 alkylene, Ci-C 6 alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C 6 alkylcarbonyl, hetarylcarbonyl, arylC
  • R 15 is selected from H, d-C 6 alkyl, and C 3 -C 6 cycloalkyl;
  • R 18 is selected from halo, OH, oxo, and cyano;
  • R 22 is selected from H, OH, oxo, halo, cyano, nitro, d-C 6 alkyl, d-C 6 alkyloxy, NR 23 R 24 , methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
  • R 23 and R 24 are independently selected from H, C r C 8 alkyl, and arylCi-C 6 alkylene;
  • m is selected from O, 1 , and 2;
  • n is selected from 1 and 2;
  • Y is selected from O and S;
  • the present invention provides the novel use of com- pounds of formula I, wherein:
  • R 2 is d-dalkyl
  • Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O) m ;
  • Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, OH, oxo, cyano, Ci-C 4 alkyloxy, Ci-C 4 alkyloxyCi-C 4 alkyl or Ci-C 4 alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R 18 ;
  • R 5 is H
  • R 6 and R 7 are independently selected from H and C r C 4 alkyl; and,
  • n 2
  • the present invention provides the novel use of com- pounds of formula I, wherein:
  • R 2 is d-dalkyl
  • Ring A is substituted with 0-3 groups selected from d-C 4 alkyl, halo, OH, oxo, cyano, Ci-C 4 alkyloxy, Ci-C 4 alkyloxyCi-C 4 alkylene or Ci-C 4 alkylcarbonyl, wherein each al- kyl/alkylene group is substituted with 0-1 R 18 ;
  • R 5 is H
  • R 6 and R 7 are independently selected from H and C r C 4 alkyl; and,
  • n 2
  • R 8 is selected from d-C 6 alkyl, C 2 -C 6 alkenyl, aryl, hetaryl, arylC r C 4 alkyl, hetarylCrC 4 alkyl, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCi-C 4 alkyl, and hetaryloxyCi-C 4 alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R 19 ;
  • R 9 is selected from d-C 6 alkyl, C 2 -C 6 alkenyl, aryl, hetaryl, arylC r C 4 alkyl, hetarylCi-C 4 alkyl, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C 4 alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R 20 ;
  • R 10 and R 11 are independently selected from H, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 21 ;
  • R 10 and R 11 together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxy- gen, and S(O) m , wherein this ring is substituted with 0-2 groups selected from d-C 8 alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, and Ci-C 6 alkylcarbonyl ;
  • R 12 is selected from OH, C r C 4 alkyl, C 3 -C 6 cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C 4 alkyloxy, aryl, arylCi-C 4 alkyl, hetaryl, hetarylCi-C 4 alkyl, aryloxy, and hetaryloxy;
  • n 2
  • R 8 is selected from d-C 6 alkyl, C 2 -C 6 alkenyl, aryl, hetaryl, arylC r C 4 alkylene, hetarylCi-C 4 alkylene, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyd-C 4 alkylene, and hetaryloxyCi-C 4 alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R 19 ;
  • R 9 is selected from d-C 6 alkyl, C 2 -C 6 alkenyl, aryl, hetaryl, arylC r C 4 alkylene, hetarylCi-C 4 alkylene, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, and ary- loxyCi-C 4 alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R 20 ;
  • R 10 and R 11 are independently selected from H, C 3 -C 6 cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R 21 ;
  • R 10 and R 11 together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown ni- trogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxy- gen, and S(O) m , wherein this ring is substituted with 0-2 groups selected from d-C 8 alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C 6 alkyloxy, arylCi-C 6 alkyloxy, hetarylCi-C 6 alkyloxy, and Ci-C 6 alkylcarbonyl ;
  • R 12 is selected from OH, C r C 4 alkyl, C 3 -C 6 cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C 4 alkyloxy, aryl, arylCi-C 4 alkylene, hetaryl, hetarylCi-C 4 alkylene, aryloxy, and hetaryloxy;
  • n 2
  • the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ia:
  • the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ib:
  • the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ic:
  • the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Id:
  • the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ie:
  • Ring A is selected from:
  • Ring A is substituted with 0-2 R ⁇ ;
  • Ring A is substituted with 0-2 R ⁇ ;
  • R is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and Ci-C 6 alkyloxy.
  • the present invention provides the novel use of compounds of formula I, wherein: ring A is
  • Ring A is substituted with 0-2 R 25 ; and,
  • R 25 is selected from d-C 8 alkyl, halo, hydroxy, oxo, cyano, and Ci-C 6 alkyloxy.
  • the present invention provides the novel use of compounds of formula I, wherein the substituted amide or a prodrug thereof is of the selected from the group:
  • Morpholine-4-carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
  • Morpholine-4-carboxylic acid [4-(6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-benzyl]- methyl-amide
  • Morpholine-4-carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide 1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3- phenyl-urea
  • Morpholine-4-carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
  • the present invention provides for the novel preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
  • the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
  • the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the pharmaceutical composition is suitable for a route of administration selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
  • the present invention provides a novel method for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound of the present invention. .
  • the present invention provides a novel method wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
  • the present invention provides a novel method wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • the present invention provides a novel method wherein the administering is via a route selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
  • the present invention provides a novel compound, which is an agent useful for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
  • the present invention provides a novel method wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
  • the present invention provides a novel method wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), im- paired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • the present invention provides a novel method pharmaceutical composition
  • a novel method pharmaceutical composition comprising, as an active ingredient, at least one compound according of the present invention together with one or more pharmaceutically acceptable carriers or excipi- ents.
  • the present invention provides a novel pharmaceutical composition, which is suitable for oral, nasal, buccal, transdermal, pulmonal, or parenteral administration.
  • the compounds of the present invention have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms being included in the present invention as well as mixtures thereof.
  • the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
  • Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, and nitric acids.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphtho- ates, glycero
  • compositions include the pharmaceutically acceptable salts listed in J. Pharm. ScL, 66, 2 (1977), which is incorporated herein by reference.
  • metal salts include lithium, sodium, potassium, barium, calcium, magnesium, zinc, and calcium salts.
  • amines and organic amines include ammonium, methylamine, di- methylamine, trimethylamine, ethylamine, diethylamine, propylamine, butylamine, tetrame- thylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylene-diamine, N-benzylphenylethylamine, N-methyl-D-glucamine, and guanidine.
  • cationic amino acids include lysine, arginine, and histidine.
  • some of the compounds of the present invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
  • the pharmaceutically acceptable salts are prepared by reacting a compound of the present invention with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium te/t-butoxide, calcium hydroxide, and magnesium hy- droxide, in solvents such as ether, THF, methanol, te/t-butanol, dioxane, and isopropanol, ethanol. Mixtures of solvents may be used.
  • Organic bases such as lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used.
  • acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, and tartaric acid in solvents such as ethyl acetate, ether, alcohols, acetone, THF, and dioxane. Mixture of solvents may also be used.
  • acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid
  • stereoisomers of the compounds forming part of this invention may be pre- pared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enanti- omer form or by resolving the mixture of stereoisomers by conventional methods.
  • Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, and lactic acid, wherever applicable or chiral bases such as brucine, (R)- or (S)- phenylethylamine, cinchona alkaloids and their derivatives. Commonly used methods are compiled by Jaques et al. in “Enantiomers, Racemates and Resolution” (Wiley Interscience, 1981 ).
  • the compound of the present invention may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydro- lysing the pure diastereomeric amide.
  • polymorphs of the compounds forming part of this invention may be pre- pared by crystallization of said compounds under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
  • the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
  • prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the present invention.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • bioavailability may be ascribed to a number of different factors such as lack of or poor absorption in the gut, first pass metabolism in the liver and/or poor uptake in cells.
  • factors determining bioavailability are not completely understood, there are many examples in the scientific literature - well known to those skilled in the art - of how to modify compounds, which are potent and selective in biochemical assays but show low or no activity in vivo, into drugs that are biologically active.
  • esters for instance methyl esters, ethyl esters, te/t-butyl, acetoxymethyl, pivaloyloxymethyl esters or other acy- loxymethyl esters.
  • esters for instance methyl esters, ethyl esters, te/t-butyl, acetoxymethyl, pivaloyloxymethyl esters or other acy- loxymethyl esters.
  • 'modified compounds' The invention also encompasses active metabolites of the present compounds.
  • the compounds according to the invention alter, and more specifically, reduce the level of active intracellular glucocorticoid and are accordingly useful for the treatment of conditions, disorders, and diseases in which such a modulation or reduction is beneficial.
  • the present compounds may be applicable for the treatment of the metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), Latent Autoimmune Diabetes in the Adult (LADA), type 1 diabetes, diabetic late complications including cardiovascular diseases, cardiovascular disorders, disorders of lipid metabolism, neurodegenerative and psychiatric disorders, dysregulation of intraocular pressure including glaucoma, immune disorders, inappropriate immune responses, musculoskeletal disorders, gastrointestinal disorders, polycystic ovarie syndrome (PCOS), reduced hair growth or other diseases, disorders or conditions that are influenced by intracellular glucocorticoid levels, adverse effects of increased blood levels of active endogenous or exogenous glucocorticoid, and any combin
  • the present compounds may be applicable for the treatment of the metabolic syndrome, type 2 diabetes, diabetes as a consequence of obesity, insulin resistance, hyperglycemia, prandial hyperglycemia, hyperinsulinemia, inappropriately low insulin secretion, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), increased hepatic glucose production, type 1 diabetes, LADA, pediatric diabetes, dyslipidemia, diabetic dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, decreased HDL cholesterol, impaired LDL/HDL ratio, other disorders of lipid metabolism, obesity, visceral obesity, obesity as a consequence of diabetes, increased food intake, hypertension, diabetic late complications, micro-/macroalbuminuria, nephropathy, retinopathy, neuropathy, diabetic ulcers, cardiovascular diseases, arteriosclerosis, atherosclero- sis, coronary artery disease, cardiac hypertrophy, myocardial ischemia, heart insufficiency, congestional heart
  • the invention relates to a compound according to the invention for use as a pharmaceutical composition.
  • the invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound according to the invention together with one or more pharmaceutically acceptable carriers or diluents.
  • the pharmaceutical composition is preferably in unit dosage form, comprising from about 0.05 mg/day to about 2000 mg/day, preferably from about 0.1 mg/day to abouti OOO mg/day, and more preferably from about 0.5 mg/day to about 500 mg/day of a compound according to the invention.
  • the patient is treated with a compound according to the invention for at least about 1 week, for at least about 2 weeks, for at least about 4 weeks, for at least about 2 months or for at least about 4 months.
  • the pharmaceutical composition is for oral, nasal, buccal, transdermal, pulmonal or parenteral administration.
  • the invention relates to the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment of disorders and diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial.
  • the invention also relates to a method for the treatment of disorders and diseases wherein a modulation or an inhibition of the activity of 1 1 ⁇ HSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to the invention.
  • the present compounds are used for the preparation of a medicament for the treatment of any diseases and conditions that are influenced by intracellular glucocorticoid levels as mentioned above.
  • the present compounds are used for the preparation of a medicament for the treatment of conditions and disorders where a decreased level of active intracellular glucocorticoid is desirable, such as the conditions and diseases mentioned above.
  • the present compounds are used for the preparation of a medicament for the treatment of metabolic syndrome, insulin resistance, dyslipidemia, hypertension obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of the metabolic syndrome into type 2 diabetes, diabetic late complications (e.g., cardiovascular diseases, arteriosclerosis, and atherosclerosis), neurodegenerative and psychiatric disor- ders, and, the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • IGT impaired glucose tolerance
  • IGF impaired fasting glucose
  • progression from IGT to type 2 diabetes progression of the metabolic syndrome into type 2 diabetes
  • diabetic late complications e.g., cardiovascular diseases, arteriosclerosis, and atherosclerosis
  • neurodegenerative and psychiatric disor- ders e.g., the adverse effects of glucocorticoid receptor agonist treatment or therapy.
  • the route of administration may be any route which effectively transports a compound according to the invention to the appropriate or desired site of action, such as oral, nasal, buccal, transdermal, pulmonal, or parenteral.
  • the present compounds are administered in combination with one or more further active substances in any suitable ratios.
  • Such further active substances may e.g., be selected from antiobesity agents, antidiabetics, agents modifying the lipid metabolism, antihypertensive agents, glucocorticoid receptor agonists, agents for the treatment and/or prevention of complications resulting from or associated with diabe- tes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • agents may be selected from the group consisting of CART (cocaine am- phetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melano- cortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, se- rotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors
  • CART cocaine am- phetamine regulated transcript
  • the antiobesity agent is leptin; dexamphetamine or amphetamine; fenfluramine or dexfenfluramine; sibutramine; orlistat; mazindol or phen- termine.
  • Suitable antidiabetic agents include insulin, insulin analogues and derivatives such as those disclosed in EP 792 290 (Novo Nordisk A/S), e.g., N ⁇ B29 -tetradecanoyl des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), e.g., Asp B28 human insulin, US 5,504,188 (EIi Lilly), e.g., Lys B28 Pro 629 human insulin, EP 368 187 (Aventis), eg Lantus, which are all incorporated herein by reference, GLP-1 (glucagon like peptide-1 ) and GLP-1 derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents.
  • EP 792 290 Novo Nordisk A/S
  • N ⁇ B29 -tetradecanoyl des B30 human insulin
  • the orally active hypoglycaemic agents preferably comprise sulphonylureas, bigua- nides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase- IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenosis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as PPAR ⁇ modulators, PPAR ⁇ modulators, cholesterol absorption inhibitors, HSL (hormone-sensitive lipase) inhibitors and HMG CoA inhibitor
  • the present compounds are administered in combination with insulin or an insulin analogue or derivative, such as N ⁇ B29 -tetradecanoyl des (B30) human insulin, Asp B28 human insulin, Lys B28 Pro 629 human insulin, Lantus®, or a mix-preparation comprising one or more of these.
  • insulin or an insulin analogue or derivative such as N ⁇ B29 -tetradecanoyl des (B30) human insulin, Asp B28 human insulin, Lys B28 Pro 629 human insulin, Lantus®, or a mix-preparation comprising one or more of these.
  • a sulphonylurea e.g., tolbutamide, glibenclamide, glipizide or glicazide.
  • the present compounds are administered in combination with a biguanide e.g., metformin.
  • a biguanide e.g., metformin.
  • the present compounds are administered in combination with a meglitinide e.g., repaglinide or senaglinide.
  • a meglitinide e.g., repaglinide or senaglinide.
  • the present compounds are administered in combination with a thiazolidinedione e.g., troglitazone, ciglitazone, pioglitazone, rosiglitazone or compounds disclosed in WO 97/41097 such as 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazo- linyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof, preferably the potassium salt.
  • the present compounds may be administered in combination with the insulin sensitizers disclosed in WO 99/19313 such as (-) 3-[4-[2-Phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salts thereof, preferably the arginine salt.
  • the present compounds are administered in combination with an ⁇ -glucosidase inhibitor e.g., miglitol or acarbose.
  • the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells e.g., tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ -cells e.g., tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • the present compounds may be administered in combination with nateglinide.
  • the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofi- brate, gemfibrozil, fenofibrate, bezafibrate, tesaglitazar, EML-4156, LY-818, MK-767, ator- vastatin, fluvastatin, lovastatin, pravastatin, simvastatin, acipimox, probucol, ezetimibe or dextrothyroxine.
  • an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofi- brate, gemfibrozil, fenofibrate, bezafibrate, tesaglitazar, EML-4156, LY-818, MK-767, ator- vastatin, fluvastatin, lovastatin, pravastat
  • the present compounds are administered in combination with more than one of the above-mentioned compounds e.g., in combination with a sulphony- lurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
  • the present compounds may be administered in combination with one or more antihypertensive agents.
  • antihypertensive agents are ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol, metoprolol, bisoprololfumerate, esmolol, acebutelol, metoprolol, acebutolol, betaxolol, celiprolol, nebivolol, tertatolol, oxprenolol, amusolalul, carvedilol, labetalol, ⁇ 2-receptor blockers e.g., S-atenolol, OPC-1085, ACE (angiotensin converting enzyme) inhibitors such as quinapril, lisinopril, enalapril, captopril, ben
  • the present compounds may be administered in combination with one or more glucocorticoid receptor agonists.
  • glucocorticoid receptor agonists examples include betametasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, beclomethasone, butixicort, clobetasol, flunisolide, flucatisone (and analogues), momethasone, triamcinolonacetonide, triamcinolonhexacetonide GW-685698, NXC-1015, NXC-1020, NXC-1021 , NS-126, P-41 12, P-41 14, RU-24858 and T-25 series.
  • the compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
  • the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and ex- cipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
  • compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the ac- tive ingredient chosen.
  • compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sus- tained or prolonged release according to methods well-known in the art.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
  • compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as ster- ile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
  • a typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages.
  • the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
  • a typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 2000 mg, e.g., from about 0.1 to about 1000 mg, from about 0.5 mg to about 500 mg., from about 1 mg to about 200 mg, e.g., about 100 mg.
  • parenteral routes such as intravenous, intrathecal, intramuscular and similar administration
  • typically doses are in the order of about half the dose employed for oral administra- tion.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • examples are an acid addition salt of a compound having the utility of a free base and a base addition salt of a compound having the utility of a free acid.
  • pharmaceutically acceptable salts refers to non-toxic salts of the com- pounds for use according to the present invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the acid with a suitable organic or inorganic base.
  • a compound for use according to the present invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable acid.
  • salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable base.
  • Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion.
  • Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds for use according to the present invention and these form a further aspect of the present invention.
  • solutions of the present compounds in sterile aqueous solution aqueous propylene glycol or sesame or peanut oil may be employed.
  • aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, syrup, phospholipids, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
  • compositions formed by combining the compounds of the inven- tion and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
  • compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically-acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulat- ing and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatine or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyc- eryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,356,108; 4,166,452; and 4,265,874, incorporated herein by reference, to form osmotic therapeutic tablets for controlled release.
  • Formulations for oral use may also be presented as hard gelatine capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatine capsule wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide such as lecithin, or condensation products of an alkyl oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example
  • the aqueous suspensions may also contain one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as a liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be pre- served by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipi- ents, for example, sweetening, flavouring, and colouring agents may also be present.
  • compositions comprising a compound for use according to the present invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example a liquid paraffin, or a mixture thereof.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
  • compositions may also contain a demulcent, preservative and flavouring and colouring agent.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known methods using suitable dispersing or wetting agents and suspend- ing agents described above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenteral ly-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conveniently employed as solvent or suspending medium. For this purpose, any bland fixed oil may be employed using synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • compositions may also be in the form of suppositories for rectal administration of the compounds of the present invention.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter and polyethylene glycols, for example.
  • compositions, ointments, jellies, solutions of suspensions, etc., containing the compounds of the present invention are contemplated.
  • topical applications shall include mouth washes and gargles.
  • the compounds for use according to the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
  • some of the compounds for use according to the present invention may form solvates with water or common organic solvents. Such solvates are also encompassed within the scope of the present invention.
  • a pharmaceutical composition comprising a compound for use according to the present invention, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable carriers, excipi- ents, or diluents.
  • the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emul- sion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain: [00382] Core: [00383] Active compound (as free compound or salt thereof) 5.0 mg [00384] Lactosum PH. Eur. 67.8 mg
  • the compounds of the invention may be administered to a patient which is a mammal, especially a human in need thereof.
  • mammals include also animals, both domestic animals, e.g., household pets, and non-domestic animals such as wildlife.
  • the present invention also relate to the below methods of preparing the compounds of the invention. [00396] The present invention is further illustrated in the following representative examples which are, however, not intended to limit the scope of the invention in any way.
  • Microwave oven synthesis The reaction was heated by microwave irradiation in sealed microwave vessels in a single mode Emrys Optimizer EXP from PersonalChemistry®.
  • Preparative HPLC Column: 1.9 x 15 cm Waters XTerra RP-18. Buffer: linear gradient 5 - 95 % in 15 min, MeCN, 0.1 % TFA, flow rate of 15 ml/min. The pooled fractions are either evaporated to dryness in vacuo, or evaporated in vacuo until the MeCN is removed, and then frozen and freeze dried.
  • CDCI 3 Deuterio chloroform
  • DIPEA Diisopropylethylamine
  • TFA Trifluoroacetic acid min: minutes hrs: hours
  • a benzyl amine (I) wherein R 2 , R 5 , R 6 , R 7 and A are defined as above to be reacted with an isocyanate (II) wherein R 10 is defined as above in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording urea (III); wherein R 2 , R 5 , R 6 , R 7 , R 10 and A are defined as above.
  • Tri-substituted urea (III) can further be reacted with an alkyl halide or mesylate (IV); wherein X is halide or OSO 2 Me and R 11 is defined above to react under basic condition (e.g.
  • a benzyl amine (I); wherein R 5 , R 6 , R 7 and A are defined as above to be reacted with an protected ethyl amine (II); wherein X is halo, Ci-C 6 alkylOS(O) 2 -, aryl-OS(O) 2 - or arylCi-C 6 alkyl0S(0) 2 - and R 26 is d-C 8 alkyl, C 3 -Ci 0 cycloalkyl, C 3 -Ci O het-cycloalkyl, C 3 -C 6 spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl, -C( O)R 12 , -S(O) n R 12 , -S(O) n NR 13 R 14 and
  • a solvent e.g. THF, DCM, DMF, NMP and the like
  • a solvent e.g. THF, DCM, DMF, NMP and the like
  • a benzyl amine (I); wherein R 5 , R 6 , R 7 and A are defined as above to be reacted with a sulphonyl halide (II); wherein m is 1 , 2 or 3 and R 26 is defined below under basic conditions (e.g. triethylamine, K 2 CO 3 , NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording cyclic sulphone amide (III); wherein m is 1 , 2 or 3 and R 5 , R 6 , R 7 and A are defined as above and R 26 is defined below.
  • basic conditions e.g. triethylamine, K 2 CO 3 , NaH and the like
  • a solvent e.g. THF, DCM, DMF, NMP and the like
  • R 26 is Ci-C 6 alkyl, aryl, hetaryl, arylCi-C 6 alkyl, hetarylCi-C 6 alkyl and Ci-C ⁇ alkyloxyCi-C ⁇ alkyI; wherein each alkyl, aryl/hetaryl group is substituted with 0-3 R 18 which is defined above.
  • Example 1-1 (General procedure (A)) N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 loctane-6-carbonyl)-benzyll-acetamide
  • Step A [4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester
  • the title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and isobutyryl chloride.
  • Example 1-5 (General procedure (A)) Piperidine-1 -carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6- carbonvD-benzyli-amide
  • the title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and piperidine-1 -carbonyl chloride.
  • Example 1-8 (General procedure (A)) 1 -Acetyl-piperidine-4-carboxylic acid methyl-
  • Example 1-11 (General procedure (A) Morpholine-4-carboxylic acid methyl-[4-(1 .S.S-trimethyl- ⁇ -aza-bicvclofS ⁇ .iioctane- ⁇ - carbonvD-benzyli-amide
  • Example 1-15 (General procedure (A)) Thiophene-2-carboxylic acid methyl-[4-(1 .S.S-trimethyl- ⁇ -aza-bicyclorS ⁇ .iioctane- ⁇ - carbonvD-benzyli-amide
  • the title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and thiophene-2-carbonyl chloride.
  • Example 1-26 (General procedure (A)) 1 -Trifluoromethyl-cvclobutanecarboxylic acid methyl- [4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1-amide
  • Example 1-31 (General procedure (A)) N-Methyl-6-morpholin-4-yl-N-r4-(1 ,3,3-trimethyl-6-aza-bicvclof3.2.1 loctane-6-ca ⁇ t)onyl)- benzyli-nicotinamide
  • the title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and ⁇ -morpholin ⁇ -yl-nicotinic acid.
  • Amount isolated 1 16 mg (58%) of the title compound as an oil.
  • Example 2-2 (General procedure (B1 )) N-Methyl-N-r4-(1 .3.3-trimethyl-6-aza-bicvclor3.2.1 loctane-6-carbonyl)-benzyll- methanesulfonamide
  • the title compound was prepared by a similar procedure as that described in Example 33, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 2,2,2-trifluoro-ethanesulfonyl chloride.
  • Step A 4-(Tetrahydro-pyran-2-yloxymethyl)-benzoic acid
  • Step B (4-Hydroxymethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone
  • Step C [4-(lsopropylamino-methyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone
  • the title compound was prepared by a similar procedure as that described in Example 46, starting from (4-ethylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and trifluoro-methanesulfonic anhydride.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)

Abstract

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Description

PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
FIELD OF INVENTION
[0001] The present invention relates to use of substituted amides and pharmaceutical compositions comprising the same for treating disorders where it is desirable to modulate the ac- tivity of 1 1 β-hydroxysteroid dehydrogenase type 1 (1 1 βHSD1 ). The present invention also relates to novel substituted amides, to their use in therapy, to pharmaceutical compositions comprising the same, to the use of said compounds in the manufacture of medicaments, and to therapeutic methods comprising the administration of the compounds. The present compounds modulate the activity of 1 1 β-hydroxysteroid dehydrogenase type 1 (1 1 βHSD1 ) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
BACKGROUND OF THE INVENTION
[0002] The metabolic syndrome is a major global health problem. In the US, the prevalence in the adult population is currently estimated to be approximately 25%, and it continues to increase both in the US and worldwide. The metabolic syndrome is characterised by a combination of insulin resistance, dyslipidemia, obesity and hypertension leading to increased morbidity and mortality of cardiovascular diseases. People with the metabolic syndrome are at increased risk of developing frank type 2 diabetes, the prevalence of which is equally escalating. [0003] In type 2 diabetes, obesity and dyslipidemia are also highly prevalent and around 70% of people with type 2 diabetes additionally have hypertension once again leading to increased mortality of cardiovascular diseases.
[0004] In the clinical setting, it has long been known that glucocorticoids are able to induce all of the cardinal features of the metabolic syndrome and type 2 diabetes. [0005] 1 1 β-hydroxysteroid dehydrogenase type 1 (1 1 βHSD1 ) catalyses the local generation of active glucocorticoid in several tissues and organs including predominantly the liver and adipose tissue, but also e.g., skeletal muscle, bone, pancreas, endothelium, ocular tissue and certain parts of the central nervous system. Thus, 1 1 βHSD1 serves as a local regulator of glucocorticoid actions in the tissues and organs where it is expressed (Tannin et al., J. Biol. Chem., 266, 16653 (1991 ); Bujalska et al., Endocrinology, UO, 3188 (1999); Whorwood et al., J. Clin Endocrinol Metab., 86, 2296 (2001 ); Cooper et al., Bone, 27, 375 (2000); Davani et al., J. Biol. Chem., 275, 34841 (2000); Brem et al., Hypertension, 31, 459 (1998); Rauz et al., Invest. Ophthalmol. Vis. ScL, 42, 2037 (2001 ); Moisan et al., Endocrinology, 127. 1450 (1990)).
[0006] The role of 1 1 βHSD1 in the metabolic syndrome and type 2 diabetes is supported by several lines of evidence. In humans, treatment with the non-specific 1 1 βHSD1 inhibitor car- benoxolone improves insulin sensitivity in lean healthy volunteers and people with type 2 diabetes. Likewise, 1 1 βHSD1 knock-out mice are resistant to insulin resistance induced by obesity and stress. Additionally, the knock-out mice present with an anti-atherogenic lipid profile of decreased VLDL triglycerides and increased HDL-cholesterol. Conversely, mice that overexpress 1 1 βHSD1 in adipocytes develop insulin resistance, hyperlipidemia and vis- ceral obesity, a phenotype that resembles the human metabolic syndrome (Andrews et al., J. Clin. Endocrinol. Metab., 88, 285 (2003); Walker et al., J. Clin. Endocrinol. Metab., 80, 3155 (1995); Morton et al., J. Biol. Chem., 276, 41293 (2001 ); Kotelevtsev et al., Proc. Natl. Acad. ScL USA, 94, 14924 (1997); Masuzaki et al., Science, 294, 2166 (2001 )). [0007] The more mechanistic aspects of 1 1 βHSD1 modulation and thereby modulation of intracellular levels of active glucocorticoid have been investigated in several rodent models and different cellular systems. 1 1 βHSD1 promotes the features of the metabolic syndrome by increasing hepatic expression of the rate-limiting enzymes in gluconeogenesis, namely phosphoenolpyuvate carboxykinase and glucose-6-phosphatase, promoting the differentiation of preadipocytes into adipocytes thus facilitating obesity, directly and indirectly stimulat- ing hepatic VLDL secretion, decreasing hepatic LDL uptake and increasing vessel contractility (Kotelevtsev et al., Proc. Natl. Acad. ScL USA, 94, 14924 (1997); Morton et al., J. Biol. Chem. 276, 41293 (2001 ); Bujalska et al., Endocrinology, t40, 3188 (1999); Souness et al., Steroids, 6_Z, 195 (2002), Brindley & Salter, Prog. Lipid Res., 30, 349 (1991 )). [0008] WO 01/90090, WO 01/90091 , WO 01/90092, WO 01/90093, and WO 01/90094 dis- closes various thiazol-sulfonamides as inhibitors of the human 1 1 β-hydroxysteroid dehydrogenase type 1 enzyme, and further states that said compounds may be useful in treating diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders and depression. [0009] We have now found substituted amides that modulate the activity of 1 1 βHSD1 lead- ing to altered intracellular concentrations of active glucocorticoid. More specifically, the present compounds inhibit the activity of 1 1 βHSD1 leading to decreased intracellular concentrations of active glucocorticoid. Thus, the present compounds can be used to treat disorders where a decreased level of active intracellular glucocorticoid is desirable, such as e.g., the metabolic syndrome, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glu- cose (IFG), dyslipidemia, obesity, hypertension, diabetic late complications, cardiovascular diseases, arteriosclerosis, atherosclerosis, myopathy, muscle wasting, osteoporosis, neurodegenerative and psychiatric disorders, and adverse effects of treatment or therapy with glucocorticoid receptor agonists. [0010] One object of the present invention is to provide compounds, pharmaceutical compositions and use of compounds that modulate the activity of 1 1 βHSD1.
DEFINITIONS
[0011] In the following structural formulas and throughout the present specification, the following terms have the indicated meaning. The examples provided in the definitions present in this application are non-inclusive unless otherwise stated. They include but are not limited to the recited examples.
[0012] The term "halo" includes fluorine, chlorine, bromine, and iodine. [0013] The term "trihalomethyl" includes trifluoromethyl, trichloromethyl, tribromomethyl, and triiodomethyl. [0014] The term "trihalomethoxy" includes trifluorometoxy, trichlorometoxy, tribromometoxy, and triiodometoxy.
[0015] The term "alkyl" includes CrC8 straight chain saturated and methylene aliphatic hydrocarbon groups and C3-C8 branched saturated hydrocarbon groups having the specified number of carbon atoms. For example, this definition includes methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, isopropyl (i-Pr), isobutyl (i-Bu), te/t-butyl (f-Bu), sec-butyl (s- Bu), isopentyl, and neopentyl.
[0016] The term "alkenyl" includes C2-C6 straight chain unsaturated aliphatic hydrocarbon groups and branched C3-C6 unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, this definition includes ethenyl, propenyl, butenyl, pentenyl, hexenyl, methylpropenyl, and methylbutenyl.
[0017] The term "alkynyl" includes C2-C6 straight chain unsaturated aliphatic hydrocarbon groups and C4-C6 branched unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, this definition includes ethynyl, propynyl, butynyl, pentynyl, hexynyl, and methylbutynyl. [0018] The term "saturated or partially saturated monocyclic, bicyclic, or tricyclic ring system" represents but is not limited to aziridinyl, azepanyl, azocanyl, pyrrolinyl, pyrrolidinyl, 2- imidazolinyl, imidazolidinyl, 2-pyrazolinyl, morpholinyl, piperidinyl, thiomorpholinyl, piperaz- inyl, phthalimide, 1 ,2,3,4-tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydro-isoquinolinyl, 1 ,2,3,4- tetrahydro-quinoxalinyl, indolinyl, 1 , 6-aza-bicyclo[3.2.1 ]octane, 2-aza-bicyclo[4.1 .1 ]octane, 2-aza-bicyclo[3.2.1]octanyl, 7-aza-bicyclo[4.1 .1]octanyl, 9-aza-bicyclo[3.3.2]decanyl, 4-aza- tricyclo[4.3.1 .13 8]undecanyl, 9-aza-tricyclo[3.3.2.03'7]decanyl.
[0019] The term "saturated or partially saturated ring" represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooc- tenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, and tetrahydropyranyl.
[0020] The term "saturated or partially saturated aromatic ring" represents cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, and pyrimid- inyl. [0021] The term "cycloalkyl" represents a saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[3.2.1 ]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, and adamantyl). [0022] The term "cycloalkylalkyl" represents a cycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms or substituted alkyl group as defined above (e.g., cyclopropylmethyl, cyclobutylethyl, and adamantylmethyl). [0023] The term "cycloalkenyl" represents a partially saturated, mono-, bi-, tri- or spirocarbocyclic group having the specified number of carbon atoms (e.g., cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl). [0024] The term "cycloalkylcarbonyl" represents a cycloalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., cyclopropylcarbonyl and cyclohexylcarbonyl).
[0025] The term "cycloalkylalkylcarbonyl" represents a cycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms or substituted alkyl group as defined above (e.g., cyclohexylmethylcarbonyl and cycloheptylethylcarbonyl). [0026] The term "hetcycloalkyl" represents a saturated mono-, bi-, tri-, or spirocarbocyclic group having the specified number of atoms with 1 -4 of the specificied number being het- eroatoms or groups selected from nitrogen, oxygen, sulphur, and S(O)m (m=0-2)(e.g., tetrahydrofuranyl, tetrahydropyranyl, tertahydrothiopyranyl, piperidine, and pyridzine). [0027] The term "hetcycloalkylalkyl" represents a hetcycloalkyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., tetrahydro- furanylmethyl, tetrahydropyranylethyl, and tertahydrothiopyranylmethyl). [0028] The term "hetcycloalkylcarbonyl" represents a hetcycloalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., 1 - piperidin-4-yl-carbonyl and 1 -(1 ,2,3,4-tetrahydro-isoquinolin-6-yl)carbonyl). [0029] The term "alkyloxy" represents an alkyl group having the indicated number of carbon atoms attached through an oxygen bridge (e.g., methoxy, ethoxy, propyloxy, allyloxy, and cyclohexyloxy).
[0030] The term "alkyloxyalkyl" represents an alkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., methyloxymethyl). [0031] The term "aryl" includes a carbocyclic aromatic ring that is monocyclic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, and biphenylenyl. Aryl also includes the partially hydrogenated derivatives of the carbocyclic aromatic enumerated above. Examples of partially hydrogenated de- rivatives include 1 ,2,3,4-tetrahydronaphthyl and 1 ,4-dihydronaphthyl.
[0032] The term "hetaryl" includes pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1 - imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazol-1 -yl, 1 ,2,3-triazol-2- yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thio- phenyl (2-thiophenyl, 3-thiophenyl, 4-thiophenyl, 5-thiophenyl), furanyl (2-furanyl, 3-furanyl, 4-furanyl, 5-furanyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl), 5-tetrazolyl, pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1 -isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6- isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3- benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo-[b]furanyl), 6-(2,3-dihydro-benzo- [b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl)), 1 ,4-benzodioxin (2-(1 ,4-benzodioxin), 3-(1 ,4- benzodioxin), 5-(1 ,4-benzodioxin), 6-(1 ,4-benzodioxin), 7-(1 ,4-benzodioxin), 8-(1 ,4- benzodioxin)), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4- benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3- dihydro-benzo[b]thiophenyl (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro- benzo[b]thiophenyl), 4-(2,3-dihydrobenzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl)), 4,5,6,7-tetrahydro- benzo[b]thiophenyl (2-(4,5,6,7-tetrahydro-benzo[b]thiophenyl), 3-(4,5,6,7-tetrahydro- benzo[b]thiophenyl), 4-(4,5,6,7-tetrahydro-benzo[b]thiophenyl), 5-(4,5,6,7-tetrahydro- benzo[b]thiophenyl), 6-(4,5,6,7-tetrahydro-benzo[b]thiophenyl), 7-(4,5,6,7-tetrahydro- benzo[b]thiophenyl)), thieno[2,3-b]thiophenyl, 4,5,6,7-tetrahydro-thieno[2,3-c]pyridyl (4- (4,5,6,7-tetrahydro-thieno[2,3-c]pyridyl), 5-4,5,6,7-tetrahydro-thieno[2,3-c]pyridyl), 6-(4, 5,6,7- tetrahydro-thieno[2,3-c]pyridyl), 7-(4,5,6,7-tetrahydro-thieno[2,3-c]pyridyl)), indolyl (1 -indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), isoindolyl (1 -isoindolyl, 2- isoindolyl, 3-isoindolyl, 4-isoindolyl, 5-isoindolyl, 6-isoindolyl, 7-isoindolyl), 1 ,3-dihydro- isoindolyl (1 -(1 ,3-dihydro-isoindolyl), 2-(1 ,3-dihydro-isoindolyl), 3-(1 ,3-dihydro-isoindolyl), A- (1 ,3-dihydro-isoindolyl), 5-(1 ,3-dihydro-isoindolyl), 6-(1 ,3-dihydro-isoindolyl), 7-(1 ,3-dihydro- isoindolyl)), indazole (1 -indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7- indazolyl), benzimidazolyl (1 -benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5- benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1 - benz-oxazolyl, 2-benzoxazolyl), benzothiazolyl (1 -benzothiazolyl, 2-benzothiazolyl, A- benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), benzo-
[1 ,2,5]oxadiazolyl, (4-benzo[1 ,2,5]oxadiazole, 5-benzo[1 ,2,5]oxadiazole), carbazolyl (1 - carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), piperidinyl (2-piperidinyl, 3-piperidinyl, A- piperidinyl), and pyrrolidinyl (1 -pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl). [0033] The term "arylalkyl" represents an aryl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., benzyl, phenylethyl, 3- phenylpropyl, 1 -naphtylmethyl, and 2-(1 -naphtyl)ethyl).
[0034] The term "hetarylalkyl" or "hetaralkyl" represents a hetaryl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, and 1 - methyl-1 -(2-pyrimidyl)ethyl).
[0035] The term "aryloxyhetaryl" represents an aryloxy group as defined above attached through a hetaryl group (e.g., 2-phenoxy-pyridyl).
[0036] The term "aryloxy" represents an aryl group as defined above attached through an oxygen bridge (e.g., phenoxy and naphthyloxy). [0037] The term "hetaryloxy" represents a hetaryl group as defined above attached through an oxygen bridge (e.g., 2-pyridyloxy).
[0038] The term "arylalkyloxy" represents an arylalkyl group as defined above attached through an oxygen bridge (e.g., phenethyloxy and naphthylmethyloxy). [0039] The term "hetarylalkyloxy" represents a hetarylalkyl group as defined above attached through an oxygen bridge (e.g., 2-pyridylmethyloxy).
[0040] The term "alkyloxycarbonyl" represents an alkyloxy group as defined above attached through a carbonyl group (e.g., methylformiat and ethylformiat).
[0041] The term "aryloxycarbonyl" represents an aryloxy group as defined above attached through a carbonyl group (e.g., phenylformiat and 2-thiazolylformiat). [0042] The term "arylalkyloxycarbonyl" represents an "arylalkyloxy" group as defined above attached through a carbonyl group (e.g., benzylformiat and phenyletylformiat). [0043] The term "alkylthio" represents an alkyl group having the indicated number of carbon atoms attached through a sulphur bridge (e.g., methylthio and ethylthio). [0044] The term "arylthio" represents an aryl group as defined above attached through a sulphur bridge (e.g., benzenthiol and naphthylthiol).
[0045] The term "hetarylthio" represents a hetaryl group as defined above attached through a sulphur bridge (e.g., pyridine-2-thiol and thiazole-2-thiol). [0046] The term "arylthioalkyl" represents an arylthio group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., methylsulfanyl benzene, and ethylsulfanyl naphthalene).
[0047] The term "hetarylthioalkyl" represents a hetarylthio group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 2-methylsulfanyl- pyridine and 1 -ethylsulfanyl-isoquinoline). [0048] The term "hetaryloxyaryl" represents a hetaryloxy group as defined above attached through an aryl group as defined above (e.g., 1 -phenoxy-isoquinolyl and 2-phenoxypyridyl). [0049] The term "hetaryloxyhetaryl" represents a hetaryloxy group as defined above attached through a hetaryl group as defined above (e.g., 1 -(2-pyridyloxy-isoquinoline) and 2- (imidazol-2-yloxy-pyridine)). [0050] The term "aryloxyalkyl" represents an aryloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., phenoxymethyl and naphthyloxyethyl).
[0051] The term "aryloxyaryl" represents an aryloxy group as defined above attached through an aryl group as defined above (e.g., 1 -phenoxy-naphthalene and phenyloxyphenyl). [0052] The term "arylalkyloxyalkyl" represents an arylalkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., ethoxy- methyl-benzene and 2-methoxymethyl-naphthalene).
[0053] The term "hetaryloxyalkyl" represents a hetaryloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 2- pyridyloxymethyl and 2-quinolyloxyethyl).
[0054] The term "hetarylalkyloxyalkyl" represents a hetarylalkyloxy group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., A- methoxymethyl-pyrimidine and 2-methoxymethyl-quinoline). [0055] The term "alkylcarbonyl" represents an alkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., octylcarbonyl, pen- tylcarbonyl, and 3-hexenylcarbonyl).
[0056] The term "arylcarbonyl" represents an aryl group as defined above attached through a carbonyl group (e.g., benzoyl).
[0057] The term "hetarylcarbonyl" represents a hetaryl group as defined above attached through a carbonyl group (e.g., 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, and oxa- zolylcarbonyl).
[0058] The term "carbonylalkyl" represents a carbonyl group attached through an alkyl group having the indicated number of carbon atoms (e.g., acetyl).
[0059] The term "alkylcarbonylalkyl" represents an alkylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., propane- one and 4,4-dimethyl-pentan-2-one). [0060] The term "arylcarbonylalkyl" represents a arylcarbonyl group as defined above at- tached through an alkyl group having the indicated number of carbon atoms (e.g., 1 -phenyl- propan-1 -one and 1 -(3-chloro-phenyl)-2-methyl-butan-1 -one).
[0061] The term "hetarylcarbonylalkyl" represents a hetarylcarbonyl group as defined above attached through an alkyl group having the indicated number of carbon atoms (e.g., 1 - pyridin-2-yl-propan-1 -one and 1 -(1 -H-imidazol-2-yl)-propan-1 -one). [0062] The term "arylalkylcarbonyl" represents an arylalkyl group as defined above having the indicated number of carbon atoms attached through a carbonyl group (e.g., phenylpro- pylcarbonyl and phenylethylcarbonyl).
[0063] The term "hetarylalkylcarbonyl" represents a hetarylalkyl group as defined above wherein the alkyl group is in turn attached through a carbonyl (e.g., imidazolylpentylcar- bonyl).
[0064] The term "alkylcarbonylamino" represents an "alkylcarbonyl" group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group (e.g., methylcarbonylamino, cyclopentylcarbonyl-aminomethyl, and methylcarbonylaminophenyl). The nitrogen atom may itself be substituted with an alkyl or aryl group. [0065] The term "alkylcarbonylaminoalkyl" represents an "alkylcarbonylamino" group attached through an alkyl group having the indicated number of carbon atoms (e.g.N-propyl- acetamide and N-butyl-propionamide).
[0066] The term "arylalkylcarbonylamino" represents an "arylalkylcarbonyl" group as defined above attached through an amino group (e.g., phenylacetamide and 3-phenyl-propionamide). [0067] The term "arylalkylcarbonylaminoalkyl" represents an "arylalkylcarbonylamino" group attached through an alkyl group having the indicated number of carbon atoms (e.g., N-ethyl- phenylacetamide and N-butyl-3-phenyl-propionamide).
[0068] The term "arylcarbonylamino" represents an "arylcarbonyl" group as defined above attached through an amino group (e.g., benzamide and naphthalene-1 -carboxylic acid amide).
[0069] The term "arylcarbonylaminoalkyl" represents an "arylcarbonylamino" group attached through an alkyl group having the indicated number of carbon atoms (e.g., N-propyl- benzamide and N-butyl-naphthalene-1 -carboxylic acid amide). [0070] The term "alkylcarboxy" represents an alkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., heptylcarboxy, cyclopropyl- carboxy, and 3-pentenylcarboxy).
[0071] The term "arylcarboxy" represents an arylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., benzoic acid). [0072] The term "alkylcarboxyalkyl" represents an alkylcarboxy group as defined above wherein the oxygen is attached via an alkyl bridge (e.g., heptylcarboxymethyl, propylcarboxy te/t-butyl, and 3-pentylcarboxyethyl).
[0073] The term "arylalkylcarboxy" represents an arylalkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., benzylcarboxy and phenylpropylcarboxy).
[0074] The term "arylalkylcarboxyalkyl" represents an arylalkylcarboxy group as defined above wherein the carboxy group is in turn attached through an alkyl group having the indicated number of carbon atoms (e.g., benzylcarboxymethyl and phenylpropylcarboxypropyl). [0075] The term "hetarylcarboxy" represents a hetarylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., pyridine-2-carboxylic acid).
[0076] The term "hetarylalkylcarboxy" represents a hetarylalkylcarbonyl group as defined above wherein the carbonyl is in turn attached through an oxygen bridge (e.g., (1 -H-imidazol- 2-yl)-acetic acid and 3-pyrimidin-2-yl-propionic acid). [0077] The term "alkylS(O)m" represents an alkyl group having the number of indicated carbon atoms, wherein the alkyl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms (m=0-2)(e.g., ethylsulfonyl and ethylsulfinyl). [0078] The term "arylS(O)m" represents an aryl group as defined above, wherein the aryl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms (m=0-2)(e.g., phenylsulfinyl and naphthyl-2-sulfonyl). [0079] The term "hetarylS(O)m" represents a hetaryl group as defined above, wherein the hetaryl group is in turn attached through a sulphur bridge wherein the sulphur is substituted with m oxygen atoms (m=0-2)(e.g., thiazol-2-sulfinyl and pyridine-2-sulfonyl). [0080] Certain of the above defined terms may occur more than once in the structural formu- lae, and upon such occurrence each term shall be defined independently of the other. [0081] The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different. [0082] The term "treatment" or "treating" is defined as the management and care of a patient for the purpose of combating or alleviating the disease, condition, or disorder, and the term includes the administration of the active compound to prevent or delay the onset of the symptoms or complications; alleviating (both temporary and permanent) the symptoms or complications; and/or eliminating the disease, condition, or disorder. Thus, "treatment" or "treating" includes prevention and/or prophylaxis of the disease, condition, or disorder.
[0083] The term "pharmaceutically acceptable" is defined as being suitable for administration to humans without adverse events.
[0084] The term "prodrug" is defined as a chemically modified form of the active drug, said prodrug being administered to the patient and subsequently being converted to the active drug. Techniques for development of prodrugs are well known in the art.
DETAILED DESCRIPTION OF THE INVENTION
[0085] Thus, in an embodiment, the present invention provides a novel substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the compound is of formula I:
Figure imgf000011_0001
[0086] wherein:
[0087] R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-; [0088] R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
[0089] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetaryld-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18;
[0090] Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
[0091] Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano, Ci-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl or d-C6alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R18;
[0092] R5 is selected from H, d-C6alkyl, C3-C6cycloalkyl, halo, OH, and cyano;
[0093] R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and triha- lomethoxy;
[0094] alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, d-C6alkyl, oxo, and d-C6alkyloxy;
[0095] R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetaryl- Ci-C6alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, hetary- loxyCi-C6alkyl, arylCi-CealkyloxyCi-Cealkyl, and hetarylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
[0096] R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCrC6alkyl, hetaryl- Ci-C6alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyCi-C6alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20;
[0097] R10 and R11 are independently selected from H, d-C8alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
[0098] alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, hydroxy, oxo, COOH, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-C6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6al- kyl-carboxy, and hetaryld-C6alkylcarboxy;
[0099] R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, Ci-C8alkyloxy, aryl, arylCi-C6alkyl, hetaryl, hetarylCi-C6alkyl, aryloxy, hetary- loxy, and NR13R14;
[00100] R13 and R14 are independently selected from H, CrC8alkyl, C3-Ci ocycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
[00101] alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring con- sisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, aryld-Cealkylcarbonyl, hetaryld-Cealkylcarbonyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
[00102] R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
[00103] R16 and R17 are independently selected from H, d-C8alkyl, C3-Ci0cycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, Ci-C8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22;
[00104] R18 is selected from halo, OH, oxo, COOH, cyano d-C6alkyloxy, C3-Ci0cyclo- alkyloxy, aryloxy, hetaryloxy, hetarylthio and arylCi-C6alkyloxy;
[00105] R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendioxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
[00106] R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy,
NR23R24, methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
[00107] R23 and R24 are independently selected from H, CrC8alkyl, and arylCi-C6alkyl;
[00108] m is selected from 0, 1 , and 2;
[00109] n is selected from 1 and 2;
[00110] Y is selected from O and S;
[00111] or a salt thereof with a pharmaceutically acceptable acid or base, or any optical iso- mer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms. [00112] In another embodiment, the present invention provides the novel substituted amides of formula I, wherein:
[00113] R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
[00114] R2 is Ci-C4alkyl;
[00115] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCrC6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkyl- carboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18;
[00116] Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
[00117] Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkyl or Ci-C4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
[00118] R5 is H;
[00119] R6 and R7 are independently selected from H and CrC4alkyl; and,
[00120] n is 2.
[00121] In another embodiment, the present invention provides the novel substituted amides of formula I, wherein:
[00122] R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-; [00123] R2 is Ci-C4alkyl;
[00124] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 1 -2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkyl- carboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18;
[00125] Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
[00126] Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, d-C4alkyloxy, d-dalkyloxyd-dalkyl or Ci-C4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
[00127] R5 is H;
[00128] R6 and R7 are independently selected from H and d-C4alkyl; and,
[00129] n is 2.
[00130] In another embodiment, the present invention provides the novel substituted amides of formula I, wherein:
[00131] R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
[00132] R2 is selected from H, CrC4alkyl and C3-C6cycloalkyl; [00133] Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
[00134] Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkyl or Ci-C4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
[00135] R5 is H;
[00136] R6 and R7 are independently selected from H and CrC4alkyl; and,
[00137] n is 2.
[00138] In another embodiment, the present invention provides the novel substituted amides of formula I, wherein:
[00139] R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
[00140] R2 is Ci-C4alkyl.
[00141] [3] In another embodiment, the present invention provides the novel substituted amides of formula I ovel use of compounds of formula I, wherein:
[00142] R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkyl, hetarylCrC4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCi-C4alkyl, and hetaryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
[00143] R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkyl, hetarylCrdalkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20; [00144] R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
[00145] alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
[00146] R12 is selected from OH, CrC4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, CrC4alkyloxy, aryl, arylCi-C4alkyl, hetaryl, hetarylCi-C4alkyl, aryloxy, and hetaryloxy;
[00147] R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, d-C4alkyloxy, aryl, hetaryl, arylCrC4alkyl, hetarylCrC4alkyl, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
[00148] n is 2.
[00149] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula Ia:
Figure imgf000018_0001
Ia.
[00150] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula Ib:
Figure imgf000019_0001
Ib.
[00151] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula Ic:
Figure imgf000019_0002
Ic.
[00152] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula Id:
Figure imgf000019_0003
Id.
[00153] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula Ie:
Figure imgf000020_0001
Ie.
[00154] In another embodiment, the present invention provides the novel substituted amide formula I, wherein:
[00155] R1 and R2, together with the nitrogen to which they are attached, form a 5-12 mem- bered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCrC6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18.
[00156] In another embodiment, the present invention provides the novel substituted amide formula I, wherein R1 and R2, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 1 -3 groups selected from d-C8alkyl, C3-Ci0cycloalkyl, C3-Ciohetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, aryld-C6alkyl, hetaryld-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetaryld-C6alkyloxy, d-Cealkyloxyd-dalkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, aryld-dalkylcarboxy, and hetaryld-dalkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18.
[00157] In another embodiment, the present invention provides the novel substituted amide formula I, wherein R1 and R2, together with the nitrogen to which they are attached, form a 5 membered saturated ring consisting of the shown nitrogen, 2-3 carbon atoms, and 0-2 addi- tional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, d-C6alkyloxy, arylCrC6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarboxy, arylcar- boxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each al- kyl and aryl/hetaryl group is substituted with 0-3 R18.
[00158] In another embodiment, the present invention provides the novel substituted amide formula I, wherein R1 and R2, together with the nitrogen to which they are attached, form a 5 membered saturated ring consisting of the shown nitrogen, 2-3 carbon atoms, and 1 -2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, aryld-C6alkyl, hetaryld-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarboxy, arylcar- boxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each al- kyl and aryl/hetaryl group is substituted with 0-3 R18.
[00159] In another embodiment, the present invention provides the novel substituted amide formula I, wherein R1 and R2, together with the nitrogen to which they are attached, form a 5 membered saturated ring consisting of the shown nitrogen, 2-3 carbon atoms, and 1 -2 additional heteroatoms selected from nitrogen and S(O)n, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-CealkyloxyCi-Cealkyl, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18.
[00160] In another embodiment, the present invention provides the novel substituted amide formula I, wherein R1 and R2, together with the nitrogen to which they are attached, are:
ΓΛ ΓΛ
NN^N N N
Il om wherein this ring is substituted with 0-2 groups selected from CrC8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-CealkyloxyCi-Cealkyl, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18. [00161] In another embodiment, the present invention provides the novel substituted amide of formula I, wherein Ring A is selected from:
Figure imgf000022_0001
[00162] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, C(=O)R12, and d-C6alkyloxy, wherein R12 is as defined above..
[00163] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein Ring A is selected from:
Figure imgf000022_0002
[00164] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
[00165] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000022_0003
[00166] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy. [00167] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000023_0001
[00168] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hy- droxy, oxo, cyano, and d-C6alkyloxy.
[00169] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000023_0002
[00170] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
[00171] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000023_0003
[00172] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
[00173] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000023_0004
[00174] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy. [00175] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000024_0001
[00176] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hy- droxy, oxo, cyano, and d-C6alkyloxy.
[00177] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000024_0002
[00178] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
[00179] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000024_0003
[00180] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
[00181] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is
Figure imgf000024_0004
[00182] Ring A is substituted with 0-2 R25; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
[00183] In another embodiment, the present invention provides the novel substituted amide or prodrug thereof of formula I, wherein ring A is azepane. [00184] In another embodiment, the present invention provides the novel compounds of formula I, wherein the substituted amide or a prodrug thereof is of the selected from the group: N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isobutyramide
Cyclopentanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
Cyclohexanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i Joctane-θ- carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-amide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- benzamide i -Acetyl-piperidine^-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide 1 -Acetyl-piperidine-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
Cyclopentanecarboxylic acid ethyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iloctane-θ- carbonyl)-benzyl]-amide
2,2-N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- propionamide
Tetrahydro-furan-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-4-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
Thiophene-2-carboxylic acid methyl-[4-(1 .S.S-trimethyl-θ-aza-bicyclop^.iJoctane-θ- carbonyl)-benzyl]-amide
Furan-2-carboxylic acid methyl-[4-(1 .S.S-trimethyl-θ-aza-bicyclop^.iJoctane-θ- carbonyl)-benzyl]-amide 3-Chloro-4-(propane-2-sulfonyl)-thiophene-2-carboxylic acid methyl-[4-(1 ,3,3- trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-amide
6-Chloro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-nicotinamide δ-Methyl-isoxazole-S-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,3,N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- butyramide
3-Cyano-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
N-Methyl-2-phenoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- malonamic acid methyl ester
3-Methyl-but-2-enoic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
N-Methyl-2-phenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
1 -Trifluoromethyl-cyclobutanecarboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,5-Dimethoxy-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
4-Methanesulfonyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-Methyl-3-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
2,2-Difluoro-1 ,3-benzodioxole-4-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-6-morpholin-4-yl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-nicotinamide
N-Methyl-4-(2,2,2-trifluoro-acetyl)-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-benzamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isophthalamic acid 2,3-Dihydro-benzofuran-7-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3-Acetyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
1 ,1 ,3-Trimethyl-3-[4-(1 ,3,3-trimethyl-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- sulphonylurea
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
2,2,2-Trifluoro-ethanesulfonic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methylphenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-isopropyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Cyclopropyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Ethyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
3-Benzoyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea
3-Cyclohexyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea
3-(4-methy-phenyl)sulfonyl-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-
6-carbonyl)-benzyl]-urea
1 ,3-Dimethyl-3-phenyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- benzyl]-urea
3-(2,3-Dihydro-1 ,4-benzodioxin-2-ylmethyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(3-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, 3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea 3-(1 ,1 -Dioxo-tetrahydro-thiophen-3-yl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(tetrahydro-pyran-4-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]-octane-6- carbonyl)-benzyl]-urea
{1 ,3-Dimethyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-acetic acid methyl ester
1 -Methyl-3-(5-trif luoromethyl-1 ,3,4-thiadiazol-2-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
2-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-arbonyl)-benzyl]- ureidoj-benzoic acid methyl ester
3-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-benzoic acid ethyl ester
1 -Methyl-3-(3-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
3-(4-Benzyloxy-phenyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Acetyl-phenyl)-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-icyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Acetyl-phenyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Cyano-phenyl)-1 -methyl-1 -[4-(1 , 3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(2,2,4,4-tetrafluoro-4H-benzo-[1 ,3]dioxin-6-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methoxy-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-urea 1 -Methyl-3-[4-(2,2,2-trifluoro-acetyl)-cyclohexyl]-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -(4-Acetyl-phenyl)-1 ,3-dimethyl-3-[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Phenyl-3-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclopropyl}-urea
Piperidine-1 -carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]- amide
Morpholine-4-carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
1 ,3-Dimethyl-3-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-1 -phenyl-urea i -^-β-Aza-bicyclo-β^^nonane-S-carbonyO-benzyll-i jS-dimethyl-S-phenyl-urea
Piperidine-1 -carboxylic acid [4-(6-aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]- methyl-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]octane-3- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid [4-(6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ΛS-trimethyl-S-aza-bicycloβ^.il-octane-S- carbonyl)-benzyl]-amide
1 -[4-(6-Aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl-urea
1 ,3-Dimethyl-1 -phenyl-3-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carbonyl)- benzyl]-urea
Piperidine-1 -carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3- phenyl-urea
1 -[4-(3-Fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3-phenyl- urea Piperidine-1 -carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyridin-2-yl-ureidomethyl)-benzamide
^^-(S-Aza-bicyclotS^^lnonane-S-carbonyO-benzyll-i ^-dimethyl-S-pyridin^-yl-urea
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyridin-
2-yl-urea
Morpholine-4-carboxylic acid [4-(adamantan-2-ylcarbamoyl)-benzyl]-methyl-amide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-thiazol-2-yl-urea
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-carbonyl)-benzyl]-1 -thiazol-2- yl-urea
4-[3-(1 -Acetyl-piperidin-4-yl)-1 ,3-dimethyl-ureidomethyl]-N-adamantan-2-yl-benzamide
1 -(1 -Acetyl-piperidin-4-yl)-3-[4-(3-aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3- dimethyl-urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyrimidin-2-yl-ureidomethyl)-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyrimidin-2-yl- urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-thiazol-2-yl-ureidomethyl)-benzamide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-phenyl-ureidomethyl)-benzamide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3- pyrimidin-2-yl-urea
N-Adamantan-2-yl-4-[3-(4-hydroxy-cyclohexyl)-1 ,3-dimethyl-ureidomethyl]-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-hydroxy-cyclohexyl)-1 ,3- dimethyl-urea
1 -(4-Hydroxy-cyclohexyl)-1 ,3-dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-urea
1 -Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-imidazo- lidin-2-one
[4-(1 ,1 -Dioxo-isothiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- oct-6-yl)-methanone [4-(1 ,1 -Dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-bicyclo[3.2.1]oct-
6-yl)-methanone
[4-(5-Methyl-1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl- bicyclo[3.2.1]oct-6-yl)-methanone
(Octahydro-quinolin-1 -yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(4-Aza-tricyclo[4.3.1 .13 8]-undec-4-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)- phenyl]-methanone
(Octahydro-isoquinolin-2-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(3-Aza-bicyclo[3.2.2]non-3-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(6-Aza-bicyclo[3.2.1 ]oct-6-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
[4-(5-Benzyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]oct-6-yl)-methanone
[00185] or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
[00186] In another embodiment, the present invention provides the novel compounds of formula I, wherein the substituted amide or a prodrug thereof is the selected from the group : [4-(1 -Amino-cyclopropyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)- methanone
Piperidine-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-amide
N-Methyl-N-[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1]-octane-6-carbonyl)-benzyl]- butyramide
N-Methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide N-[4-(3-Aza-bicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-N-methyl-benzamide 3-Cyano-N-methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide N-[4-(3-Azabicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-3-cyano-N-methyl-benzamide 3-Fluoro-N-methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide N-[4-(3-Aza-bicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-3-fluoro-N-methyl-benzamide N-[4-(Azepane-1 -carbonyl)-benzyl]-3-fluoro-N-methyl-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-N-methyl-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-3-cyano-N-methyl-benzamide
Piperidine-1 -carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
N-[4-(Octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide
N-[4-(3-Azabicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-N-methyl-benzamide
4-[(Benzoyl-methyl-amino)-methyl]-N-(3-hydroxy-adamantan-1 -yl)-benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-3-cyano-N-methyl-benzamide
4-[(3-Cyano-benzoyl-methyl-amino)-methyl]-N-(3-hydroxy-adamantan-1 -yl)- benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-3-fluoro-N-methyl-benzamide
4-[(3-Fluoro-benzoyl-methyl-amino)-methyl]-N-(3-hydroxy-adamantan-1 -yl)-benzamide
1 -Acetyl-piperidine^-carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)- benzyl]-amide
N-[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl-benzamide
3-Fluoro-N-methyl-N-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]octane-3-carbonyl)- benzyl]-benzamide
3-Fluoro-N-[4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
N-Methyl-N-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]-octane-3-carbonyl)-benzyl]- benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-benzamide
N-[4-(1 ,8,8-Trimethyl-3-aza-bicyclo[3.2.1]octane-3-carbonyl)-benzyl]-benzamide
N-[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-benzamide
1 -Acetyl-piperidine^-carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
4-(Benzoylamino-methyl)-N-(3-hydroxy-adamantan-1 -yl)-benzamide
3-Cyano-N-methyl-N-[4-(1 ,8,8-trimethyl-3-aza-bi-cyclo[3.2.1 ]octane-3-car-bonyl)- benzyl]-benzamide
3-Cyano-N-[4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
3-Fluoro-N-[4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
4-(3-Fluoro-benzoylamino-methyl)-N-methly-N-(3-fluoro-adamantan-1 -yl)-benzamide
4-(3-Cyano-benzoylamino-methyl)-N-methly-N-(3-fluoro-adamantan-1 -yl)-benzamide i -Acetyl-piperidine^-carboxylic acid methyl-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]- octane-3-carbonyl)-benzyl]-amide
N-[4-(3-Fluoro-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl-benzamide
4-[(Benzoyl-methyl-amino)-methyl]-N-(3-fluoro-adamantan-1 -yl)-benzamide
3-Cyano-N-[4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
4-(Benzoylamino-methyl)-N-(3-fluoro-adamantan-1 -yl)-benzamide
1 -Acetyl-piperidine^-carboxylic acid [4-(3-aza-bicyclo[3.2.2]nonane-3-carbonyl)- benzyl]-methyl-amide
N-[4-(3-Fluoro-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-benzamide
4-(3-Cyano-benzoylamino-methyl)-N-(adamantan-2-yl)-benzamide
4-(3-Fluoro-benzoylamino-methyl)-N-(adamantan-2-yl)-benzamide
N-[4-(4-Azatricyclo-[4.3.1 .1 *3,8*]undecane-4-carbonyl)-benzyl]-3-fluoro-N-methyl- benzamide
N-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo-propyl}- benzamide
N-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo-propyl}- acetamide
4-Methanesulfonyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- phenyl]-cyclo-propyl}-benzamide
N-Methyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclo-propyl}-benzamide
N-Methyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclo-propyl}-acetamide
4-Methanesulfonyl-N-methyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-phenyl]-cyclo-propyl}-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-N-methyl-methane-sulfonamide N-[4-(3-Aza-bicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-N-methyl-methane-sulfonamide N-Methyl-N-[4-(1 ,8,8-tri-methyl-3-aza-bicyclo[3.2.1]-octane-3-carbonyl)-benzyl]- methane-sulfonamide N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-N-methyl-methane-sulfonamide
N-[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- methanesulfonamide
N-Methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-methanesulfon-amide
N-(3-Hydroxy-adamantan-1 -yl)-4-[(methanesulfonyl-methyl-amino)-methyl]-benzamide
N-(3-Fluoro-adamantan-1 -yl)-4-[(methanesulfonyl-methyl-amino)-methyl]-benzamide
N-[4-(3-Fluoro-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl-methane- sulfonamide
N-Adamantan-2-yl-4-[(methanesulfonyl-methyl-amino)-methyl]-benzamide
N-(4-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo- propylsulfamoyl}-phenyl)-acetamide
4-Chloro-N-{1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclo-propylj-benzene-sulfonamide
1 -Methyl-1 H-imidazole-4-sulfonic acid {1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]- octane-6-carbonyl)-phenyl]-cyclopropyl}-amide
N-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo-propyl}- ethanesulfonamide
1 -[4-(Azepane-1 -carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl-urea
Piperidine-1 -carboxylic acid [4-(3-hydroxy-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide
Morpholine-4-carboxylic acid [4-(3-hydroxy-adamantan-1 -yl-carbamoyl)-benzyl]- methyl-amide
4-(1 ,3-Dimethyl-3-phenyl-ureidomethyl)-N-(3-hydroxy-adamantan-1 -yl)-benzamide
Piperidine-1 -carboxylic acid [4-(3-fluoro-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide
Morpholine-4-carboxylic acid [4-(3-fluoro-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide
4-(1 ,3-Dimethyl-3-phenyl-ureidomethyl)-N-(3-fluoro-adamantan-1 -yl)-benzamide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyridin-2-yl-ureidomethyl)-benzamide
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-carbonyl)-benzyl]-1 -pyridin-2- yl-urea
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-thiazol-
2-yl-urea 1 -(1 -Acetyl-piperidin-4-yl)-1 ,3-dimethyl-3-[4-(2-oxa-5-aza-icyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-urea
1 -(1 -Acetyl-piperidin-4-yl)-3-[4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]-octane-8-carbonyl)- benzyl]-1 ,3-dimethyl-urea
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-arbonyl)-benzyl]-1 -pyrimidin- 2-yl-urea
Morpholine-4-carboxylic acid [4-(4-aza-tricyclo[4.3.1 .1 *3,8*]-undecane-4-carbonyl)- benzyl]-methyl-amide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-3-(4-hydroxy- cyclohexyl)-1 ,3-dimethyl-urea
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-fluoro-cyclohexyl)-1 ,3- dimethyl-urea
N-Adamantan-2-yl-4-[3-(1 -cyclopropyl-piperidin-4-yl)-1 ,3-dimethyl-ureidomethyl]- benzamide
1 -[4-(3-Methoxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl- urea
N-Adamantan-2-yl-4-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1 -ylmethyl]-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-fluoro-phenyl)-imidazolidin-
2-one
1 -(4-Fluoro-phenyl)-3-[4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]- imidazolidin-2-one
N-Adamantan-2-yl-4-(2-oxo-3-phenyl-imidazolidin-1 -ylmethyl)-benzamide
N-Adamantan-1 -yl-4-(1 ,1 -dioxo~[1 ,2,5]thiadiazolidin-2-ylmethyl) -benzamide
N-Adamantan-2-yl-4-(1 ,1 -dioxo~[1 ,2,5]thiadiazolidin-2-ylmethyl) -benzamide
(4-Azatricyclo[4.3.1 .1 *3,8*]-undec-4-yl)-[4-(1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)- phenyl]-methanone
Azepan-1 -yl-[4-(1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-methanone
Azepan-1 -yl-[4-(5-methyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]- methanone
N-Adamantan-1 -yl-4-(5-methoxymethyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)- benzamide
4-(1 ,1 -Dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-N-(3-hydroxy-adamantan-1 -yl)- benzamide
{5-[4-(Adamantan-1 -yl-carbamoyl)-benzyl]-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-yl}-acetic acid te/t-butyl ester or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
[00187] [1 u] In another embodiment, the present invention provides for the novel use of a substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the substituted amide or a prodrug thereof is of formula I:
Figure imgf000036_0001
[00188] wherein:
[00189] R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-;
[00190] R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
[00191] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCrC6alkyl-oxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-dalkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, aryld-dalkylcarboxy, and hetaryld-dalkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18; [00192] Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
[00193] Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano, Ci-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl or Ci-C6alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R18;
[00194] R5 is selected from H, d-C6alkyl, C3-C6cycloalkyl, halo, OH, and cyano;
[00195] R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and triha- lomethoxy;
[00196] alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, d-C6alkyl, oxo, and d-C6alkyloxy;
[00197] R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, hetary- loxyCi-C6alkyl, arylCi-CealkyloxyCi-Cealkyl, and hetarylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
[00198] R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20;
[00199] R10 and R11 are independently selected from H, CrC8alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ; [00200] alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups se- lected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, hydroxy, oxo, COOH, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCrC6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6al- kyl-carboxy, and hetaryld-C6alkylcarboxy;
[00201] R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C8alkyloxy, aryl, aryld-C6alkyl, hetaryl, hetaryld-C6alkyl, aryloxy, hetary- loxy, and NR13R14;
[00202] R13 and R14 are independently selected from H, d-C8alkyl, C3-Ci ocycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
[00203] alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-C6alkylcarbonyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
[00204] R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
[00205] R16 and R17 are independently selected from H, CrC8alkyl, C3-Ciocycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, d-C8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22; [00206] R18 is selected from halo, OH, oxo, COOH, cyano d-C6alkyloxy, C3-Ci0cyclo- alkyloxy, aryloxy, hetaryloxy, hetarylthio and arylCi-C6alkyloxy;
[00207] R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendioxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
[00208] R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy, NR23R24, methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
[00209] R23 and R24 are independently selected from H, d-C8alkyl, and arylCi-C6alkyl;
[00210] m is selected from 0, 1 , and 2;
[00211] n is selected from 1 and 2;
[00212] Y is selected from O and S;
[00213] or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
[00214] [1 ] In another embodiment, the present invention provides the novel use of com- pounds of formula I, wherein:
[00215] R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-;
[00216] R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
[00217] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarboxy, arylcarboxy, hetarylcar- boxy, arylCi-C6alkylcarboxy, and hetaryld-Cealkylcarboxy, wherein each aryl/hetaryl group is substituted with 0-3 R18;
[00218] Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
[00219] Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano, d-C6alkyloxy, d-Cealkyloxyd-Cealkylene or d-C6alkylcarbonyl, wherein each al- kyl/alkylene group is substituted with 0-3 R18;
[00220] R5 is selected from H, d-C6alkyl, C3-C6cycloalkyl, halo, OH, and cyano;
[00221] R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and triha- lomethoxy;
[00222] alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, d-C6alkyl, oxo, and d-C6alkyloxy;
[00223] R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCrC6alkylene, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkylene, hetaryloxyCi-C6alkylene, arylCi-CealkyloxyCi-Cealkylene, and hetaryl- Ci-CealkyloxyCi-Cealkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloal- kyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
[00224] R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkylene, and arylCi-CealkyloxyCi-Cealkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20; [00225] R10 and R11 are independently selected from H, CrC8alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkylene, and hetarylCi-C6alkylene, wherein each of the alkyl/alkylene, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
[00226] alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups se- lected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, hydroxy, oxo, COOH, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkylene, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCrC6alkylcarbonyl, hetarylCrC6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkyl-carboxy, and hetaryld-C6alkylcarboxy;
[00227] R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, Ci-C8alkyloxy, aryl, arylCi-C6alkylene, hetaryl, hetarylCi-C6alkylene, aryloxy, hetaryloxy, and NR13R14;
[00228] R13 and R14 are independently selected from H, CrC8alkyl, C3-Ci ocycloalkyl, aryl, hetaryl, arylCi-C6alkylene, and hetarylCi-C6alkylene, wherein each of the alkyl/alkylene, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
[00229] alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkylene, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCrC6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, aryl- Ci-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
[00230] R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl; [00231] R16 and R17 are independently selected from H, CrC8alkyl, C3-Ci0cycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, CrC8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22;
[00232] R18 is selected from halo, OH, oxo, and cyano;
[00233] R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendioxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
[00234] R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy, NR23R24, methylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
[00235] R23 and R24 are independently selected from H, CrC8alkyl, and arylCi-C6alkylene;
[00236] m is selected from O, 1 , and 2;
[00237] n is selected from 1 and 2;
[00238] Y is selected from O and S;
[00239] [2u] In another embodiment, the present invention provides the novel use of com- pounds of formula I, wherein:
[00240] R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
[00241] R2 is d-dalkyl;
[00242] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkyl- carboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetaryld-Cealkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18;
[00243] Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
[00244] Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkyl or Ci-C4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
[00245] R5 is H;
[00246] R6 and R7 are independently selected from H and CrC4alkyl; and,
[00247] n is 2.
[00248] [2] In another embodiment, the present invention provides the novel use of com- pounds of formula I, wherein:
[00249] R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
[00250] R2 is d-dalkyl;
[00251] alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetaryl- Ci-C6alkylcarboxy, wherein each aryl/hetaryl group is substituted with 0-3 R18; [00252] Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
[00253] Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkylene or Ci-C4alkylcarbonyl, wherein each al- kyl/alkylene group is substituted with 0-1 R18;
[00254] R5 is H;
[00255] R6 and R7 are independently selected from H and CrC4alkyl; and,
[00256] n is 2.
[00257] [3u] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein:
[00258] R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkyl, hetarylCrC4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCi-C4alkyl, and hetaryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
[00259] R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkyl, hetarylCi-C4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20;
[00260] R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
[00261] alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxy- gen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
[00262] R12 is selected from OH, CrC4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C4alkyloxy, aryl, arylCi-C4alkyl, hetaryl, hetarylCi-C4alkyl, aryloxy, and hetaryloxy;
[00263] R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, Ci-C4alkyloxy, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
[00264] n is 2.
[00265] [3] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein:
[00266] R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkylene, hetarylCi-C4alkylene, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyd-C4alkylene, and hetaryloxyCi-C4alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
[00267] R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkylene, hetarylCi-C4alkylene, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and ary- loxyCi-C4alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20;
[00268] R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
[00269] alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown ni- trogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxy- gen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
[00270] R12 is selected from OH, CrC4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C4alkyloxy, aryl, arylCi-C4alkylene, hetaryl, hetarylCi-C4alkylene, aryloxy, and hetaryloxy;
[00271] R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, d-C4alkyloxy, aryl, hetaryl, aryld-C4alkylene, hetarylCi-C4alkylene, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
[00272] n is 2.
[00273] [4u] In another embodiment, the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ia:
Figure imgf000046_0001
Ia.
[00274] [5] In another embodiment, the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ib:
Figure imgf000046_0002
Ib. [00275] [6] In another embodiment, the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ic:
Figure imgf000047_0001
Ic.
[00276] [7] In another embodiment, the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Id:
Figure imgf000047_0002
Id.
[00277] [8] In another embodiment, the present invention provides the novel use of compounds wherein the substituted amide or prodrug thereof is of formula Ie:
Figure imgf000047_0003
Ie
[00278] [9u] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein: [00279] R1 and R2, together with the nitrogen to which they are attached, form a 5-12 mem- bered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCrC6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18.
[00280] [9] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein:
[00281] R1 and R2, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12,
-N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each aryl/hetaryl group is substituted with 0-3 R18.
[00282] [1 Ou] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein:
[00283] Ring A is selected from:
Figure imgf000049_0001
[00284] Ring A is substituted with 0-2 RΛ; and,
[00285] Frb is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, C(=O)R , and Ci-C6alkyloxy, wherein R12 is as defined above..
[00286] [10] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein: [00287] Ring A is selected from:
Figure imgf000049_0002
[00288] Ring A is substituted with 0-2 RΛ; and,
[00289] R is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and Ci-C6alkyloxy.
[00290] [1 1] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein: ring A is
Figure imgf000049_0003
[00291] Ring A is substituted with 0-2 R25; and,
[00292] R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and Ci-C6alkyloxy.
[00293] In another embodiment, the present invention provides the novel use of compounds of formula I, wherein the substituted amide or a prodrug thereof is of the selected from the group:
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isobutyramide
Cyclopentanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
Cyclohexanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i Joctane-θ- carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-amide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- benzamide
1 -Acetyl-piperidine-4-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
1 -Acetyl-piperidine-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
Cyclopentanecarboxylic acid ethyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iloctane-θ- carbonyl)-benzyl]-amide
2,2-N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- propionamide
Tetrahydro-furan-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-4-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
Thiophene-2-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iloctane-θ- carbonyl)-benzyl]-amide
Furan-2-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
3-Chloro-4-(propane-2-sulfonyl)-thiophene-2-carboxylic acid methyl-[4-(1 ,3,3- trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-amide
6-Chloro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-nicotinamide
5-Methyl-isoxazole-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,3,N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- butyramide
3-Cyano-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
N-Methyl-2-phenoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- malonamic acid methyl ester
3-Methyl-but-2-enoic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
N-Methyl-2-phenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
1 -Trifluoromethyl-cyclobutanecarboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,5-Dimethoxy-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
4-Methanesulfonyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-Methyl-3-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
2,2-Difluoro-1 ,3-benzodioxole-4-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-6-morpholin-4-yl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-nicotinamide
N-Methyl-4-(2,2,2-trifluoro-acetyl)-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-benzamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isophthalamic acid
2,3-Dihydro-benzofuran-7-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3-Acetyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
1 ,1 ,3-Trimethyl-3-[4-(1 ,3,3-trimethyl-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- sulphonylurea
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
2,2,2-Trifluoro-ethanesulfonic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methylphenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-isopropyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Cyclopropyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Ethyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
3-Benzoyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea
3-Cyclohexyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea
3-(4-methy-phenyl)sulfonyl-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-
6-carbonyl)-benzyl]-urea
1 ,3-Dimethyl-3-phenyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- benzyl]-urea 3-(2,3-Dihydro-1 ,4-benzodioxin-2-ylmethyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(3-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, S-trimethyl-θ-aza-bicyclotS.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(1 ,1 -Dioxo-tetrahydro-thiophen-3-yl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(tetrahydro-pyran-4-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]-octane-6- carbonyl)-benzyl]-urea
{1 ,3-Dimethyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-acetic acid methyl ester
1 -Methyl-3-(5-trifluoromethyl-1 ,3,4-thiadiazol-2-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
2-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-arbonyl)-benzyl]- ureidoj-benzoic acid methyl ester
3-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-benzoic acid ethyl ester
1 -Methyl-3-(3-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
3-(4-Benzyloxy-phenyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Acetyl-phenyl)-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-icyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Acetyl-phenyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Cyano-phenyl)-1 -methyl-1 -[4-(1 , 3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea 1 -Methyl-3-(2,2,4,4-tetrafluoro-4H-benzo-[1 ,3]dioxin-6-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methoxy-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-[4-(2,2,2-trifluoro-acetyl)-cyclohexyl]-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -(4-Acetyl-phenyl)-1 ,3-dimethyl-3-[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Phenyl-3-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclopropyl}-urea
Piperidine-1 -carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]- amide
Morpholine-4-carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
1 ,3-Dimethyl-3-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-1 -phenyl-urea i -^-β-Aza-bicyclo-β^^nonane-S-carbonyO-benzyll-i jS-dimethyl-S-phenyl-urea
Piperidine-1 -carboxylic acid [4-(6-aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]- methyl-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]octane-3- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid [4-(6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ΛS-trimethyl-S-aza-bicycloβ^.il-octane-S- carbonyl)-benzyl]-amide
1 -[4-(6-Aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl-urea
1 ,3-Dimethyl-1 -phenyl-3-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carbonyl)- benzyl]-urea
Piperidine-1 -carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide 1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3- phenyl-urea
1 -[4-(3-Fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3-phenyl- urea
Piperidine-1 -carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyridin-2-yl-ureidomethyl)-benzamide
^^-(S-Aza-bicyclotS^^lnonane-S-carbonyO-benzyll-i ^-dimethyl-S-pyridin^-yl-urea
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyridin-
2-yl-urea
Morpholine-4-carboxylic acid [4-(adamantan-2-ylcarbamoyl)-benzyl]-methyl-amide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-thiazol-2-yl-urea
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-carbonyl)-benzyl]-1 -thiazol-2- yl-urea
4-[3-(1 -Acetyl-piperidin-4-yl)-1 ,3-dimethyl-ureidomethyl]-N-adamantan-2-yl-benzamide
1 -(1 -Acetyl-piperidin-4-yl)-3-[4-(3-aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3- dimethyl-urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyrimidin-2-yl-ureidomethyl)-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyrimidin-2-yl- urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-thiazol-2-yl-ureidomethyl)-benzamide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-phenyl-ureidomethyl)-benzamide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3- pyrimidin-2-yl-urea
N-Adamantan-2-yl-4-[3-(4-hydroxy-cyclohexyl)-1 ,3-dimethyl-ureidomethyl]-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-hydroxy-cyclohexyl)-1 ,3- dimethyl-urea
1 -(4-Hydroxy-cyclohexyl)-1 ,3-dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-urea
1 -Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-imidazo- lidin-2-one [4-(1 ,1 -Dioxo-isothiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- oct-6-yl)-methanone
[4-(1 ,1 -Dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-bicyclo[3.2.1]oct-
6-yl)-methanone
[4-(5-Methyl-1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl- bicyclo[3.2.1]oct-6-yl)-methanone
(Octahydro-quinolin-1 -yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(4-Aza-tricyclo[4.3.1 .13 8]-undec-4-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)- phenyl]-methanone
(Octahydro-isoquinolin-2-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(3-Aza-bicyclo[3.2.2]non-3-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(6-Aza-bicyclo[3.2.1 ]oct-6-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
[4-(5-Benzyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]oct-6-yl)-methanone
[00294] or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
[00295] In another embodiment, the present invention provides for the novel preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial.
[00296] In another embodiment, the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
[00297] In another embodiment, the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
[00298] In another embodiment, the present invention provides for the novel preparation of a pharmaceutical composition, wherein: the pharmaceutical composition is suitable for a route of administration selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
[00299] In another embodiment, the present invention provides a novel method for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound of the present invention. .
[00300] In another embodiment, the present invention provides a novel method wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
[00301] In another embodiment, the present invention provides a novel method wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
[00302] In another embodiment, the present invention provides a novel method wherein the administering is via a route selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
[00303] In another embodiment, the present invention provides a novel compound, which is an agent useful for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial.
[00304] In another embodiment, the present invention provides a novel method wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels. [00305] In another embodiment, the present invention provides a novel method wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), im- paired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
[00306] In another embodiment, the present invention provides a novel method pharmaceutical composition comprising, as an active ingredient, at least one compound according of the present invention together with one or more pharmaceutically acceptable carriers or excipi- ents.
[00307] In another embodiment, the present invention provides a novel pharmaceutical composition, which is suitable for oral, nasal, buccal, transdermal, pulmonal, or parenteral administration.
[00308] The compounds of the present invention have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms being included in the present invention as well as mixtures thereof.
[00309] The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, and nitric acids. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphtho- ates, glycerophosphates, and ketoglutarates. Further examples of pharmaceutically accept- able inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. ScL, 66, 2 (1977), which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, barium, calcium, magnesium, zinc, and calcium salts. Examples of amines and organic amines include ammonium, methylamine, di- methylamine, trimethylamine, ethylamine, diethylamine, propylamine, butylamine, tetrame- thylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylene-diamine, N-benzylphenylethylamine, N-methyl-D-glucamine, and guanidine. Examples of cationic amino acids include lysine, arginine, and histidine. [00310] Further, some of the compounds of the present invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
[00311] The pharmaceutically acceptable salts are prepared by reacting a compound of the present invention with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium te/t-butoxide, calcium hydroxide, and magnesium hy- droxide, in solvents such as ether, THF, methanol, te/t-butanol, dioxane, and isopropanol, ethanol. Mixtures of solvents may be used. Organic bases such as lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, and tartaric acid in solvents such as ethyl acetate, ether, alcohols, acetone, THF, and dioxane. Mixture of solvents may also be used.
[00312] The stereoisomers of the compounds forming part of this invention may be pre- pared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enanti- omer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, and lactic acid, wherever applicable or chiral bases such as brucine, (R)- or (S)- phenylethylamine, cinchona alkaloids and their derivatives. Commonly used methods are compiled by Jaques et al. in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981 ). More specifically the compound of the present invention may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydro- lysing the pure diastereomeric amide.
[00313] Various polymorphs of the compounds forming part of this invention may be pre- pared by crystallization of said compounds under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
[00314] The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the present invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. [00315] It is a well known problem in drug discovery that compounds, such as enzyme in- hibitors, may be very potent and selective in biochemical assays, yet be inactive in vivo. This lack of so-called bioavailability may be ascribed to a number of different factors such as lack of or poor absorption in the gut, first pass metabolism in the liver and/or poor uptake in cells. Although the factors determining bioavailability are not completely understood, there are many examples in the scientific literature - well known to those skilled in the art - of how to modify compounds, which are potent and selective in biochemical assays but show low or no activity in vivo, into drugs that are biologically active.
[00316] It is within the scope of the invention to modify the compounds of the present invention, termed the Original compound', by attaching chemical groups that will improve the bioavailability of said compounds in such a way that the uptake in cells or mammals is facili- tated.
[00317] Examples of said modifications, which are not intended in any way to limit the scope of the invention, include changing of one or more carboxy groups to esters (for instance methyl esters, ethyl esters, te/t-butyl, acetoxymethyl, pivaloyloxymethyl esters or other acy- loxymethyl esters). Compounds of the invention, original compounds, such modified by at- taching chemical groups are termed 'modified compounds'. [00318] The invention also encompasses active metabolites of the present compounds. [00319] The compounds according to the invention alter, and more specifically, reduce the level of active intracellular glucocorticoid and are accordingly useful for the treatment of conditions, disorders, and diseases in which such a modulation or reduction is beneficial. [00320] Accordingly, the present compounds may be applicable for the treatment of the metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), Latent Autoimmune Diabetes in the Adult (LADA), type 1 diabetes, diabetic late complications including cardiovascular diseases, cardiovascular disorders, disorders of lipid metabolism, neurodegenerative and psychiatric disorders, dysregulation of intraocular pressure including glaucoma, immune disorders, inappropriate immune responses, musculoskeletal disorders, gastrointestinal disorders, polycystic ovarie syndrome (PCOS), reduced hair growth or other diseases, disorders or conditions that are influenced by intracellular glucocorticoid levels, adverse effects of increased blood levels of active endogenous or exogenous glucocorticoid, and any combina- tion thereof, adverse effects of increased plasma levels of endogenous active glucocorticoid, Cushing's disease, Cushing's syndrome, adverse effects of glucocorticoid receptor agonist treatment of autoimmune diseases, adverse effects of glucocorticoid receptor agonist treatment of inflammatory diseases, adverse effects of glucocorticoid receptor agonist treatment of diseases with an inflammatory component, adverse effects of glucocorticoid receptor ago- nist treatment as a part of cancer chemotherapy, adverse effects of glucocorticoid receptor agonist treatment for surgical/post-surgical or other trauma, adverse effects of glucocorticoid receptor agonist therapy in the context of organ or tissue transplantation or adverse effects of glucocorticoid receptor agonist treatment in other diseases, disorders or conditions where glucocorticoid receptor agonists provide clinically beneficial effects. [00321] More specifically the present compounds may be applicable for the treatment of the metabolic syndrome, type 2 diabetes, diabetes as a consequence of obesity, insulin resistance, hyperglycemia, prandial hyperglycemia, hyperinsulinemia, inappropriately low insulin secretion, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), increased hepatic glucose production, type 1 diabetes, LADA, pediatric diabetes, dyslipidemia, diabetic dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, decreased HDL cholesterol, impaired LDL/HDL ratio, other disorders of lipid metabolism, obesity, visceral obesity, obesity as a consequence of diabetes, increased food intake, hypertension, diabetic late complications, micro-/macroalbuminuria, nephropathy, retinopathy, neuropathy, diabetic ulcers, cardiovascular diseases, arteriosclerosis, atherosclero- sis, coronary artery disease, cardiac hypertrophy, myocardial ischemia, heart insufficiency, congestional heart failure, stroke, myocardial infarction, arrythmia, decreased blood flow, erectile dysfunction (male or female), myopathy, loss of muscle tissue, muscle wasting, muscle catabolism, osteoporosis, decreased linear growth, neurodegenerative and psychiatric disorders, Alzheimers disease, neuronal death, impaired cognitive function, depression, anxiety, eating disorders, appetite regulation, migraine, epilepsia, addiction to chemical substances, disorders of intraocular pressure, glaucoma, polycystic ovary syndrome (PCOS), inappropriate immune responses, inappropriate T helper-1/T helper-2 polarisation, bacterial infections, mycobacterial infections, fungal infections, viral infections, parasitic infestations, suboptimal responses to immunizations, immune dysfunction, partial or complete baldness, or other diseases, disorders or conditions that are influenced by intracellular glucocorticoid levels and any combination thereof, adverse effects of glucocorticoid receptor agonist treatment of allergic-inflammatory diseases such as asthma and atopic dermatitis, adverse effects of glucocorticoid receptor agonist treatment of disorders of the respiratory system e.g., asthma, cystic fibrosis, emphysema, bronchitis, hypersensitivity, pneumonitis, eosinophilic pneumonias, pulmonary fibrosis, adverse effects of glucocorticoid receptor agonist treatment of inflammatory bowel disease such as Crohn's disease and ulcerative colitis; adverse effects of glucocorticoid receptor agonist treatment of disorders of the immune system, connective tissue and joints e.g., reactive arthritis, rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, lupus nephritis, Henoch-Schόnlein purpura, Wegener's granulo- matosis, temporal arteritis, systemic sclerosis, vasculitis, sarcoidosis, dermatomyositis- polymyositis, pemphigus vulgaris; adverse effects of glucocorticoid receptor agonist treatment of endocrinological diseases such as hyperthyroidism, hypoaldosteronism, hypopituitarism; adverse effects of glucocorticoid receptor agonist treatment of hematological diseases e.g., hemolytic anemia, thrombocytopenia, paroxysmal nocturnal hemoglobinuria; adverse effects of glucocorticoid receptor agonist treatment of cancer such as spinal cord diseases, neoplastic compression of the spinal cord, brain tumours, acute lymphoblastic leukemia, Hodgkin's disease, chemotherapy-induced nausea, adverse effects of glucocorticoid receptor agonist treatment of diseases of muscle and at the neuro-muscular joint e.g., myasthenia gravis and heriditary myopathies (e.g., Duchenne muscular dystrophy), adverse effects of glucocorticoid receptor agonist treatment in the context of surgery & transplantation e.g., trauma, post-surgical stress, surgical stress, renal transplantation, liver transplantation, lung transplantation, pancreatic islet transplantation, blood stem cell transplantation, bone marrow transplantation, heart transplantation, adrenal gland transplantation, tracheal transplantation, intestinal transplantation, corneal transplantation, skin grafting, keratoplasty, lens implanta- tion and other procedures where immunosuppression with glucocorticoid receptor agonists is beneficial; adverse effects of glucocorticoid receptor agonist treatment of brain absess, nausea/vomiting, infections, hypercalcemia, adrenal hyperplasia, autoimmune hepatitis, spinal cord diseases, saccular aneurysms or adverse effects to glucocorticoid receptor agonist treatment in other diseases, disorders and conditions where glucocorticoid receptor agonists provide clinically beneficial effects.
[00322] Accordingly, in a further aspect the invention relates to a compound according to the invention for use as a pharmaceutical composition.
[00323] The invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound according to the invention together with one or more pharmaceutically acceptable carriers or diluents.
[00324] The pharmaceutical composition is preferably in unit dosage form, comprising from about 0.05 mg/day to about 2000 mg/day, preferably from about 0.1 mg/day to abouti OOO mg/day, and more preferably from about 0.5 mg/day to about 500 mg/day of a compound according to the invention. [00325] In another embodiment, the patient is treated with a compound according to the invention for at least about 1 week, for at least about 2 weeks, for at least about 4 weeks, for at least about 2 months or for at least about 4 months.
[00326] In yet another embodiment, the pharmaceutical composition is for oral, nasal, buccal, transdermal, pulmonal or parenteral administration. [00327] Furthermore, the invention relates to the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment of disorders and diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial. [00328] The invention also relates to a method for the treatment of disorders and diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to the invention.
[00329] In a preferred embodiment of the invention the present compounds are used for the preparation of a medicament for the treatment of any diseases and conditions that are influenced by intracellular glucocorticoid levels as mentioned above. [00330] Thus, in a preferred embodiment of the invention the present compounds are used for the preparation of a medicament for the treatment of conditions and disorders where a decreased level of active intracellular glucocorticoid is desirable, such as the conditions and diseases mentioned above. [00331] In yet a preferred embodiment of the invention the present compounds are used for the preparation of a medicament for the treatment of metabolic syndrome, insulin resistance, dyslipidemia, hypertension obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of the metabolic syndrome into type 2 diabetes, diabetic late complications (e.g., cardiovascular diseases, arteriosclerosis, and atherosclerosis), neurodegenerative and psychiatric disor- ders, and, the adverse effects of glucocorticoid receptor agonist treatment or therapy.
[00332] In another embodiment of the present invention, the route of administration may be any route which effectively transports a compound according to the invention to the appropriate or desired site of action, such as oral, nasal, buccal, transdermal, pulmonal, or parenteral. [00333] In still a further aspect of the invention the present compounds are administered in combination with one or more further active substances in any suitable ratios. Such further active substances may e.g., be selected from antiobesity agents, antidiabetics, agents modifying the lipid metabolism, antihypertensive agents, glucocorticoid receptor agonists, agents for the treatment and/or prevention of complications resulting from or associated with diabe- tes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
[00334] Thus, in a further aspect of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents. [00335] Such agents may be selected from the group consisting of CART (cocaine am- phetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melano- cortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, se- rotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome proliferator-activated receptor) modulators, RXR (retinoid X receptor) modulators, TR β agonists, AGRP (Agouti related protein) inhibitors, H3 histamine antagonists, opioid antagonists (such as naltrexone), exendin-4, GLP-1 and ciliary neurotrophic factor. [00336] In one embodiment of the invention the antiobesity agent is leptin; dexamphetamine or amphetamine; fenfluramine or dexfenfluramine; sibutramine; orlistat; mazindol or phen- termine. [00337] Suitable antidiabetic agents include insulin, insulin analogues and derivatives such as those disclosed in EP 792 290 (Novo Nordisk A/S), e.g., NεB29-tetradecanoyl des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), e.g., AspB28 human insulin, US 5,504,188 (EIi Lilly), e.g., LysB28 Pro629 human insulin, EP 368 187 (Aventis), eg Lantus, which are all incorporated herein by reference, GLP-1 (glucagon like peptide-1 ) and GLP-1 derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents. [00338] The orally active hypoglycaemic agents preferably comprise sulphonylureas, bigua- nides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase- IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenosis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as PPARα modulators, PPARδ modulators, cholesterol absorption inhibitors, HSL (hormone-sensitive lipase) inhibitors and HMG CoA inhibitors (statins), nicotinic acid, fibrates, anion exchangers, compounds lowering food intake, bile acid resins, RXR agonists and agents acting on the ATP-dependent potassium channel of the β-cells. [00339] In one embodiment, the present compounds are administered in combination with insulin or an insulin analogue or derivative, such as NεB29-tetradecanoyl des (B30) human insulin, AspB28 human insulin, LysB28 Pro629 human insulin, Lantus®, or a mix-preparation comprising one or more of these. [00340] In a further embodiment the present compounds are administered in combination with a sulphonylurea e.g., tolbutamide, glibenclamide, glipizide or glicazide.
[00341] In another embodiment the present compounds are administered in combination with a biguanide e.g., metformin.
[00342] In yet another embodiment the present compounds are administered in combination with a meglitinide e.g., repaglinide or senaglinide. [00343] In still another embodiment the present compounds are administered in combination with a thiazolidinedione e.g., troglitazone, ciglitazone, pioglitazone, rosiglitazone or compounds disclosed in WO 97/41097 such as 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazo- linyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof, preferably the potassium salt. [00344] In yet another embodiment the present compounds may be administered in combination with the insulin sensitizers disclosed in WO 99/19313 such as (-) 3-[4-[2-Phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salts thereof, preferably the arginine salt. [00345] In a further embodiment the present compounds are administered in combination with an α-glucosidase inhibitor e.g., miglitol or acarbose.
[00346] In another embodiment the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells e.g., tolbutamide, glibenclamide, glipizide, glicazide or repaglinide. [00347] Furthermore, the present compounds may be administered in combination with nateglinide.
[00348] In still another embodiment the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofi- brate, gemfibrozil, fenofibrate, bezafibrate, tesaglitazar, EML-4156, LY-818, MK-767, ator- vastatin, fluvastatin, lovastatin, pravastatin, simvastatin, acipimox, probucol, ezetimibe or dextrothyroxine.
[00349] In a further embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds e.g., in combination with a sulphony- lurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
[00350] Further, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol, metoprolol, bisoprololfumerate, esmolol, acebutelol, metoprolol, acebutolol, betaxolol, celiprolol, nebivolol, tertatolol, oxprenolol, amusolalul, carvedilol, labetalol, β2-receptor blockers e.g., S-atenolol, OPC-1085, ACE (angiotensin converting enzyme) inhibitors such as quinapril, lisinopril, enalapril, captopril, benazepril, perindopril, trandolapril, fosinopril, ramipril, cilazapril, delapril, imidapril, moexipril, spirapril, temocapril, zofenopril, S-5590, fasidotril, Hoechst-Marion Roussel: 100240 (EP 00481522), omapatrilat, gemopatrilat and GW-66051 1 , calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem, amlodipine, nitrendipine, verapamil, lacidipine, lercanidipine, aranidipine, cilnidipine, clevidipine, azelnidipine, barnidipine, efonodipine, iasidipine, iemildipine, iercanidipine, manidipine, nilvadipine, pranidipine, furnidipine, α-blockers such as doxazosin, urapidil, prazosin, terazosin, bunazosin and OPC-28326, diuretics such as thiazides/sulphonamides (e.g., bendro- flumetazide, chlorthalidone, hydrochlorothiazide and clopamide), loop-diuretics (e.g., bumetanide, furosemide and torasemide) and potassium sparing diuretics (e.g., amiloride, spironolactone), endothelin ET-A antagonists such as ABT-546, ambrisetan, atrasentan, SB- 234551 , CI-1034, S-0139 and YM-598, endothelin antagonists e.g., bosentan and J-104133, renin inhibitors such as aliskiren, vasopressin V1 antagonists e.g., OPC-21268, vasopressin V2 antagonists such as tolvaptan, SR-121463 and OPC-31260, B-type natriuretic peptide agonists e.g., Nesiritide, angiotensin Il antagonists such as irbesartan, candesartancilexetil, losartan, valsartan, telmisartan, eprosartan, candesartan, CL-329167, eprosartan, iosartan, olmesartan, pratosartan, TA-606, and YM-358, 5-HT2 agonists e.g., fenoldopam and ketanserin, adenosine A1 antagonists such as naftopidil, N-0861 and FK-352, thromboxane A2 antagonists such as KT2-962, endopeptidase inhibitors e.g., ecadotril, nitric oxide agonists such as LP-805, dopamine D1 antagonists e.g., MYD-37, dopamine D2 agonists such as nolomirole, n-3 fatty acids e.g., omacor, prostacyclin agonists such as treprostinil, beraprost, PGE1 agonists e.g., ecraprost, Na+/K+ ATPase modulators e.g., PST-2238, Potassium channel activators e.g., KR-30450, vaccines such as PMD-31 17, Indapamides, CGRP-unigene, guanylate cyclase stimulators, hydralazines, methyldopa, docarpamine, moxonidine, CoAprovel, MondoBiotech-81 1 .
[00351] Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. [00352] Furthermore, the present compounds may be administered in combination with one or more glucocorticoid receptor agonists. Examples of such glucocorticoid receptor agonists are betametasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, beclomethasone, butixicort, clobetasol, flunisolide, flucatisone (and analogues), momethasone, triamcinolonacetonide, triamcinolonhexacetonide GW-685698, NXC-1015, NXC-1020, NXC-1021 , NS-126, P-41 12, P-41 14, RU-24858 and T-25 series.
[00353] It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
PHARMACEUTICAL COMPOSITIONS
[00354] The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and ex- cipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
[00355] The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the ac- tive ingredient chosen.
[00356] Pharmaceutical compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sus- tained or prolonged release according to methods well-known in the art.
[00357] Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
[00358] Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as ster- ile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
[00359] Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc. [00360] A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
[00361] The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 2000 mg, e.g., from about 0.1 to about 1000 mg, from about 0.5 mg to about 500 mg., from about 1 mg to about 200 mg, e.g., about 100 mg.
[00362] For parenteral routes, such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administra- tion.
[00363] The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. Examples are an acid addition salt of a compound having the utility of a free base and a base addition salt of a compound having the utility of a free acid. The term "pharmaceutically acceptable salts" refers to non-toxic salts of the com- pounds for use according to the present invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the acid with a suitable organic or inorganic base. When a compound for use according to the present invention, contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable acid. When a com- pounds for use according to the present invention, contains a free acid such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable base. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion. Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds for use according to the present invention and these form a further aspect of the present invention.
[00364] For parenteral administration, solutions of the present compounds in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. [00365] Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, syrup, phospholipids, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
[00366] The pharmaceutical compositions formed by combining the compounds of the inven- tion and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy. [00367] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
[00368] Compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically-acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulat- ing and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatine or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyc- eryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,356,108; 4,166,452; and 4,265,874, incorporated herein by reference, to form osmotic therapeutic tablets for controlled release.
[00369] Formulations for oral use may also be presented as hard gelatine capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatine capsule wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
[00370] Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide such as lecithin, or condensation products of an alkyl oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin. [00371] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as a liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be pre- served by the addition of an anti-oxidant such as ascorbic acid.
[00372] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipi- ents, for example, sweetening, flavouring, and colouring agents may also be present.
[00373] The pharmaceutical compositions comprising a compound for use according to the present invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example a liquid paraffin, or a mixture thereof. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents. [00374] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, preservative and flavouring and colouring agent. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known methods using suitable dispersing or wetting agents and suspend- ing agents described above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenteral ly-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conveniently employed as solvent or suspending medium. For this purpose, any bland fixed oil may be employed using synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
[00375] The compositions may also be in the form of suppositories for rectal administration of the compounds of the present invention. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols, for example.
[00376] For topical use, creams, ointments, jellies, solutions of suspensions, etc., containing the compounds of the present invention are contemplated. For the purpose of this application, topical applications shall include mouth washes and gargles. [00377] The compounds for use according to the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines. [00378] In addition, some of the compounds for use according to the present invention may form solvates with water or common organic solvents. Such solvates are also encompassed within the scope of the present invention.
[00379] Thus, in a further embodiment, there is provided a pharmaceutical composition comprising a compound for use according to the present invention, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable carriers, excipi- ents, or diluents.
[00380] If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emul- sion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
[00381] A typical tablet which may be prepared by conventional tabletting techniques may contain: [00382] Core: [00383] Active compound (as free compound or salt thereof) 5.0 mg [00384] Lactosum PH. Eur. 67.8 mg
[00385] Cellulose, microcryst. (Avicel) 31 .4 mg
[00386] Amberlite®IRP88* 1. .0 mg
[00387] Magnesii stearas PH. Eur. q.s.
[00388] Coating:
[00389] Hydroxypropyl methylcellulose approx. . 9 mg
[00390] Mywacett 9-40 T** approx. . 0. .9 mg
[00391] Polacrillin potassium NF, tablet disintegrant, Rohm and Haas.
[00392] ** Acylated monoglyceride used as plasticizer for film coating.
[00393] The compounds of the invention may be administered to a patient which is a mammal, especially a human in need thereof. Such mammals include also animals, both domestic animals, e.g., household pets, and non-domestic animals such as wildlife.
[00394] Any novel feature or combination of features described herein is considered essential to this invention.
[00395] The present invention also relate to the below methods of preparing the compounds of the invention. [00396] The present invention is further illustrated in the following representative examples which are, however, not intended to limit the scope of the invention in any way.
EXAMPLES, COMPOUNDS OF GENERAL FORMULA (I)
[00397] The following examples and general procedures refer to intermediate compounds and final products for general formula (I) identified in the specification and in the synthesis schemes. The preparation of the compounds of general formula (I) of the present invention is described in detail using the following examples. Occasionally, the reaction may not be applicable as described to each compound included within the disclosed scope of the invention. The compounds for which this occurs will be readily recognised by those skilled in the art. In these cases the reactions can be successfully performed by conventional modifications known to those skilled in the art, which is, by appropriate protection of interfering groups, by changing to other conventional reagents, or by routine modification of reaction conditions. Alternatively, other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of the invention. In all preparative methods, all starting materials are known or may easily be prepared from known starting materials. The structures of the compounds are confirmed by either elemental analysis or nuclear magnetic resonance (NMR), where peaks assigned to characteristic protons in the title compounds are presented where appropriate. 1H NMR shifts (δH) are given in parts per million (ppm) down field from tetramethylsilane as internal reference standard. M. p.: is melting point and is given in 0C and is not corrected. Column chromatography was carried out using the technique described by W. C. Still et al., J. Org. Chem. 43/ 2923 (1978) on Merck silica gel 60 (Art. 9385). HPLC analyses are performed using 5μm C18 4 x 250 mm column eluted with various mixtures of water and acetonitrile, flow = 1 ml/min, as described in the experimental section.
[00398] Microwave oven synthesis: The reaction was heated by microwave irradiation in sealed microwave vessels in a single mode Emrys Optimizer EXP from PersonalChemistry®.
[00399] Preparative HPLC: Column: 1.9 x 15 cm Waters XTerra RP-18. Buffer: linear gradient 5 - 95 % in 15 min, MeCN, 0.1 % TFA, flow rate of 15 ml/min. The pooled fractions are either evaporated to dryness in vacuo, or evaporated in vacuo until the MeCN is removed, and then frozen and freeze dried.
[00400] The abbreviations as used in the examples have the following meaning:
TLC: Thin layer chromatography
CDCI3: Deuterio chloroform
CD3OD: Tetradeuterio methanol
DCM: Dichloromethane
DMF: N,N-dimethylformamide
DMSO-d6: Hexadeuterio dimethylsulfoxide
DMSO: Dimethylsulfoxide
DIPEA: Diisopropylethylamine
EDAC: 1 -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EtOAc: Ethyl acetate
THF: Tetrahydrofuran
HOBT: 1 -Hydroxy-benzotriazole
MeCN: Acetonitrile
NMP: N-Methylpyrrolidinone
TFA: Trifluoroacetic acid min: minutes hrs: hours
[00401] General method A:
(H)
Figure imgf000075_0001
O
R8^X
(H)
By allowing a benzyl amine (I) wherein R2, R5, R6, R7 and A are defined as above to be coupled with an acid (II) wherein R8 is defined as above under standard amide forming conditions using a coupling reagent (III) (e.g. HOBT, EDAC and DIPEA in dry THF) affording amide (IV) wherein R2, R5, R6, R7, R8 and A are defined as above; or by allowing a benzyl amine (I) wherein R2, R5, R6, R7 and A are defined as above to be reacted with an acid derivative (II) wherein X is halo, R8(C=O)O-, d-C6alkyloxy or aryld- C6alkyloxy and R8 is defined as above under basic conditions (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording amide wherein R2, R5, R6, R7, R8 and A are defined as above.
[00402] General method B:
(H)
Figure imgf000075_0002
By allowing a benzyl amine (I) wherein R2, R5, R6, R7 and A are defined as above to be reacted with a sulphonyl halide (II) wherein X is halo and R9 is defined as above under basic conditions (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording sulphone amide (III); wherein R2, R5, R6, R7, R9 and A are defined as above.
[00403] General method C:
Figure imgf000076_0001
By allowing a benzyl amine (I) wherein R2, R5, R6, R7 and A are defined as above to be reacted with an isocyanate (II) wherein R10 is defined as above in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording urea (III); wherein R2, R5, R6, R7, R10 and A are defined as above. Tri-substituted urea (III) can further be reacted with an alkyl halide or mesylate (IV); wherein X is halide or OSO2Me and R11 is defined above to react under basic condition (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording tetra-substituted urea (V); wherein R2, R5, R6, R7, R10, R11 and A are defined as above.
[00404] General method D:
Figure imgf000077_0001
By allowing a benzyl amine (I) wherein R2, R5, R6, R7 and A are defined as above to be reacted with an isothiocyanate (II) wherein R10 is defined as above in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording thiourea (III); wherein R2, R5, R6, R7, R10 and A are defined as above. Tri-substituted thiourea (III) can further be reacted with an alkyl halide or mesylate (IV); wherein X is halide or OSO2Me and R11 is defined above to react under basic condition (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording tetra-substituted thiourea (V); wherein R2, R5, R6, R7, R10, R11 and A are defined as above.
[00405] General method E:
(H)
Figure imgf000077_0002
Figure imgf000077_0003
(IV) ;0R
Figure imgf000078_0001
Figure imgf000078_0002
By allowing a benzyl amine (I); wherein R5, R6, R7 and A are defined as above to be reacted with an protected ethyl amine (II); wherein X is halo, Ci-C6alkylOS(O)2-, aryl-OS(O)2- or arylCi-C6alkyl0S(0)2- and R26 is d-C8alkyl, C3-Ci0cycloalkyl, C3-Ci Ohet-cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-CealkyloxyCi-Cealkyl to react under basic condition (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording ethylene diamine (III); wherein R5, R6, R7 and A are defined as above and R26 is Ci-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0het-cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-CealkyloxyCi-Cealkyl. Deprotection of ethylene diamine (III); wherein R5, R6, R7 and A are defined as above and R26 is Ci-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-CealkyloxyCi-Cealkyl, in a mixtyre of e.g. TFA/DCM followed by reaction with phosgene under basic conditions (e.g. triethylamine, DIPEA, DBU ad the like) in a solvent (e.g. THF, DCM, toluene and the like) affords 2-oxo-imidazolidine (IV); wherein R5, R6, R7 and A are defined as above and R26 is d-C8alkyl, C3-Ciocycloalkyl, C3-Ciohet- cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-CealkyloxyCi-Cealkyl; or by allowing a benzyl sulphonate (V); wherein R5, R6, R7, A are defined as above and R27 is Ci-C6alkyl and aryl, to be reacted with an protected ethylene di-amine (II); wherein R26 is Ci-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0het-cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-CealkyloxyCi-Cealkyl to react under basic condition (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording ethylene di-amine (III); wherein R5, R6, R7 and A are defined as above and R26 is d-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0het-cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloal- kyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-C6alkyloxyCi-C6alkyl. Deprotection of ethylene diamine (III); wherein R5, R6, R7 and A are defined as above and R26 is d-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0het-cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-CealkyloxyCi-Cealkyl in a mix- tyre of e.g. TFA/DCM followed by reaction with phosgene under basic conditions (e.g. triethylamine, DIPEA, DBU ad the like) in a solvent (e.g. THF, DCM, toluene and the like) affords 2-oxo-imidazolidine (IV); wherein R5, R6, R7 and A are defined as above and R26 isCrC8alkyl, C3-Ci0cycloalkyl, C3-Ci ohet-cycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-C6alkyloxyCi-C6alkyl.
R26 is Ci-C8alkyl, C3-Ci0cycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14 and Ci-C6alkyloxyCi-C6alkyl wherein R12, R13, and R14 are defined above and each alkyl, aryl/hetaryl group is substituted with 0-3 R18 which is defined above.
[00406] General method F:
Figure imgf000079_0001
By allowing a benzyl amine (I); wherein R5, R6, R7 and A are defined as above to be reacted with a sulphonyl halide (II); wherein m is 1 , 2 or 3 and R26 is defined below under basic conditions (e.g. triethylamine, K2CO3, NaH and the like) in a solvent (e.g. THF, DCM, DMF, NMP and the like) affording cyclic sulphone amide (III); wherein m is 1 , 2 or 3 and R5, R6, R7 and A are defined as above and R26 is defined below. R26 is Ci-C6alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-C6alkyloxy- Ci-C6alkyl; wherein R12, R13 and R14 are defined above and each alkyl, aryl/hetaryl group is substituted with 0-3 R18 which is defined above.
[00407] General method G:
(H)
Figure imgf000080_0001
I)
Figure imgf000080_0002
(VIII) By allowing a sulfamide (I); wherein R5, R6, R7 and A are defined as above to be reacted with a hydroxyl ethyl halide (II); wherein R26 is as defined below under Mitsunobu conditions (e.g. PPh3 and DIAD) in a solvent (e.g. THF and the like) affording substituted sulfamide (III); wherein R5, R6, R7 and A are defined as above and R26 is as defined below. Substituted sulfamide (III); wherein R5, R6, R7 and A are defined as above and R26 is as de- fined below is cyclised under basic conditions (e.g. K2CO3 in DMSO) affording substituted [1 ,2,5]thiadiazolidine 1 ,1 -dioxide (IV); wherein R5, R6, R7 and A are defined as above and R26 is as defined below. Introduction of further substituents can be accomblished when allowing a substituted [1 ,2,5]thiadiazolidine 1 ,1 -dioxide (IV); wherein R5, R6, R7 and A are defined as above and R26 is as defined below to undergo deprotection (e.g. TFA/DCM) affording substi- tuted [1 ,2,5]thiadiazolidine 1 ,1 -dioxide (V); wherein R5, R6, R7 and A are defined as above and R26 is as defined below which can be alkylated with (Vl); wherin R27 is as defined below under basic conditions (e.g. NaH in DMSO or DMF) or via a Mitsunobu reaction (e.g. PPh3 and DIAD) in a solvent (e.g. THF and the like) with alcohol (VII); wherin R27 is as defined below affording substituted 1 ,2,5]thiadiazolidine 1 ,1 -dioxide (VIII); wherein R5, R6, R7 and A are defined as above and R26 and R27 are defined below.
R26 is Ci-C6alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl and Ci-CβalkyloxyCi-CβalkyI; wherein each alkyl, aryl/hetaryl group is substituted with 0-3 R18 which is defined above.
R27 is Ci-C6alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, Ci-CβalkyloxyCi-Cβalkyl; wherein R12, R13 and R14 are defined above and each alkyl, aryl/hetaryl group is substituted with 0-3 R18 which is defined above.
SPECIFIC EXAMPLES
Example 1-1 (General procedure (A)) N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 loctane-6-carbonyl)-benzyll-acetamide
Figure imgf000081_0001
Step A: [4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester
Figure imgf000081_0002
To a solution of 4-(te/t-butoxycarbonylamino-methyl)-benzoic acid (15.0 g, 59.69 mmol) in THF (200 ml_) was added with stirring HOBt (8.87 g, 65.66 mmol) followed by EDAC (12.59 g, 65.66 mmol) and the mixture was stirred for 30 min. at ambient temperature. To the resulting mixture was added 1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane, hydrochloride (12.46 g, 65.66 mmol) and DIPEA (21 .84 ml_, 125.36 mmol). The reaction mixture was stirred for 16 hrs. at ambient temperature. The solvent was evaporated and to the residue was added water (100 ml_). The mixture was extracted with EtOAc (3x50 ml_) and the combined organic phases were washed with saturated aqueous ammonium chloride (3x50 ml_). The organic phase was dried (MgSO4) and the solvent evaporated affording crude amide which was dissolved in EtOAc (50 ml_) and filtered through a patch of silica gel using EtOAc as eluent. The combined fractions were evaporated which afforded 23 g (99 %) of [4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester. 1H NMR (400 MHz, CDCI3) δ 0.94 (d, 3H), 1 .02 (d, 3H), 1.12 (d, 3H), 1 .17-1 .59 (m, 14.5H), 1 .75 (m, 1 H), 2.23 (m, 0.5H), 3.23 (q, 0.5H), 3.26 (d, 0.5H), 3.58 (d, 0.5H), 3.96 (m, 0.5 H), 4.33 (bs, 2H), 4.60 (m, 0.5 H), 5.02 (bs, 0.5 H), 7.29 (m, 2H), 7.40 (t, 2H). HPLC-MS (Method Z1 ): m/z = 387 (M+1 ); tr = x.xx min (yy % ELS).
Step B:
Methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-carbamic acid te/t- butyl ester .
Figure imgf000082_0001
To a solution of the above carbamate (560 mg, 1 .45 mmol) in THF (30 mL) was added with stirring sodium hydride (151 mg, 3.77 mmol, 60 % in mineral oil) and the mixture was stirred for 1 h. at ambient temperature. To the resulting mixture was added methyl iodine (514 mg, 3.62 mmol) dissolved in THF (1 mL). The reaction mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated and to the residue was added water (30 mL). The mixture was extracted with EtOAc (3x25 mL) and the combined organic phases were washed with water (3x25 mL), brine (25 mL), dried (MgSO4) and the solvent evaporated affording 560 mg (97 %) of methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- carbamic acid te/t-butyl ester as a solid.
1H NMR (400 MHz, DMSO-d6) δ 0.89 (d, 3H), 0.96 (d, 3H), 1.05 (d, 3H), 1 .15-1.50 (m, 13.5H), 1 .74 (m, 1 H), 2.04 (m, 0.5H), 2.78 (s, 3H), 3.1 1 (m, 1 H), 3.28 (d, 0.5H), 3.42 (d, 0.5H), 3.92 (m, 0.5 H), 4.39 (m, 2.5H), 7.26 (m, 2H), 7.38 (d, 1 H), 7.44 (d, 1 H). HPLC-MS (Method Z1 ): m/z = 401 (M+1 ); tr = x.xx min (yy % ELS).
Step C:
(4-Methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone .
Figure imgf000082_0002
To a solution of the above amide (560 mg, 1.4 mmol) in DCM (9 ml_) was added with stirring TFA (3 ml_) and the mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated and to the residue was added water (10 ml_) and the pH adjusted to 1 1. The mixture was extracted with DCM (3x15 ml_) and the combined organic phases were washed with brine (15 ml_), dried (MgSO4) and the solvent evaporated affording 410 mg (97 %) of (4- methylaminomethyl-phenyl)-(1 ^S-trimethyl-e-aza-bicycloβ^.i Joct-e-yO-methanone as an oil.
1H NMR (400 MHz, MeOD) δ 0.95 (d, 3H), 1 .02 (d, 3H), 1.12 (d, 3H), 1 .2-1 .68 (m, 5H), 1.84 (m, 1 H), 2.16 (m, 0.5H), 2.72 (s, 3H), 3.19 (m, 1 H), 3.59 (d, 0.5H), 4.01 (t, 0.5H), 4.20 (s, 2H), 4.52 (t, 0.5 H), 7.50-7.58 (m, 4H).
HPLC-MS (Method Z1 ): m/z = 301 (M+1 ); tr = 1 .44 min (100 % ELS).
Step D:
To a solution of the above benzyl amine (155 mg, 0.516 mmol) in DCM (3 mL) was added with stirring TEA (107 μL, 0.774 mmol) followed by acetyl chloride (41 μL, 0.568 mmol) and the mixture was stirred for 16 h. at ambient temperature. The mixture was washed with water (3x1 mL), dried (MgSO4) and the solvent evaporated. The residue was purified using preparative HPLC (Method ZA): Amount isolated = 47 mg; tr = 10.48 min (27 %) of the title compound as an oil. 1H NMR (400 MHz, MeOD) δ 0.95 (d, 3H), 1 .02 (d, 3H), 1.12 (d, 3H), 1 .2-1 .67 (m, 5H), 1.82 (m, 1 H), 2.17 (m, 3.5H), 2.93 + 3.02 (2 x s, 3H, rotamers), 3.19 (m, 1 H), 3.57 (d, 0.5H), 4.03 (m, 0.5H), 4.50 (m, 0.5 H), 4.62-4.68 (m, 2H), 7.3-7.52 (m, 4H). HPLC-MS (Method Z1 ): m/z = 343 (M+1 ); tr = 1 .78 min (100 % ELS).
Example 1-2 (General procedure (A))
N-Methyl-N-r4-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.11octane-6-carbonyl)-benzyl1-isobutyramide
Figure imgf000083_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and isobutyryl chloride.
HPLC-MS (Method Z1 ): m/z = 371 (M+1 ); tr = 1 .89 min (100 % ELS). Example 1-3 (General procedure (A))
Cyclopentanecarboxylic acid methyl-[4-(1 .S.S-trimethyl-θ-aza-bicvclorS^.iioctane-θ- carbonvD-benzyli-amide
Figure imgf000084_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and cyclopentanecarbonyl chloride. HPLC-MS (Method Z1 ): m/z = 397 (M+1 ); tr = 2.08 min (100 % TIC).
Example 1-4 (General procedure (A))
Cvclohexanecarboxylic acid methyl-[4-(1.S.S-trimethyl-θ-aza-bicvclofS^.i ioctane-θ- carbonvD-benzyli-amide
Figure imgf000084_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and cyclohexanecarbonyl chloride. HPLC-MS (Method Z1 ): m/z = 41 1 (M+1 ); tr = 2.16 min (100 % ELS).
Example 1-5 (General procedure (A)) Piperidine-1 -carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6- carbonvD-benzyli-amide
Figure imgf000084_0003
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and piperidine-1 -carbonyl chloride.
HPLC-MS (Method Z1 ): m/z = 412 (M+1 ); tr = 2.09 min. Example 1-6 (General procedure (A))
1 ,3-Dimethyl-3-phenyl-1 -f4-(1 ,3,3-trimethyl-6-aza-bicvclof3.2.1loctane-6-carbonyl)-benzyll- urea
Figure imgf000085_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and N-methyl-N-phenylcarbamoyl chloride. HPLC-MS (Method Z1 ): m/z = 435 (M+1 ); tr = 2.19 min.
Example 1-7 (General procedure (A))
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1-benzamide
Figure imgf000085_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and benzoyl chloride. HPLC-MS (Method Z1 ): m/z = 405 (M+1 ); tr = 1 .98 min.
Example 1-8 (General procedure (A)) 1 -Acetyl-piperidine-4-carboxylic acid methyl-|4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6- carbonvD-benzyll-amide
Figure imgf000085_0003
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 1 -acetyl-piperidine-4-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 454 (M+1 ); tr = 1 .61 min.
Example 1-9 (General procedure (A))
1 -Acetyl-piperidine-S-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6- carbonvD-benzyli-amide
Figure imgf000086_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 1 -acetyl-piperidine-3-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 454 (M+1 ); tr = 1 .65 min.
Example 1-10 (General procedure (A))
Cvclopentanecarboxylic acid ethyl-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6-carbonyl)- benzylj-amide
Figure imgf000086_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-ethylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and cyclopentanecarbonyl chloride. HPLC-MS (Method Z1 ): m/z = 41 1 (M+1 ); tr = 2.17 min.
Example 1-11 (General procedure (A)) Morpholine-4-carboxylic acid methyl-[4-(1 .S.S-trimethyl-θ-aza-bicvclofS^.iioctane-θ- carbonvD-benzyli-amide
Figure imgf000087_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and morpholine-4-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 414 (M+1 ); tr = 1 .74 min.
Example 1-12 (General procedure (A))
2,2-N-Trimethyl-N-f4-(1 ,3,3-trimethyl-6-aza-bicvclof3.2.1 loctane-6-carbonyl)-benzyll- propionamide
Figure imgf000087_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 2,2-dimethyl-propionyl chloride. HPLC-MS (Method Z1 ): m/z = 385 (M+1 ); tr = 2.04 min.
Example 1-13 (General procedure (A))
Tetrahvdro-furan-3-carboxylic acid methyl-[4-(1 .S.S-trimethyl-θ-aza-bicvclofS^.i ioctane-θ- carbonyl)-benzyl]-amide
Figure imgf000087_0003
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and tetrahydro-furan-3-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 399 (M+1 ); tr = 1 .68 min.
Example 1-14 (General procedure (A)) N-Methyl-4-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)- benzyli-benzamide
Figure imgf000088_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 4-trifluoromethoxy-benzoyl chloride. HPLC-MS (Method Z1 ): m/z = 489 (M+1 ); tr = 2.24 min.
Example 1-15 (General procedure (A)) Thiophene-2-carboxylic acid methyl-[4-(1 .S.S-trimethyl-θ-aza-bicyclorS^.iioctane-θ- carbonvD-benzyli-amide
Figure imgf000088_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and thiophene-2-carbonyl chloride.
HPLC-MS (Method Z1 ): m/z = 41 1 (M+1 ); tr = 1 .97 min.
Example 1-16 (General procedure (A))
Furan-2-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1]octane-6-carbonyl)- benzyli-amide
Figure imgf000088_0003
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and furane-2-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 395 (M+1 ); tr = 1 .96 min. Example 1-17 (General procedure (A))
3-Chloro-4-(propane-2-sulfonyl)-thiophene-2-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicvclor3.2.11octane-6-carbonyl)-benzyl1-amide
Figure imgf000089_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3-chloro-4-(propane-2-sulfonyl)-thiophene-2-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 551 (M+1 ); tr = 2.0 min.
Example 1-18 (General procedure (A))
6-Chloro-N-methyl-N-[4-(1 .3.3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1- nicotinamide
Figure imgf000089_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 6-chloro-nicotinoyl chloride. HPLC-MS (Method Z1 ): m/z = 440 (M+1 ); tr = 1 .90 min.
Example 1-19 (General procedure (A))
5-Methyl-isoxazole-3-carboxylic acid methyl-[4-(1.S.S-trimethyl-θ-aza-bicvclofS^.i ioctane-θ- carbonvD-benzyli-amide
Figure imgf000089_0003
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 5-methyl-isoxazole-3-carbonyl chloride. HPLC-MS (Method Z1 ): m/z = 410 (M+1 ); tr = 1 .91 min.
Example 1-20 (General procedure (A))
3.3.N-Trimethyl-N-r4-(1 .3.3-trimethyl-6-aza-bicvclor3.2.1loctane-6-carbonyl)-benzyll- butyramide
Figure imgf000090_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3,3-dimethyl-butyryl chloride. HPLC-MS (Method Z1 ): m/z = 399 (M+1 ); tr = 2.12 min.
Example 1-21 (General procedure (A))
3-Cvano-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1- benzamide
Figure imgf000090_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3-cyano-benzoyl chloride. HPLC-MS (Method Z1 ): m/z = 430 (M+1 ); tr = 1 .92 min.
Example 1-22 (General procedure (A)) N-Methyl-2-phenoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1- acetamide
Figure imgf000091_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and phenoxy-acetyl chloride. HPLC-MS (Method Z1 ): m/z = 435 (M+1 ); tr = 2.02 min.
Example 1-23 (General procedure (A))
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1-malonamic acid methyl ester
Figure imgf000091_0002
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and chlorocarbonyl-acetic acid methyl ester. HPLC-MS (Method Z1 ): m/z = 401 (M+1 ); tr = 1 .69 min.
Example 1-24 (General procedure (A))
3-Methyl-but-2-enoic acid methvH4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6-carbonyl)- benzyli-amide
Figure imgf000091_0003
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3-methyl-but-2-enoyl chloride. HPLC-MS (Method Z1 ): m/z = 383 (M+1 ); tr = 1 .92 min.
Example 1-25 (General procedure (A)) N-Methyl-2-phenyl-N-r4-(1 .3.3-trimethyl-6-aza-bicvclor3.2.1 loctane-6-carbonyl)-benzyll- acetamide
Figure imgf000092_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and phenyl-acetyl chloride. HPLC-MS (Method Z1 ): m/z = 419 (M+1 ); tr = 2.03 min.
Example 1-26 (General procedure (A)) 1 -Trifluoromethyl-cvclobutanecarboxylic acid methyl- [4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1-amide
Figure imgf000092_0002
To a solution of 1 -trifluoromethyl-cyclobutanecarboxylic acid (33.6 mg, 0.2 mmol) in THF (5 ml_) was added with stirring HOBt (27 mg, 0.2 mmol) followed by EDAC (38 mg, 0.2 mmol) and the mixture was stirred for 30 min. at ambient temperature. To the resulting mixture was added (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone (50 mg, 0.17 mmol, Example 1 ) and DIPEA (35 μl_, 0.2 mmol). The reaction mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated and the residue purified using preparative HPLC (Method Z4): Amount isolated = 40 mg (53 %) of the title compound as an oil. 1H NMR (400 MHz, CDCI3) δ 0.94 (d, 3H), 1 .04 (d, 3H), 1.13 (d, 3H), 1 .17-1 .60 (m, 4.5H),
1 .75-1 .90 (m, 2H), 2.10 (m, 1 H), 2.24 (m, 0.5H), 2.55 (m, 2H), 2.73 (m, 2H), 2.83+2.86 (2 x s, 3H, rotamers), 3.15 (d, 0.5H), 3.26 (t, 1 H), 3.60 (d, 0.5H), 3.98 (bs, 0.5 H), 4.46 (bs, 0.5H), 4.63 (m, 2H), 7.29 (m, 2H), 7.40 (t, 2H). HPLC-MS (Method Z1 ): m/z = 451 (M+1 ); tr = 2.18 min.
Example 1-27 (General procedure (A))
3,5-Dimethoxy-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1- benzamide
Figure imgf000093_0001
The title compound was prepared by a similar procedure as that described in Example 1 , starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3,5-dimethoxy-benzoyl chloride. HPLC-MS (Method Z1 ): m/z = 465 (M+1 ); tr = 2.05 min.
Example 1-28 (General procedure (A))
4-Methanesulfonyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)- benzyli-benzamide
Figure imgf000093_0002
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 4-methanesulfonyl-benzoic acid. HPLC-MS (Method Z1 ): m/z = 483 (M+1 ); tr = 1 .78 min.
Example 1-29 (General procedure (A))
N-Methyl-3-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)- benzyli-benzamide
Figure imgf000093_0003
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3-trifluoromethoxy-benzoic acid. HPLC-MS (Method Z1 ): m/z = 489 (M+1 ); tr = 2.23 min.
Example 1-30 (General procedure (A)) 2,2-Difluoro-1.S-benzodioxole^-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicvclor3.2.11octane-6-carbonyl)-benzyl1-amide
Figure imgf000094_0001
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 2,2-difluoro-benzo[1 ,3]dioxole-4-carboxylic acid. HPLC-MS (Method Z1 ): m/z = 485 (M+1 ); tr = 2.21 min.
Example 1-31 (General procedure (A)) N-Methyl-6-morpholin-4-yl-N-r4-(1 ,3,3-trimethyl-6-aza-bicvclof3.2.1 loctane-6-caιt)onyl)- benzyli-nicotinamide
Figure imgf000094_0002
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and θ-morpholin^-yl-nicotinic acid.
HPLC-MS (Method Z1 ): m/z = 491 (M+1 ); tr = 1 .52 min.
Example 1-32 (General procedure (A))
N-Methyl-4-(2.2.2-trifluoro-acetyl)-N-r4-(1 .3.3-trimethyl-6-aza-bicvclor3.2.1loctane-6- carbonyl)-benzyl]-benzamide
Figure imgf000094_0003
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 4-(2,2,2-trifluoro-acetyl)-benzoic acid. HPLC-MS (Method Z1 ): m/z = 519 (M+18); tr = 1 .84 min. Example 1-33 (General procedure (A)) 3-Acetyl-N-methyl-N-r4-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.11octane-6-carbonyl)-benzyl1- benzamide
Figure imgf000095_0001
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3-acetyl-benzoic acid. HPLC-MS (Method Z1 ): m/z = 447 (M+1 ); tr = 1 .90 min.
Example 1-34 ] (General procedure (A)) N-Methyl-N-r4-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.11octane-6-carbonyl)-benzyl1-isophthalamic
Figure imgf000095_0002
To a solution of isophthalic acid monomethyl ester (72 mg, 0.4 mmol) in THF (10 ml_) was added with stirring HOBt (54 mg, 0.4 mmol) followed by EDAC (77 mg, 0.4 mmol) and the mixture was stirred for 30 min. at ambient temperature. To the resulting mixture was added (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone (100 mg, 0.33 mmol, Example 1 ) and DIPEA (70 μl_, 0.4 mmol). The reaction mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated and the residue purified using preparative HPLC (Method Z4): Amount isolated = 100 mg (65 %) of N-Methyl-N-[4-(1 ,3,3- trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-isophthalamic acid methyl ester as an oil. To a solution of the ester (100 mg) in EtOH (5 mL) was added water (2 mL) and 1 N NaOH (0.5 mL). The mixture was stirred at ambient temperature for 6 h and the volatiles evaporated. The residue was dissolved in water (5 mL) and washed with Et2O (2 x10 mL) and pH adjusted to 1 by 1 N HCI. The aqueous phase was extracted with EtOAc (3x10 mL), the combined organic phases dried (MgSO4) and evaporated which afforded 73 mg (49 %) of the title compound as a solid. 1H NMR (400 MHz, CDCI3) δ 0.95 (d, 3H), 1 .05 (s, 3H), 1.14 (d, 3H), 1 .33-1 .49 (m, 3.5H), 1 .58 (m, 1 H), 1.79 (m, 1 H), 2.27 (m, 0.5H), 2.88+3.08 (2 x s, 3H, rotamers), 3.28 (m, 1 .5H), 3.63 (d, 0.5H), 4.02 (m, 0.5 H), 4.53-4.79 (m, 2.5H), 7.21 -7.70 (m, 6H), 8.15 (m, 2H). HPLC-MS (Method Z1 ): m/z = 449 (M+1 ); tr = 1 .76 min.
Example 1-35 (General procedure (A))
2,3-Dihvdro-benzofuran-7-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicvclor3.2.11octane-6-carbonyl)-benzyl1-amide
Figure imgf000096_0001
The title compound was prepared by a similar procedure as that described in Example 23, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 2,3-dihydro-benzofuran-7-carboxylic acid. HPLC-MS (Method Z1 ): m/z = 447 (M+1 ); tr = 2.02 min.
Example 1 -36 (General procedure (A))
N-[4-(1 ,3,3-Trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1-benzamide
Figure imgf000096_0002
To a solution of [4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester (1 1 g, 28.5 mmol, Example 1 ) in DCM (40 mL) was added with stirring TFA (20 mL) and the mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated and to the residue was added water (50 mL) and the pH adjusted to 1 1. The mixture was extracted with DCM (3x20 mL) and the combined organic phases were washed with brine (20 mL), dried (MgSO4) and the solvent evaporated affording 7.7 g (94 %) of (4- aminomethyl-phenyl)-(1 ^S-trimethyl-e-aza-bicycloβ^.i Joct-e-yO-methanone as an oil. 1H NMR (400 MHz, CDCI3) δ 0.97 (d, 3H), 1 .02 (d, 3H), 1.12 (d, 3H), 1 .15-1 .44 (m, 4.5H), 1 .56 (t, 1 H), 1 .75 (m, 1 H), 2.23 (m, 0.5H), 3.01 (bs, 2H, NH2), 3.15 (d, 0.5H), 3.57 (d, 0.5H), 3.89 (d, 2H), 3.97 (t, 0.5H), 4.58 (t, 0.5 H), 7.38 (m, 4H). HPLC-MS (Method Z1 ): m/z = 287 (M+1 ); tr = 1 .2 min (100 % ELS). To a solution of the above benzyl amine (100 mg, 0.35 mmol) in DCM (5 ml_) was added with stirring TEA (150 μl_, 1 .05 mmol) followed by benzoyl chloride (60 μl_, 0.52 mmol) and the mixture was stirred for 16 h. at ambient temperature. The mixture was washed with water (3x1 ml_), dried (MgSO4) and the solvent evaporated. The residue was purified using prepa- rative HPLC (Method Z4): Amount isolated = 95 mg (70 %) of the title compound as an oil. 1H NMR (400 MHz, CDCI3) δ 0.92 (d, 3H), 0.95 (d, 3H), 1.01 (d, 3H), 1 .13-1 .58 (m, 4.5H), 1 .74 (m, 1 H), 2.21 (m, 0.5H), 3.12 (d, 0.5H), 3.22 (t, 1 H), 3.56 (d, 0.5H), 3.94 (t, 0.5H), 4.58 (m, 2.5 H), 7.22-7.32 (m, 4H), 7.40 (t, 2H), 7.49 (m, 2H), 7.87 (d, 2H). HPLC-MS (Method Z1 ): m/z = 391 (M+1 ); tr = 1 .91 min (100 % ELS).
Example 1 -(General procedure (A)) r4-(1 -Amino-cvclopropyl)-phenyl1-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.11oct-6-yl)-methanone
To a solution of NaH (1 .95 g, 0.049 mol, 60% in mineral oil, washed twice with dry THF) in dry DMF (50 mL) was added dropwise a solution of [4-(1 ,3,3-Trimethyl-6-aza-bicyclo-
[S^.iloctane-δ-carbonyO-phenyO-acetonitrile (7,0 g, 0,024 mol) in dry DMF (180 ml) at 0° C. To the resulting mixture was added dropwise a solution of 1 ,2-dibromoethan (8,14 mL, 0,094 mol) in dry DMF (25 mL) and the mixture was stirred for 16 hrs at room temperature at which time it was quinced by addition of crused ice. The aqueous phase was extrached with AcOEt (3x250 mL) and the combined organic phases were washed with water (2x100 mL), brine (1 x100 mL), dried (MgSO4) and filtered followed by evaporation of the volatiles. This afforded crud 5.28 g (69%) of 1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- phenyl]-cyclopropanecarbonitrile as an oil. HPLC-MS (Method Z1 ): m/z = 323 (M+1 ); tr = 2.02 min (100 % ELS).
The above nitrile (5.25 g, 16.28 mmol) was added to a mixture of cone. HCI (120 mL) and AcOH (30 mL) and stirred at 80° C for 18 hrs. The reaction mixture is diluted with ice-water (300 mL) and the pH adjusted to 3 by addition of 4 N NaOH. The oily precipitate was extracted with diethyl ether (3x200 mL) and the combined organic phases were washed with water (2x100 mL), brine (1 x80 mL), dried (MgSO4), filtered and the volatiles evaporated in vacuo affording 4.7 g( 85 %) of 1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- phenyl]-cyclopropane-carboxylic acid as a solid. HPLC-MS (Method Z1 ): m/z = 342 (M+1 ); tr = 1 .83 min (100 % ELS). To a solution of the above carboxylic acid (3.00 g, 8.79 mmol) in DCM (600 ml_) was added H2SO4 (7.2 ml_) followed by NaN3 (1 .38 g, 21.23 mmol). The mixture was stirred at 45° C for 16 hrs cooled to room temperature and quenched by addition of ice-water (300 ml_). The pH was adjusted to 1 1 by addition of 4N NaOH and the mixture was extracted with DCM (2x150 ml_). The volatiles were evaporated and the residue was subjected to preperative HPLC purification affording 2.7 g (98 %) of the [4-(1 -amino-cyclopropyl)-phenyl]-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]oct-6-yl)-methanoneas an oil.
HPLC-MS (Method Z1 ): m/z = 313 (M+1 ); tr = 1 .30 min (100 % ELS). 1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 0.99-1.03 (m, 5H), 1 .13 (m, 5H), 1.17-1 .5 (m, 3.5H), 1 .58 (d, 1 H), 1 .75 (m, 1 H), 2.17 (bs, 2H, NH2), 2.24 (dd, 0.5H), 3.17 (d, 0.5H), 3.28 (t, 1 H), 3.58 (d, 0.5H), 3.99 (t, 0.5H), 4.60 (m, 0.5 H), 7.29-7.33 (m, 2H), 7.37-7.42 (m, 2H).
To a solution of [4-(1 -amino-cyclopropyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6- yl)-methanone (150 mg, 0.48 mmol) in DCM (4 mL) was added with stirring TEA (100 μL, 0.72 mmol) followed by benzoyl chloride (61 μL, 0.53 mmol) and the mixture was stirred for
16 h. at ambient temperature. The mixture was washed with water (3x1 mL), dried (MgSO4) and the solvent evaporated. The residue was purified using preparative HPLC (Method Z4):
Amount isolated = 1 16 mg (58%) of the title compound as an oil.
1H NMR (400 MHz, CDCI3) δ 0.92 (d, 3H), 1 .00 (s, 3H), 1.1 1 (s, 3H), 1 .13-1 .44 (m, 5.5H), 1 .57 (m, 1 H), 1.71 (m, 2H), 2.20 (m, 0.5H), 3.1 1 (d, 0.5H), 3.25 (m, 1 H), 3.55 (d, 1 H), 3.96
(m, 0.5H), 4.58 (m, 0.5 H), 7.09 (t, 2H), 7.28 (dd, 2H), 7.44 (t, 2H), 7.51 (t, 1 H), 7.63 (d, 1 H),
7.90 )d, 2H).
HPLC-MS (Method Z1 ): m/z = 417 (M+1 ); tr = 2.0 min (100 % ELS).
[00408] The following compounds were made as outlined in general method A above.
Figure imgf000098_0001
carbonyl)-benzyl]-amide -39 370,54 N-Methyl-N-[4-(1 ,3,3-tri- 371 methyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-
Figure imgf000099_0001
butyramide -40 390,53 N-Methyl-N-[4-(octahydro- 391 quinoline-1 -carbonyl)- benzyl]-benzamide
-41 376,50 N-[4-(3-Aza-bicyclo[3.2.2]- 377 nonane-3-carbonyl)-benzyl]- N-methyl-benzamide
Figure imgf000099_0002
-42 415,54 3-Cyano-N-methyl-N-[4- 416
(octahydro-quinoline-1 -car- bonyl)-benzyl]-benzamide
-43 .01 ,51 N-[4-(3-Azabicyclo[3.2.2]- 402 nonane-3-carbonyl)-benzyl]- 3-cyano-N-methyl- benzamide -44 408.52 3-Fluoro-N-methyl-N-[4- 409 (octahydro-quinoline-1 -car- bonyl)-benzyl]-benzamide
-45 394,49 N-[4-(3-Aza-bicyclo[3.2.2]- 395 nonane-3-carbonyl)-benzyl]- 3-fluoro-N-methyl-benz- amide -46 368,46 N-[4-(Azepane-1 -carbonyl)- 369 benzyl]-3-fluoro-N-methyl- benzamide
Figure imgf000099_0003
-47 350,46 N-[4-(Azepane-1 -carbonyl)- 351 benzyl]-N-methyl-benz- amide
-48 375,47 N-[4-(Azepane-1 -carbonyl)- 376 benzyl]-3-cyano-N-methyl- benzamide
-49 357,50 Piperidine-i -carboxylic acid 358 [4-(azepane-1 -carbonyl)- benzyl]-methyl-amide
-50 359,47 Morpholine-4-carboxylic 360 acid [4-(azepane-1 -carbo- nyl)-benzyl]-methyl-amide
Figure imgf000100_0001
-51 376,50 N-[4-(Octahydro-quinoline- 377 1 -carbonyl)-benzyl]-benz- amide
-52 362,48 N-[4-(3-Azabicyclo[3.2.2]- 363 nonane-3-carbonyl)-benzyl]- benzamide
-53 336,44 N-[4-(Azepane-1 -carbonyl)- 337 benzyl]-benzamide
-54 362,48 N-[4-(6-Aza-bicyclo[3.2.1 ]- 363 octane-6-carbonyl)-benzyl]- N-methyl-benzamide
Figure imgf000100_0002
-55 418.54 4-[(Benzoyl-methyl-amino)- 419 methyl]-N-(3-hydroxy- adamantan-1 -yl)-benzamide -56 387,49 N-[4-(6-Aza-bicyclo[3.2.1 ]- 388 octane-6-carbonyl)-benzyl]- 3-cyano-N-methyl-benz- amide -57 443.55 4-[(3-Cyano-benzoyl- 444 methyl-amino)-methyl]-N-(3- hydroxy-adamantan-1 -yl)- benzamide -58 380.47 N-[4-(6-Aza-bicyclo[3.2.1 ]- 381 octane-6-carbonyl)-benzyl]- 3-fluoro-N-methyl- benzamide -59 436,53 4-[(3-Fluoro-benzoyl- 437 methyl-amino)-methyl]-N-(3- hydroxy-adamantan-1 -yl)- benzamide -60 439,6 1 -Acetyl-piperidine-4-car- 440 boxylic acid methyl-[4-(octa- hydro-quinoline-1 -carbonyl)- benzyl]-amide -61 378.48 N-[4-(3-Hydroxy-8-aza- 379 bicyclo[3.2.1]octane-8-car- bonyl)-benzyl]-N-methyl- benzamide -62 422,55 3-Fluoro-N-methyl-N-[4- 423
(1 ,8,8-trimethyl-3-aza-bi- cyclo[3.2.1 ]octane-3-car-
Figure imgf000101_0001
bonyl)-benzyl]-benzamide -63 3-Fluoro-N-[4-(3-hydroxy-8- 397 aza-bicyclo[3.2.1 ]octane-8-
Figure imgf000102_0001
carbonyl)-benzyl]-N-methyl- benzamide -64 404,56 N-Methyl-N-[4-(1 ,8,8-tri- 405 methyl-3-aza-bicyclo[3.2.1 ]- octane-3-carbonyl)-benzyl]- benzamide -65 348,45 N-[4-(6-Aza-bicyclo[3.2.1 ]- 349 octane-6-carbonyl)-benzyl]- benzamide
-66 390,53 N-[4-(1 ,8,8-Trimethyl-3-aza- 391 bicyclo[3.2.1]octane-3- carbonyl)-benzyl]- benzamide -67 364,45 N-[4-(3-Hydroxy-8-aza- 365 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]- benzamide -68 399,54 1 -Acetyl-piperidine-4-carb- 400 oxylic acid [4-(azepane-1 -
Figure imgf000102_0002
carbonyl)-benzyl]-methyl- amide -69 404,51 4-(Benzoylamino-methyl)-N- 405
(3-hydroxy-adamantan-1 - yl)-benzamide
-70 429,57 3-Cyano-N-methyl-N-[4- 430 (1 ,8,8-trimethyl-3-aza-bi- cyclo[3.2.1 ]octane-3-car-
Figure imgf000102_0003
bonyl)-benzyl]-benzamide -71 405,48 3-Cyano-N-[4-(3-fluoro-8- 406 aza-bicyclo[3.2.1 ]octane-8- carbonyl)-benzyl]-N-methyl- benzamide -72 398,46 3-Fluoro-N-[4-(3-fluoro-8- 399 aza-bicyclo[3.2.1 ]octane-8- carbonyl)-benzyl]-N-methyl-
Figure imgf000103_0001
benzamide -73 438,52 4-(3-Fluoro-benzoylamino- 439 methyl)-N-methly-N-(3- fluoro-adamantan-1 -yl)- benzamide -74 445,54 4-(3-Cyano-benzoylamino- 446 methyl)-N-methly-N-(3- fluoro-adamantan-1 -yl)- benzamide
-75 453,63 1 -Acetyl-piperidine-4- 454 carboxylic acid methyl-[4-
Figure imgf000103_0002
(1 ,8,8-trimethyl-3-aza- bicyclo[3.2.1]octane-3- carbonyl)-benzyl]-amide -76 380,47 N-[4-(3-Fluoro-8-aza- 381 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]-N-methyl-
Figure imgf000103_0003
benzamide -77 420,53 4-[(Benzoyl-methyl-amino)- 421 methyl]-N-(3-fluoro-ada- mantan-1 -yl)-benzamide
-78 403,49 3-Cyano-N-[4-(3-hydroxy-8- 404 aza-bicyclo[3.2.1 ]octane-8- carbonyl)-benzyl]-N-methyl-
Figure imgf000103_0004
benzamide -79 4-(Benzoylamino-methyl)-N- 407 (3-fluoro-adamantan-1 -yl)- benzamide
Figure imgf000104_0001
-80 425,58 1 -Acetyl-piperidine-4- 426 carboxylic acid [4-(3-aza-
Figure imgf000104_0002
bicyclo[3.2.2]nonane-3- carbonyl)-benzyl]-methyl- amide -81 366,44 N-[4-(3-Fluoro-8-aza-bi- 367 cyclo[3.2.1 ]octane-8-carbo- nyl)-benzyl]-benzamide
Figure imgf000104_0003
-82 427,55 4-(3-Cyano-benzoylamino- 428 methyl)-N-(adamantan-2- yl)-benzamide
-83 420,53 4-(3-Fluoro-benzoylamino- 421 methyl)-N-(adamantan-2- yl)-benzamide
-84 420,53 N-[4-(4-Azatricyclo- 421
[4.3.1.1 *3,8*]undecane-4- carbonyl)-benzyl]-3-fluoro- N-methyl-benzamide -85 416,57 N-{1 -[4-(1 ,3,3-Trimethyl-6- 417 aza-bicyclo[3.2.1 ]octane-6- carbonyl)-phenyl]-cyclo- propylj-benzamide -86 354,50 N-{1 -[4-(1 ,3,3-Trimethyl-6- 355 aza-bicyclo[3.2.1 ]octane-6- carbonyl)-phenyl]-cyclo-
Figure imgf000104_0004
propylj-acetamide 494,66 4-Methanesulfonyl-N-{1 -[4- 495
(1 ,3,3-trimethyl-6-aza-
Figure imgf000105_0001
bicyclo[3.2.1]octane-6- carbonyl)-phenyl]-cyclo- propylj-benzamide
1 -88 430,60 N-Methyl-N-{1 -[4-(1 ,3,3- 431 trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-
Figure imgf000105_0002
phenyl]-cyclo-propyl}- benzamide
1 -89 368,52 N-Methyl-N-{1 -[4-(1 ,3,3- 369 trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-
Figure imgf000105_0003
phenyl]-cyclo-propyl}- acetamide
1 -90 508,69 4-Methanesulfonyl-N- 509 methyl-N-{1 -[4-(1 ,3,3-
Figure imgf000105_0004
trimethyl-6-aza- bicyclo[3.2.1]octane-6- carbonyl)-phenyl]-cyclo- propylj-benzamide
Example 2-1 (General procedure (B1 ))
1 ,1 -Dimethyl-3-methyl-3-r4-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.11octane-6-carbonyl)-benzyl1- sulfamide
Figure imgf000105_0005
To a solution of (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone (100 mg, 0.33 mmol, Example 1 ) in DCM (25 ml_) was added with stirring TEA (140 μl_, 1 mmol) followed by dimethylsulfamoyl chloride (54 μl_, 0.5 mmol) and the mixture was stirred for 1 h. at ambient temperature. The mixture was evaporated and the residue pu- rified using preparative HPLC (Method Z4): Amount isolated = 28 mg (21 %) of the title compound as an oil.
1H NMR (400 MHz, CDCI3) δ 0.94 (d, 3H), 1 .03 (d, 3H), 1.13 (d, 3H), 1 .17-1 .61 (m, 4.5H), 1 .77 (m, 1 H), 2.24 (m, 0.5H), 2.70 (s, 3H), 2.86 (s, 6H), 3.16 (d, 0.5H), 3.26 (m, 1 H), 3.60 (d, 0.5H), 3.97 (t, 0.5 H), 4.34 (d, 2H), 4.61 (m, 0.5H), 7.38 (m, 2H), 7.44 (t, 2H). HPLC-MS (Method Z1 ): m/z = 408 (M+1 ); tr = 1 .98 min (100 % ELS).
Example 2-2 (General procedure (B1 )) N-Methyl-N-r4-(1 .3.3-trimethyl-6-aza-bicvclor3.2.1 loctane-6-carbonyl)-benzyll- methanesulfonamide
Figure imgf000106_0001
The title compound was prepared by a similar procedure as that described in Example 33, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and methanesulfonyl chloride. HPLC-MS (Method Z1 ): m/z = 379 (M+1 ); tr = 1 .8 min (100 % ELS).
Example 2-3 (General procedure (B1 ))
2,2,2-Trifluoro-ethanesulfonic acid methyl-[4-(1 .S.S-trimethyl-e-aza-bicvclofS^.i ioctane-e- carbonvD-benzyli-amide
Figure imgf000106_0002
The title compound was prepared by a similar procedure as that described in Example 33, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 2,2,2-trifluoro-ethanesulfonyl chloride.
HPLC-MS (Method Z1 ): m/z = 447 (M+1 ); tr = 2.09 min.
Example 2-4 (General procedure (B1 ))
N-Methylphenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 ]octane-6-carbonyl)-benzyl1- methanesulfonamide
Figure imgf000107_0001
The title compound was prepared by a similar procedure as that described in Example 33, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and benzylsulfonyl chloride. HPLC-MS (Method Z1 ): m/z = 455 (M+1 ); tr = 2.17 min.
The following compounds were made as outlined in general procedure (B2) above.
Example 2-(General procedure (B2)) Trifluoro-N-isopropyl-N-r4-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.11octane-6-carbonyl)-benzyl1- methanesulfonamide
Figure imgf000107_0002
Step A: 4-(Tetrahydro-pyran-2-yloxymethyl)-benzoic acid
Figure imgf000107_0003
To a ice-water cooled solution of 4-hydroxymethyl-benzoic acid methyl ester (6.0 g, 36.1 1 mmol) and 3,4-dihydro-2H-pyran (16.47 ml_, 180.53 mmol) in DCM (125 ml_) was added p- toluenesulfonic acid mono hydrate (69 mg, 0.36 mmol). The mixture was stirred for 4 h. at ambient temperature. The solvent was evaporated affording crude (~ 9 g) of 4-(tetrahydro- pyran-2-yloxymethyl)-benzoic acid methyl ester (LC/MS: 272 [M+23]) as an oil.
To a solution of the ester (~ 9 g) in EtOH (50 ml_) was added 1 N NaOH (55 ml_) and the mixture was stirred for 16 h. at ambient temperature. The volatiles were evaporated and the aqueous phase washed with Et2O (50 ml_). pH of the aqueous phase was adjusted to 3 by addition of 1 N HCI. The precipitate was extracted with Et2O (2 x 50 ml_), dried (Na2SO4) and evaporated which afforded 6 g (71 %) of 4-(tetrahydro-pyran-2-yloxymethyl)-benzoic acid as a solid.
1H NMR (400 MHz, CDCI3) δ 1 .55-1 .92 (m, 6H), 3.55 (m, 1 H), 3.91 (t, 1 H), 4.59 (d, 1 H), 4.74 (t, 1 H), 4.87 (d, 1 H), 7.48 (d, 2H), 8.09 (d, 2H). HPLC-MS (Method Z1 ): m/z = 259 (M+23); tr = 1 .42 min.
Step B: (4-Hydroxymethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone
Figure imgf000108_0001
To a solution of the above benzoic acid (6.0 g, 25.40 mmol) in dry THF (100 ml_) was added with stirring HOBt (3.8 g, 27.93 mmol) followed by EDAC (5.36 g, 27.93 mmol) and the mixture was stirred for 30 min. at ambient temperature. To the resulting mixture was added 1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane, hydrochloride (5.3 g, 27.93 mmol) and DIPEA (9.29 ml_, 53.33 mmol). The reaction mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated and to the residue was added water (100 ml_). The mixture was extracted with Et2O (3x35 ml_) and the combined organic phases were dried (MgSO4) and the solvent evaporated affording crude amide which was dissolved in MeOH (100 ml_). To this mixture was added p-toluenesulfonic acid (1 g) and the mixture was stirred for 2 h at ambient temperature. The solvent was evaporated and the residue purified using silica gel column chromatography (Flash 40) using first as mixture of EtOAc-Heptane (1 :2) (500 ml_) followed by EtOAc-Heptane 2:1 as eluents. Pure fractions were collected, evaporated to 1/10 volume and the precipitate filtered off and washed with a Et2O (20 ml_) which afforded after drying 5.2 g (71 %) of (4-hydroxymethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone as a solid. TLC (EtOAc-Heptane) 2:1 Rf: 0.2.
1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .02 (d, 3H), 1.12 (s, 3H), 1 .14-1 .60 (m, 5H), 1 .75 (m, 1 H), 2.23 (m, 0.5H), 2.54 (bs, 1 H), 3.19 (q, 0.5H), 3.26 (d, 0.5H), 3.59 (d, 0.5H), 3.96 (t, 0.5 H), 4.60 (m, 0.5 H), 4.69 (d, 2H), 7.34-7.40 (m, 4H). HPLC-MS (Method Z1 ): m/z = 288 (M+1 ); tr = 1 .81 min.
Step C: [4-(lsopropylamino-methyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone
Figure imgf000109_0001
To a ice-water cooled solution of the above benzyl alcohol (500 mg, 1.74 mmol), TEA (0.5 ml_, 3.48 mmol) in DCM (40 ml_) was added with stirring methanesulfonyl chloride (203 μl_, 2.61 mmol) and the mixture was stirred for 1 h at ambient temperature. The mixture was washed with water (20 ml_), dried (MgSO4) and the solvent evaporated. To the residue dissolved in DCM (20 ml_) was added isopropyl amine (800 ml_) and the mixture was stirred for for 1 h at ambient temperature followed by evaporation of the solvent. The residue was purified using silicagel column chromatography (Flash 40) and AcOEt as eluent. Pure fractions were collected and evaporated affording 300 mg (53 %) of [4-(isopropylamino-methyl)- phenyl]-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoct-θ-yO-methanone as an oil.
1H NMR (400 MHz, CDCI3) δ 0.92 (d, 3H), 1 .02 (d, 3H), 1.12 (m, 9H), 1.18-1 .45 (m, 4H), 1 .56 (m, 1 H), 1.75 (m, 1 H), 1 .94 (bs, 1 H), 2.24 (dd, 0.5H), 2.87 (m, 1 H), 3.20 (q, 0.5H), 3.27 (dd, 0.5H), 3.57 (d, 0.5H), 3.82 (d, 2H), 3.97 (d, 0.5H), 4.60 (m, 0.5H), 7.38 (m, 4H). HPLC-MS (Method Z1 ): m/z = 329 (M+1 ); tr = 1 .28 min (100 % ELS).
Step D:
To a solution of the above isopropyl amine (100 mg, 0.304 mmol) in DCM (15 mL) cooled to - 50° C (dry ice/acetone) was added with stirring TEA (130 μL, 0.913 mmol) followed by trifluoromethansulfonic anhydride (100 μL, 0.61 mmol) and the mixture was stirred for 30 min. at -5O0 C. To the mixture was added water (0.2 mL), the solvent evaporated and the residue purified using preparative HPLC (Method 24); Amount isolated = 65 mg (46 %) of the title compound as an oil.
1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .03 (d, 3H), 1.13 (bs, 9H), 1 .16-1 .61 (m, 4.5H), 1 .77 (m, 1 H), 2.24 (dd, 0.5H), 3.18 (q, 1 H), 3.28 (d, 0.5H), 3.60 (d, 0.5H), 3.94 (t, 0.5 H), 4.25 (m, 1 H), 4.31 -4.85 (bs, 2H), 4.62 (m, 0.5H), 7.45 (m, 4H).
HPLC-MS (Method Z1 ): m/z = 461 (M+1 ); tr = 2.50 min (100 % ELS).
Example 2-6 (General procedure (B2))
N-Cvclopropyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1- methanesulfonamide
Figure imgf000110_0001
The title compound was prepared by a similar procedure as that described in Example 46, starting from (4-cyclopropylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6- yl)-methanone and trifluoro-methanesulfonic anhydride. HPLC-MS (Method Z1 ): m/z = 459 (M+1 ); tr = 2.45 min.
Example 2-7 (General procedure (B2))
N-Ethyl-trifluoro-N-f4-(1 ,3,3-trimethyl-6-aza-bicvclof3.2.1 loctane-6-carbonyl)-benzyll- methanesulfonamide
Figure imgf000110_0002
The title compound was prepared by a similar procedure as that described in Example 46, starting from (4-ethylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and trifluoro-methanesulfonic anhydride.
HPLC-MS (Method Z1 ): m/z = 447 (M+1 ); tr = 2.43 min (100 % ELS).
Example 2-8 (General procedure (B2))
Trifluoro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.1 loctane-6-carbonyl)-benzyll- methanesulfonamide
Figure imgf000110_0003
The title compound was prepared by a similar procedure as that described in Example 46, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and trifluoro-methanesulfonic anhydride. HPLC-MS (Method Z1 ): m/z = 433 (M+1 ); tr = 2.35 min. [00409] The following compounds were made as outlined in general method B1 and B2 above.
Ex. Structure MW IUPAC Name LC/MS
2-9 324,45 N-[4-(Azepane-1 - 325 carbonyl)-benzyl]-N- methyl-methane- sulfonamide
2-10 350,48 N-[4-(3-Aza-bicyclo[3.2.2]- 351 nonane-3-carbonyl)- benzyl]-N-methyl-
Figure imgf000111_0001
methane-sulfonamide
2-1 1 378,54 N-Methyl-N-[4-(1 ,8,8-tri- 379 methyl-3-aza- bicyclo[3.2.1]-octane-3-
Figure imgf000111_0002
carbonyl)-benzyl]- methane-sulfonamide
2-12 336,46 N-[4-(6-Aza-bicyclo[3.2.1 ]- 337 octane-6-carbonyl)- benzyl]-N-methyl- methane-sulfonamide
2-13 352,46 N-[4-(3-Hydroxy-8-aza- 353 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]-N-
Figure imgf000111_0003
methyl- methanesulfonamide
2-1 1 354,61 N-Methyl-N-[4-(octahydro- 355 quinoline-1 -carbonyl)- benzyl]-methanesulfon- amide
2-12 392,52 N-(3-Hydroxy-adamantan- 393
1 -yl)-4-[(methanesulfonyl- methyl-amino)-methyl]-
Figure imgf000111_0004
benzamide -13 394.51 N-(3-Fluoro-adamantan-1 - 395 yl)-4-[(methanesulfonyl- methyl-amino)-methyl]-
Figure imgf000112_0001
benzamide
-14 354,45 N-[4-(3-Fluoro-8-aza- 355 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]-N-
Figure imgf000112_0002
methyl -methanesulfonamide -15 376.52 N-Adamantan-2-yl-4- 377 [(methanesulfonyl-methyl- amino)-methyl]-benzamide
-16 509,67 N-(4-{1 -[4-(1 ,3,3- 510
Trimethyl-6-aza-
Figure imgf000112_0003
bicyclo[3.2.1]octane-6- carbonyl)-phenyl]-cyclo- propylsulfamoylj-phenyl)- acetamide -17 487,07 4-Chloro-N-{1 -[4-(1 ,3,3-tri- 488 methyl-6-aza-bicyclo-
Figure imgf000112_0004
[3.2.1]octane-6-carbonyl)- phenyl]-cyclo-propyl}- benzene-sulfonamide -18 456,61 i -Methyl-I H-imidazole-4- 457 sulfonic acid {1 -[4-(1 ,3,3-
Figure imgf000112_0005
trimethyl-6-aza-bicyclo- [3.2.1]octane-6-carbonyl)- phenyl]-cyclopropyl}- amide 2-19 390,55 N-{1 -[4-(1 ,3,3-Trimethyl-6- 391 aza-bicyclo[3.2.1 ]octane- 6-carbonyl)-phenyl]-cyclo-
Figure imgf000113_0001
propylj-ethanesulfonamide
Example 3-1 (General procedure (C))
3-Benzoyl-1 -methyl-1 -F4-(1 ,3,3-trimethyl-6-aza-bicvclor3.2.πoctane-6-carbonyl)-benzvπ-urea
Figure imgf000113_0002
To a solution of (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone (70 mg, 0.23 mmol, Example 1 ) in DCM (20 ml_) was added benzoyl isocyanate (51 mg, 0.35 mmol) and the mixture was stirred for 16 h. at ambient temperature. The mixture was evaporated and the residue purified on silica gel column chromatography (Flash 40) using first a mixture of AcOEt-Heptane (1 :1 ) as eluent followed by pure AcOEt. Pure fractions were collected and evaporated which afforded 45 mg (43 %) of the title compound. 1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .03 (s, 3H), 1.13 (s, 3H), 1 .16-1 .60 (m, 4.5H), 1 .76 (m, 1 H), 2.23 (m, 0.5H), 2.99 (bs, 3H), 3.16 (d, 0.5H), 3.26 (m, 1 H), 3.58 (d, 0.5H), 3.96 (m, 0.5 H), 4.61 (m, 0.5 H), 4.64 (s, 2H), 7.42 (m, 6H), 7.55 (t, 1 H), 7.89 (m, 2H), 8.66 (bs, 1 H).
HPLC-MS (Method Z1 ): m/z = 448 (M+1 ); tr = 1 .85 min (100 % ELS).
Example 3-2 (General procedure (C))
3-Cvclohexyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1- urea
Figure imgf000113_0003
The title compound was prepared by a similar procedure as that described in Example 37, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and isocyanato-cyclohexane. HPLC-MS (Method Z1 ): m/z = 426 (M+1 ); tr = 2.06 min.
Example 3-3 (General procedure (C))
3-(4-Methyl-benzenesulfonyl)-1 -methyl-1 -F4-(1 ■3.3-trimethyl-6-aza-bicvclor3.2.1 loctane-6- carbonvD-benzyll-urea
Figure imgf000114_0001
The title compound was prepared by a similar procedure as that described in Example 37, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 4-methyl-benzenesulfonyl isocyanate. HPLC-MS (Method Z1 ): m/z = 499 (M+1 ); tr = 2.02 min.
Example 3-4 (General procedure (C))
3-(2.3-Dihvdro-1.4-benzodioxin-2-ylmethyl)-1 -methyl-1 -F4-(1 ,3.3-trimethyl-6-aza- bicvclo[3.2.11octane-6-carbonyl)-benzyl1-urea
Figure imgf000114_0002
Step A: 1 -Methyl-3-{methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- carbamoyl}-3H-imidazol-1 -ium, iodide
Figure imgf000114_0003
To a solution of (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone (1 .1 g, 3.66 mmol, Example 1 ) in DCM (40 mL) was added CDI (0.9 g, 5.49 mmol) and the mixture was stirred for 16 h. at ambient temperature. The mixture was washed with water (25 mL), dried (Na2SO4) and evaporated. To the residue dissolved in MeCN (40 ml_) was added methyl iodine (2.5 ml_, 36.61 mmol) and the resulting mixture was stirred for 16 h. at ambient temperature. The solvent was evaporated affording 2 g (-100 %) of 1 -methyl-3-{methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- carbamoyl}-3H-imidazol-1 -ium, iodide.
Step B:
To a solution of 2,3-dihydro-benzo[1 ,4]dioxin-2-yl-methylamine (22 mg, 0.134 mmol) in a mixture of DCM (2 ml_) and TEA (16 μl_, 0.134 mmol) was added a solution of the above imi- dazolium salt (60 mg, 0.1 12 mmol) in DCM (2 ml_). The mixture was stirred for 16 h. at ambi- ent temperature and the solvent evaporated. The residue was purified using pieparative HPLC (Method Z4V Amount isolated = 50 mg (91 ^ of the title compound as a solid. 1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .02 (s, 3H), 1.12 (s, 3H), 1 .16-1 .60 (m, 4.5H), 1 .76 (m, 1 H), 2.23 (m, 0.5H), 2.88 (s, 3H), 2.97 (bs, 1 H), 3.14 (d, 0.5H), 3.25 (t, 1 H), 3.53 (m, 0.5H), 3.59 (d, 0.5H), 3.68 (m, 0.5H), 3.97 (m, 2H), 4.30 (d, 2H), 4.53 (d, 2H), 4.60 (m, 0.5H), 4.96 (t, 0.5H), 6.85 (m, 4H), 7.27 (m, 2H), 7.41 (t, 2H).
HPLC-MS (Method Z1 ): m/z = 493 (M+1 ); tr = 2.10 min (100 % ELS).
Example 3-5 (General procedure (C))
3-(3-Methoxy-benzyl)-1 -methyl-1 -r4-(1 .3.3-trimethyl-6-aza-bicvclor3.2.1 loctane-6-carbonvl)- benzvll-urea
Figure imgf000115_0001
The title compound was prepared by a similar procedure as that described in Example 40, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 3-methoxy-benzylamine. HPLC-MS (Method Z1 ): m/z = 465 (M+1 ); tr = 2.02 min (100 % ELS).
Example 3-6 (General procedure (C)) 3-(1 .1 -Dioxo-tetrahvdro-thiophen-3-yl)-1 -methyl-1 -[4-(1 ,3.3-trimethyl-6-aza- bicvclo[3.2.11octane-6-carbonyl)-benzyl1-urea
Figure imgf000116_0001
The title compound was prepared by a similar procedure as that described in Example 40, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 1 ,1 -dioxo-tetrahydro-thiophen-3-ylamine. HPLC-MS (Method Z1 ): m/z = 463 (M+1 ); tr = 1 .63 min (100 % ELS).
Example 3-7 (General procedure (C)) 1 -Methyl-3-(tetrahvdro-pyran-4-yl)-1 -f4-(1 ,3,3-trimethyl-6-aza-bicvclof3.2.1loctane-6- carbonvD-benzyll-urea
Figure imgf000116_0002
The title compound was prepared by a similar procedure as that described in Example 40, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and tetrahydro-pyran-4-yl-amine.
HPLC-MS (Method Z1 ): m/z = 429 (M+1 ); tr = 1 .69 min (100 % ELS).
Example 3-8 (General procedure (C)) f 1 ,3-Dimethyl-3-r4-(1.S.S-trimethyl-e-aza-bicvcloβ^.i loctane-6-carbonyl)-benzyll-ureido)- acetic acid methyl ester
Figure imgf000116_0003
The title compound was prepared by a similar procedure as that described in Example 40, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and methylamino-acetic acid methyl ester. HPLC-MS (Method Z1 ): m/z = 431 (M+1 ); tr = 1 .85 min (100 % ELS). Example 3-9 (General procedure (C)) i -Methyl-S-fS-trifluoromethyl-I .SΛ-thiadiazol^-vD-i -r^d .S.S-trimethyl-S-aza-bicvclors^.n- octane-6-carbonyl)-benzyl1-urea
Figure imgf000117_0001
The title compound was prepared by a similar procedure as that described in Example 40, starting from (4-methylaminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone and 5-trifluoromethyl-[1 ,3,4]thiadiazol-2-ylamine. HPLC-MS (Method Z1 ): m/z = 497 (M+1 ); tr = 2.19 min (100 % ELS).
[00410] The following compounds were made as outlined in general method C above.
Ex. Structure MW IUPAC Name LC/
MS
3-10 477.6 2-{3-Methyl-3-[4-(1 ,3,3- 478 trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-arbonyl)-
Figure imgf000117_0002
benzyl]-ureido}-benzoic acid methyl ester
3-1 1 491 .6 3-{3-Methyl-3-[4-(1 ,3,3- 492 trimethyl-6-aza-bicyclo-
Figure imgf000117_0003
[3.2.1]octane-6-carbonyl)- benzyl]-ureido}-benzoic acid ethyl ester
3-12 465.7 1 -Methyl-3-(3-ethylsulfanyl- 466 phenyl)-1 -[4-(1 ,3,3-trimethyl-6- aza-bicyclo-[3.2.1 ]octane-6-
Figure imgf000117_0004
carbonyl)-benzyl]-urea
3-13 465.7 1 -Methyl-3-(4-ethylsulfanyl- 466 phenyl)-1 -[4-(1 ,3,3-trimethyl-6-
Figure imgf000117_0005
aza-bicyclo-[3.2.1 ]octane-6- carbonyl)-benzyl]-urea -14 525.7 3-(4-Benzyloxy-phenyl)-1 - 526 methyl-1 -[4-(1 ,3,3-trimethyl-6- aza-bicyclo[3.2.1 ]octane-6-
Figure imgf000118_0001
carbonyl)-benzyl]-urea
-15 519.6 1 -Methyl-3-(4-trifluoro-methyl- 520 sulfanyl-phenyl)-1 -[4-(1 ,3,3-tri- methyl-6-aza-bicyclo[3.2.1]-
Figure imgf000118_0002
octane-6-carbonyl)-benzyl]- urea -16 461 .6 3-(4-Acetyl-phenyl)-1 -methyl- 462
1 -[4-(1 ,3,3-tri-methyl-6-aza- bicyclo-[3.2.1 ]octane-6-
Figure imgf000118_0003
carbonyl)-benzyl]-urea
-17 461 .6 3-(3-Acetyl-phenyl)-1 -methyl- 462 1 -[4-(1 ,3,3-tri-methyl-6-aza- bicyclo-[3.2.1 ]octane-6-
Figure imgf000118_0004
carbonyl)-benzyl]-urea -18 444.6 3-(3-Cyano-phenyl)-1 -methyl- 445 1 -[4-(1 ,3,3-tri-methyl-6-aza- bicyclo-[3.2.1 ]octane-6-
Figure imgf000118_0005
carbonyl)-benzyl]-urea -19 487.6 1 -Methyl-3-(4-trifluoro-methyl- 488 phenyl)-1 -[4-(1 ,3,3-trimethyl-6- aza-bicyclo-[3.2.1 ]octane-6-
Figure imgf000118_0006
carbonyl)-benzyl]-urea
-20 463.6 3-(4-Methoxy-benzyl)-1 - 464 methyl-1 -[4-(1 ,3,3-tri-methyl-6- aza-bicyclo-[3.2.1 ]octane-6-
Figure imgf000118_0007
carbonyl)-benzyl]-urea -21 549.6 1 -Methyl-3-(2,2,4,4-tetraf luoro- 550
4H-benzo-[1 ,3]dioxin-6-yl)-1 -
[4-(1 ,3,3-trimethyl-6-aza-
Figure imgf000119_0001
bicyclo-[3.2.1 ]octane-6- carbonyl)-benzyl]-urea -22 503.6 1 -Methyl-3-(4-trif luoro- 504 methoxy-phenyl)-1 -[4-(1 ,3,3- trimethyl-6-aza-
Figure imgf000119_0002
bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-urea -23 521 .6 1 -Methyl-3-[4-(2,2,2-trif luoro- 523 acetyl)-cyclohexyl]-1 -[4-(1 ,3,3- trimethyl-6-aza-bicyclo[3.2.1 ]-
Figure imgf000119_0003
octane-6-carbonyl)-benzyl]- urea -24 475.6 1 -(4-Acetyl-phenyl)-1 ,3- 476 dimethyl-3-[4-(1 ,3,3-tri-methyl-
6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-urea -25 431 .6 1 -Phenyl-3-{1 -[4-(1 ,3,3- 432 trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)- phenyl]-cyclopropyl}-urea -26 397.6 Piperidine-i -carboxylic acid 398 methyl-[4-(octahydro- quinoline-1 -carbonyl)-benzyl]- amide -27 383.5 Piperidine-1 -carboxylic acid 384
[4-(3-aza-bicyclo-
[3.2.2]nonane-3-carbonyl)-
Figure imgf000119_0004
benzyl]-methyl-amide -28 399.5 Morpholine-4-carboxylic acid 400 methyl-[4-(octahydro- quinoline-1 -carbonyl)-benzyl]- amide -29 385.5 Morpholine-4-carboxylic acid 386
[4-(3-aza-bicyclo-
[3.2.2]nonane-3-carbonyl)- benzyl]-methyl-amide -30 419.6 1 ,3-Dimethyl-3-[4-(octahydro- 420 quinoline-1 -carbonyl)-benzyl]-
1 -phenyl-urea
-31 405.5 1 -[4-(3-Aza-bicyclo-[3.2.2]- 406 nonane-3-carbonyl)-benzyl]-
1 ,3-dimethyl-3-phenyl-urea
-32 369.5 Piperidine-1 -carboxylic acid 370
[4-(6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)- benzyl]-methyl-amide -33 41 1 .6 Piperidine-1 -carboxylic acid 412 methyl-[4-(1 ,8,8-trimethyl-3- aza-bicyclo[3.2.1 ]octane-3- carbonyl)-benzyl]-amide -34 371 .5 Morpholine-4-carboxylic acid 372 [4-(6-aza-bicyclo- [3.2.1]octane-6-carbonyl)- benzyl]-methyl-amide -35 413.6 Morpholine-4-carboxylic acid 414 methyl-[4-(1 ,8,8-trimethyl-3- aza-bicyclo[3.2.1 ]octane-3-
Figure imgf000120_0001
carbonyl)-benzyl]-amide -36 392 onyl)- -3-phenyl-
Figure imgf000121_0001
-37 433.6 1 ,3-Dimethyl-1 -phenyl-3-[4- 434 (1 ,8,8-trimethyl-3-aza-bicyclo- [3.2.1]octane-3-carbonyl)- benzyl]-urea -38 385.5 Piperidine-1 -carboxylic acid 386 [4-(3-hydroxy-8-aza- bicyclo[3.2.1]-octane-8-
Figure imgf000121_0002
carbonyl)-benzyl]-methyl- amide -39 387.5 Morpholine-4-carboxylic acid 388 [4-(3-hydroxy-8-aza-bicyclo- [3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide
-40 407.5 1 -[4-(3-Hydroxy-8-aza-bicyclo- 408 [3.2.1]octane-8-carbonyl)- benzyl]-1 ,3-di-methyl-3- phenyl-urea
-41 409.5 1 -[4-(3-Fluoro-8-aza-bicyclo- 410 [3.2.1]octane-8-carbonyl)- benzyl]-1 ,3-di-methyl-3- phenyl-urea -42 387.5 Piperidine-1 -carboxylic acid 388
[4-(3-fluoro-8-aza- bicyclo[3.2.1]octane-8-
Figure imgf000121_0003
carbonyl)-benzyl]-methyl- amide -43 389.5 Morpholine-4-carboxylic acid 390
[4-(3-fluoro-8-aza- bicyclo[3.2.1]-octane-8-
Figure imgf000122_0001
carbonyl)-benzyl]-methyl- amide -44 432.6 N-Adamantan-2-yl-4-(1 ,3- 433 dimethyl-3-pyridin-2-yl- ureidomethyl)-benzamide
Figure imgf000122_0002
-45 407
-46 o- 409
n-
Figure imgf000122_0003
-47 41 1 .5 Morpholine-4-carboxylic acid 412 [4-(adamantan-2- ylcarbamoyl)-benzyl]-methyl-
Figure imgf000122_0004
amide
-48 413 onyl)- 3-thiazol-
Figure imgf000122_0005
-49 386.5 1 ,3-Dimethyl-3-[4-(2-oxa-5- 387 aza-bicyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-1 -thiazol-2-
Figure imgf000122_0006
yl-urea -50 480.7 4-[3-(1 -Acetyl-piperidin-4-yl)- 481 1 ,3-dimethyl-ureidomethyl]-N- adamantan-2-yl-benzamide
Figure imgf000123_0001
-51 454.6 1 -(1 -Acetyl-piperidin-4-yl)-3-[4- 455 (3-aza-bicyclo[3.2.2]nonane-3- carbonyl)-benzyl]-1 ,3- dimethyl-urea
Figure imgf000123_0002
-52 433.6 N-Adamantan-2-yl-4-(1 ,3- 434 dimethyl-3-pyrimidin-2-yl- ureidomethyl)-benzamide
Figure imgf000123_0003
-53 407.5 1 -[4-(3-Aza-bicyclo- 408 [3.2.2]nonane-3-carbonyl)- benzyl]-1 ,3-dimethyl-3- pyrimidin-2-yl-urea -54 438.6 N-Adamantan-2-yl-4-(1 ,3- 439 dimethyl-3-thiazol-2-yl- ureidomethyl)-benzamide
Figure imgf000123_0004
-55 431 .6 N-Adamantan-2-yl-4-(1 ,3- 432 dimethyl-3-phenyl-ureido- methyl)-benzamide
Figure imgf000123_0005
-56 409.5 1 -[4-(3-Hydroxy-8-aza- 410 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]-1 ,3-
Figure imgf000123_0006
dimethyl-3-pyrimidin-2-yl-urea -57 453.6 N-Adamantan-2-yl-4-[3-(4- 454 hydroxy-cyclohexyl)-1 ,3- dimethyl-ureidomethyl]-
Figure imgf000124_0001
benzamide
-58 427.6 1 -[4-(3-Aza-bicyclo[3.2.2]- 428 nonane-3-carbonyl)-benzyl]-3- (4-hydroxy-cyclohexyl)-1 ,3- dimethyl-urea -59 401 .5 1 -(4-Hydroxy-cyclohexyl)-1 ,3- 402 dimethyl-3-[4-(2-oxa-5-aza- bicyclo[2.2.1]heptane-5-
Figure imgf000124_0002
carbonyl)-benzyl]-urea -60 --[[44--((AAzzeeppaannee--11 --ccaarrbboonnyyll))-- 380 1 ,3-dimethyl-3-phenyl-
Figure imgf000124_0003
-61 425,58 Piperidine-1 -carboxylic acid 426 H [4-(3-hydroxy-adamantan-1 -yl- carbamoyl)-benzyl]-methyl-
Figure imgf000124_0004
amide -62 427,55 Morpholine-4-carboxylic acid 428 H [4-(3-hydroxy-adamantan-1 -yl- carbamoyl)-benzyl]-methyl-
Figure imgf000124_0005
amide -63 447,58 4-(1 ,3-Dimethyl-3-phenyl- 448 ureidomethyl)-N-(3-hydroxy- adamantan-1 -yl)-benzamide
Figure imgf000124_0006
-64 427,54 Piperidine-1 -carboxylic acid 428 [4-(3-fluoro-adamantan-1 -yl- carbamoyl)-benzyl]-methyl-
Figure imgf000124_0007
amide -65 429,54 Morpholine-4-carboxylic acid 430
[4-(3-fluoro-adamantan-1 -yl- carbamoyl)-benzyl]-methyl-
Figure imgf000125_0001
amide
-66 449,57 4-(1 ,3-Dimethyl-3-phenyl- 450 ureidomethyl)-N-(3-fluoro- adamantan-1 -yl)-benzamide
Figure imgf000125_0002
-67 432,57 N-Adamantan-2-yl-4-(1 ,3- 433 dimethyl-3-pyridin-2-yl- ureidomethyl)-benzamide
Figure imgf000125_0003
-68 2-oxa-5- 381 eptane-5- -pyridin-2-
Figure imgf000125_0004
-69 414,53 1 -[4-(3-Hydroxy-8-aza- 415 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]-1 ,3-
Figure imgf000125_0005
dimethyl-3-thiazol-2-yl-urea -70 428,54 1 -(1 -Acetyl-piperidin-4-yl)-1 ,3- 429 d etimhyl-3-[4-(2-oxa-5-aza-
Figure imgf000125_0006
icyclo[2.2
.1 ]heptane-5-carbonyl)- benzyl]-urea -71 456,59 1 -(1 -Acetyl-piperidin-4-yl)-3-[4- 457 (3-hydroxy-8-aza-bicyclo- [3.2.1]-octane-8-carbonyl)-
Figure imgf000125_0007
benzyl]-1 ,3-dimethyl-urea 3-72 2-oxa-5- 382 eptane-5- -pyrimidin-2-
Figure imgf000126_0001
3-73 41 1 ,55 Morpholine-4-carboxylic acid 412
[4-(4-aza-tricyclo[4.3.1 .1 *3,8*]- undecane-4-carbonyl)-benzyl]-
Figure imgf000126_0002
methyl-amide 3-74 o 429,56 1 -[4-(3-Hydroxy-8-aza- 430
I I if T i Tϊ bicyclo[3.2.1]octane-8-
I J I carbonyl)-benzyl]-3-(4- hydroxy-cyclohexyl)-1 ,3- dimethyl-urea
3-75 429,58 1 -[4-(3-Aza-bicyclo- 430
[3.2.2]nonane-3-carbonyl)- benzyl]-3-(4-fluoro-cyclo-
Figure imgf000126_0003
hexyl)-1 ,3-dimethyl-urea
3-76 478,68 N-Adamantan-2-yl-4-[3-(1 - 479 cyclopropyl-piperidin-4-yl)-1 ,3- dimethyl-ureidomethyl]- benzamide
3-77 421 ,54 1 -[4-(3-Methoxy-8-aza- 422 bicyclo[3.2.1]octane-8- carbonyl)-benzyl]-1 ,3-
Figure imgf000126_0004
dimethyl-3-phenyl-urea
Example 4-1 (General procedure (E))
1 -Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicvclo[3.2.11octane-6-carbonyl)-benzyl1-imidazolidin-2- one
Figure imgf000127_0001
Step A:
(2-Hydroxy-ethyl)-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester
Figure imgf000127_0002
To a solution of [4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester (1 .7 g, 4.4 mmol, Example 1 ) in DMF (50 ml_) was added with stirring sodium hydride (21 1 mg, 8.8 mmol, 60 % in mineral oil) and the mixture was stirred for 15 min. at ambient temperature. To the resulting mixture was added (2-bromo-ethoxymethyl)- benzene (1 .1 ml_, 5.28 mmol). The reaction mixture was stirred for 16 h. at ambient temperature and quenched by addition of saturated aqueous ammonium chloride (50 ml_) followed by water (50 ml_). The mixture was extracted with Et2O (2x100 ml_) and the combined organic phases were washed with saturated aqueous ammonium chloride (2x100 ml_), dried (Na2SO4) and the solvent evaporated. The residue was purified using silicagel column chro- matography (Flash 40) affording 1 .4 g of (2-benzyloxy-ethyl)-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester as an oil. HPLC-MS (Method Z1 ): m/z = 521 (M+1 ); tr = 2.67 min.
To the above benzyl ether (1 .4 g, 2.69 mmol) dissolved in EtOH (50 ml_) was added 10% Pd/C (750 mg, 50 % water) and the resulting mixture was hydrogenated at 1 atm. until 1 eqv. of H2 was used. The mixture was filtered and the solvent evaporated affording 0.9 g (47 %) of
(2-hydroxy-ethyl)-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-carbamic acid te/t-butyl ester as a solid.
1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .03 (d, 3H), 1.13 (d, 3H), 1 .17-1 .79 (m, 15H), 2.23 (m, 0.5H), 3.15 (m, 0.5H), 3.26 (m, 0.5H), 3.41 (bs, 3H), 3.59 (d, 0.5H), 3.71 (m, 2H),
3.97 (t, 0.5H), 4.50 (m, 2H), 4.61 (m, 0.5H), 7.27 (m, 2H), 7.42 (t, 2H).
HPLC-MS (Method Z1 ): m/z = 431 (M+1 ); tr = 1 .99 min.
Step B: {4-[(2-Methylamino-ethylamino)-methyl]-phenyl}-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)- methanone
Figure imgf000128_0001
To a ice-water cooled solution of the above te/t-butyl ester (300 mg, 0.696 mmol), TEA (0.3 ml_, 2.3 mmol) in DCM (40 ml_) was added with stirring methanesulfonyl chloride (135 μl_, 1 .72 mmol) and the mixture was stirred for 1 h at ambient temperature. Methylamine (5 ml_, 33 % in EtOH) was added and the mixture was stirred for 16 h at ambient temperature. The solvent was evaporated and to the residue was added water (50 m) and AcOEt (50 ml_). The organic phase was separated and evaporated and to the residue was added DCM (20 ml_) followed by TFA (10 ml_). The resulting mixture was stirred for 4 h at ambient temperature and the solvent evaporated. The residue was purified using preparative HF5LC (Method Z4): Amount isolated = 175 mg (44 %) of {4-[(2-methylamino-ethylamino)-methyl]-phenyl}-(1 ,3,3- trimethyl-e-aza-bicycloβ^.i Joct-e-yO-methanone as an oil. 1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .02 (d, 3H), 1.12 (d, 3H), 1 .15-1 .46 (m, 3H), 1.56 (m, 1 H), 1.75 (m, 1 H), 2.16 (d, 0.5H), 2.25 (m, 0.5H), 2.42 (s, 3H), 2.74 (m, 4H), 3.15-3.29 (m, 1 .5H), 3.60 (d, 0.5H), 3.82 (d, 2H), 3.98 (m, 0.5 H), 4.60 (m, 0.5H), 7.38 (m, 4H). HPLC-MS (Method Z1 ): m/z = 344 (M+1 ); tr = 1 .09 min.
Step C: To a solution of the above amide (50 mg, 0.146 mmol) in DCM (10 mL) was added phosgene (0.1 mL, 0.29 mmol, 30 % in toluene) and the mixture was stirred for 30 min. at ambient temperature. The solvent was evaporated and the residue was purified using preparative HPLC (Method Z4): Amount isolated ■■■■■■ 1 1 mg (21 %) of the title compound as an oil. 1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .02 (d, 3H), 1.13 (d, 3H), 1 .15-1 .60 (m, 4.5H), 1 .75 (m, 1 .5H), 2.23 (m, 0.5H), 2.84 (s, 3H), 3.16 (m, 2H), 3.28 (m, 3H), 3.58 (d, 0.5H), 3.97 (t, 0.5 H), 4.39 (d, 2H), 4.60 (m, 0,5H), 7.29 (dd, 2H), 7.40 (t, 2H). HPLC-MS (Method Z1 ): m/z = 370 (M+1 ); tr = 1 .71 min.
[00411] The following compound was made as outlined in general method E above. Ex. Structure MW IUPAC Name LC/ MS
4-2 447.56 N-Adamantan-2-yl-4-[3-(4- 448 fluoro-phenyl)-2-oxo- imidazolidin-1 -ylmethyl]- benzamide
4-3 421 ,52 1 -[4-(3-Aza-bicyclo[3.2.2]- 422 nonane-3-carbonyl)- benzyl]-3-(4-fluoro-phenyl)- imidazolidin-2-one
4-4 423,49 1 -(4-Fluoro-phenyl)-3-[4-(3- 424 hydroxy-8-aza-bicyclo-
Figure imgf000129_0001
[3.2.1]octane-8-carbonyl)- benzyl]-imidazolidin-2-one
4-5 429.57 N-Adamantan-2-yl-4-(2- 430 oxo-3-phenyl-imidazolidin- 1 -ylmethyl)-benzamide
Figure imgf000129_0002
Example 5-1 (General procedure (F))
F4-(1 .1 -Dioxo-isothiazolidin-2-ylmethyl)-phenyll-(1 ,3.3-trimethyl-6-aza-bicvclor3.2.1 loct-6-yl)- methanone
Figure imgf000129_0003
To a mixture of (4-aminomethyl-phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)- methanone (100 mg, 0.349 mmol), TEA (100 μl_, 0.698 mmol) and DCM (20 ml_) was added 3-chloro-propane-1 -sulfonyl chloride (51 μL, 0.419 mmol) and the mixture was stirred for 2 h at ambient temperature. The solvent was evaporated and the residues dissolved in dry THF (20 ml_). Sodium hydride (25 mg, 1 .05 mmol, 60 % in mineral oil) was added and the mixture stirred for 90 min. at reflux temperature. The cooled mixture was quenched with water (100 μl_) and evaporated. The residue was purified using preparative HPLC (Merhod ZA] isolated = 39 mg (29 %) of the title compound as an oil
1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .03 (d, 3H), 1.13 (d, 3H), 1 .17-1 .60 (m, 4.5H), 1 .71 -1 .79 (m, 2H), 2.23 (m, 0.5H), 2.32 (m, 2H), 3.09-3.29 (m, 4.5H), 3.60 (d, 0.5H), 3.97 (t, 0.5H), 4.20 (d, 2H), 4.61 (m, 0.5H), 7.38-7.45 (m, 4H). HPLC-MS (Method Z1 ): m/z = 391 (M+1 ); tr = 1 .8 min.
Example 6-1 (General procedure (G))
[4-(1 ,1 -DJQXQ-2/-/-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl1-(1 ,3,3-trimethyl-6-aza- bicvclor3.2.noct-6-yl)-methanone
Figure imgf000130_0001
Step A:
1 -te/t-Butyloxycarbonyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-sulfamide
Figure imgf000130_0002
To an ice water cooled solution of chlorosulfonyl isocyanate (360 μL, 4.19 mmol) in DCM (20 mL) was added te/t-butanol (400 μL, 4.19 mmol) and the mixture was stirred for 30 min. at ambient temperature. The resulting mixture was added to a solution of (4-aminomethyl- phenyl)-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-methanone (1 .2 g, 4.19 mmol), TEA (1.7 mL, 12.57 mmol) in DCM (25 mL) at 0° C. The mixture was stirred for 2 h allowing it to reach room temperature before it was washed with water (25 mL), dried (Na2SO4) and evaporated which afforded 1 .8 g (92 %) of 1 -te/t-butyloxycarbonyl-3-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-sulfamide as an oil. 1H NMR (400 MHz, CDCI3) δ 0.93 (d, 3H), 1 .03 (s, 3H), 1.12 (s, 3H), 1 .15-1 .59 (m, 13.5H), 1 .76 (m, 1 H), 2.23 (m, 0.5H), 3.13-3.28 (m, 1 .5H), 3.58 (d, 0.5H), 3.96 (m, 0.5 H), 4.1 1 (s, 2H), 4.59 (m, 0.5H), 5.75 (bs, 1 H), 7.39 (m, 4H), 9.0 (bs, 1 H). HPLC-MS (Method Z1 ): m/z = 466 (M+1 ); tr = 1 .98 min. Step B:
1 ,1 -Dioxo-5-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-1 ,2,5- thiadiazolidine-2-carboxylic acid te/t-butyl ester
Figure imgf000131_0001
To a mixture of 1 -te/t-butyloxycarbonyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-sulfamide (0.8 g, 1 .72 mmol), 2-chloro-ethanol (130 μL, 1 .89 mmol), triphenylphosphine (0.7 g, 2.58 mmol) in THF (50 ml_) was added DIAD (0.5 ml_, 2.58 mmol) and the mixture stirred for 1 h. The solvent was evaporated and the residue purified using silicagel column chromatography (Flash 40) and a mixture of AcOEt-Heptane (1 :1 ) as eluent afforded crude 1 -te/t-butyloxycarbonyl-1 -(2-hydroxy ethyl)-3-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-sulfamide which was used in the next step without further purification.
HPLC-MS (Method Z1 ): m/z = 528 (M+1 ).
To a solution of the above 1 -te/t-butyloxycarbonyl-i -(2-hydroxy ethyl)-3-[4-(1 ,3,3-trimethyl-6- aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-sulfamide in DMSO (15 ml_) was added K2CO3 (0.36 g, 2.58 mmol) and the mixture was stirred for 2 at ambient temperature. Water (25 ml_) was added and the resulting mixture was extracted with AcOEt (2x25 ml_). The combined organic phases were evaporated and the residue purified using silicagel column chromatography (Flash 40) and first a mixture of AcOEt-Heptane (1 :1 ) followed by a mixture of AcOEt- Heptane (4:1 ) as eluents which afforded 250 mg (30 %) of 1 ,1 -dioxo-5-[4-(1 ,3,3-trimethyl-6- aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-1 ,2,5-thiadiazolidine-2-carboxylic acid te/t-butyl ester as an oil. HPLC-MS (Method Z1 ): m/z = 492 (M+1 ); tr = 2.24 min (100 % ELS).
Step C:
[4-(1 ,1 -Dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct- 6-yl)-methanone To a solution of 1 ,1 -dioxo-5-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-1 ,2,5-thiadiazolidine-2-carboxylic acid te/t-butyl ester (0.25 g, 0.51 mmol) in DCM (10 ml_) was added TFA (5 ml_) and the mixture was stirred for 16 at ambient temperature. The mixture was evaporated and the residue purified using preparative HPLC (Method 24): Amount isolated = 190 mg (95 %) of the title compound as an oil
1H NMR (400 MHz, CDCI3) δ 0.94 (d, 3H), 1 .04 (s, 3H), 1.13 (s, 3H), 1 .18-1 .60 (m, 4.5H), 1 .77 (m, 1 H), 2.23 (m, 0.5H), 3.15-3.30 (m, 3.5H), 3.44 (t, 2H), 3.60 (d, 0.5H), 3.97 (t, 0.5 H), 4.18 (m, 2H), 4.61 (m, 0.5H), 5.01 (bs, 1 H), 7.43 (m, 4H). HPLC-MS (Method Z1 ): m/z = 392 (M+1 ); tr = 1 .73 min (100 % ELS).
Example 6-2 (General procedure (G))
[4-(5-Methyl-1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenylH1 ,3,3-trimethyl-6-aza- bicvclo[3.2.11oct-6-yl)-methanone
Figure imgf000132_0001
To a mixture of [4-(1 ,1 -dioxo-2H-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6- aza-bicyclo[3.2.1 ]oct-6-yl)-methanone (60 mg, 0.15 mmol), K2CO3 (30 mg, 0.31 mmol) in DMSO (4 mL) was added iodomethane (13 μL, 0.31 mmol). The mixture was stirred for 1 h at ambient temperature and evaporated. The residue was purified using preparative HF5LC (Method Z4): Amount isolated ■■■■■■ 45 mg (73 %) of the title compound as an oil 1H NMR (400 MHz, CDCI3) δ 0.94 (d, 3H), 1 .04 (s, 3H), 1.13 (s, 3H), 1 .18-1 .61 (m, 4.5H), 1 .77 (m, 1 H), 2.23 (m, 0.5H), 2.79 (s, 3H), 3.15-3.20 (m, 2H), 3.23-3.30 (m, 3.5H), 3.61 (d, 0.5H), 3.98 (t, 0.5 H), 4.24 (d, 2H), 4.61 (m, 0.5H), 7.42 (m, 4H). HPLC-MS (Method Z1 ): m/z = 406 (M+1 ); tr = 1 .86 min (100 % ELS).
[00412] The following compounds were made as outlined in general method G above.
Ex. Structure MW IUPAC Name LC/
MS -3 377.5 (Octahydro-quinolin-1 -yl)- 378 [4-(1 ,1 -dioxo-1 ,2,5-thia- diazolidin-2-ylmethyl)- phenyl]-methanone -4 389.5 (4-Aza-tricyclo[4.3.1 .13 8]- 390 undec-4-yl)-[4-(1 ,1 -dioxo- 1 ,2,5-thiadiazolidin-2-yl- methyl)-phenyl]-methanone -5 377.5 (Octahydro-isoquinolin-2- 378 yl)-[4-(1 ,1 -dioxo-1 , 2,5- thiadiazolidin-2-ylmethyl)- phenyl]-methanone -6 363.5 (3-Aza-bicyclo[3.2.2]non-3- 364 yl)-[4-(1 ,1 -dioxo-1 , 2,5- thiadiazolidin-2-ylmethyl)- phenyl]-methanone -7 349.5 (6-Aza-bicyclo[3.2.1 ]oct-6- 350 yl)-[4-(1 ,1 -dioxo-1 , 2,5- thiadiazolidin-2-ylmethyl)- phenyl]-methanone -8 481 .6 [4-(5-Benzyl-1 ,1 -dioxo- 482
1 ,2,5-thiadiazolidin-2- ylmethyl)-phenyl]-(1 ,3,3-
Figure imgf000133_0001
trimethyl-6-aza-bicyclo- [3.2.1]oct-6-yl)-methanone -9 389,52 N-Adamantan-1 -yl-4-(1 ,1 - 390 dioxo~[1 ,2,5]thiadiazolidin- 2-ylmethyl) -benzamide
-10 389,52 N-Adamantan-2-yl-4-(1 ,1 - 390 dioxo~[1 ,2,5]thiadiazolidin- 2-ylmethyl) -benzamide
Figure imgf000133_0002
6-1 1 389,52 (4-Azatricyclo[4.3.1 .1 *3,8*]- 390 undec-4-yl)-[4-(1 ,1 -dioxo- [1 ,2,5]thiadiazolidin-2-yl- methyl)-phenyl]-methanone
6-12 337,44 Azepan-1 -yl-[4-(1 ,1 -dioxo- 338 [1 ,2,5]thiadiazolidin-2-yl- methyl)-phenyl]-methanone
6-13 351 ,47 Azepan-1 -yl-[4-(5-methyl- 352
1 ,1 -dioxo-
[1 ,2,5]thiadiazolidin-2-
Figure imgf000134_0001
ylmethyl)-phenyl]- methanone
6-14 433,57 N-Adamantan-1 -yl-4-(5- 434 methoxymethyl-1 ,1 -dioxo-
[1 ,2,5]thiadiazolidin-2-
Figure imgf000134_0002
ylmethyl)-benzamide
6-15 405,52 4-(1 ,1 -Dioxo-[1 ,2,5]thia 406 diazolidin-2-ylmethyl)-N-(3- hydroxy-adamantan-1 -yl)- benzamide
6-16 503,67 {5-[4-(Adamantan-1 -yl- 504 carbamoyl)-benzyl]-1 ,1 -
Figure imgf000134_0003
dioxo-[1 ,2,5]thiadiazolidin- 2-yl}-acetic acid fe/t-butyl ester
PHARMACOLOGICAL METHODS
[00413] 1 1 βHSD1 enzyme assay
[00414] Materials
[00415] 3H-cortisone and anti-rabbit Ig coated scintillation proximity assay (SPA) beads were purchased from Amersham Pharmacia Biotech, β-NADPH was from Sigma and rabbit anti- Cortisol antibodies were from Fitzgerald. An extract of yeast transformed with h-1 1 βHSD1 (HuIt et al., FEBS Lett., 441, 25 (1998)) was used as the source of enzyme. The test compounds were dissolved in DMSO (10 mM). All dilutions were performed in a buffer containing 50 mM TRIS-HCI (Sigma Chemical Co), 4 mM EDTA (Sigma Chemical Co), 0.1 % BSA (Sigma Chemical Co), 0.01 % Tween-20 (Sigma Chemical Co) and 0.005% bacitracin (Novo Nordisk A/S), pH=7.4. Optiplate 96 wells plates were supplied by Packard. The amount of 3H-cortisol bound to the SPA beads was measured on TopCount NXT, Packard.
[00416] Methods
[00417] h-1 1 βHSD1 , 12O nM 3H-cortisone, 4 mM β-NADPH, antibody (1 :200), serial dilutions of test compound and SPA particles (2 mg/well) were added to the wells. The reaction was initiated by mixing the different components and was allowed to proceed under shaking for 60 min at 3O0C. The reaction was stopped be the addition of 10 fold excess of a stopping buffer containing 500 μM carbenoxolone and 1 μM cortisone. Data was analysed using Graph Pad Prism software.
[00418] Table 1
[00419] Inhibition of 1 1 βHSD1 by compounds of the invention
Figure imgf000135_0001
[00420] While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications, and substitutions can be made therein without departing from the spirit and scope of the present invention. Likewise, the specific pharmacological responses observed may vary according to and depending on the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. Accordingly, the invention is not to be limited as by the appended claims. [00421] The features disclosed in the foregoing description and/or in the claims may both separately ans in any combination thereof be material for realising the invention in diverse forms thereof.
[00422] Preferred features of the invention:
1 . A substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the compound is of formula I:
Figure imgf000136_0001
I wherein:
R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-;
R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18;
Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m; Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano, Ci-C6alkyloxy, d-Cealkyloxyd-Cealkyl or Ci-C6alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R18;
R5 is selected from H, d-C6alkyl, C3-C6cycloalkyl, halo, OH, and cyano;
R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and trihalometh- oxy;
alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, Ci-C6alkyl, oxo, and Ci-C6alkyloxy;
R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, hetaryloxyd-C6alkyl, arylCi-CealkyloxyCi-Cealkyl, and hetarylCi-CealkyloxyCi-Cealkyl, wherein each of the al- kyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20;
R10 and R11 are independently selected from H, CrC8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the al- kyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, hydroxy, oxo, COOH, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, aryld-Cealkylcarbonyl, hetaryld-Cealkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6al- kyl-carboxy, and hetarylCi-C6alkylcarboxy;
R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, d-C8alkyloxy, aryl, arylCi-C6alkyl, hetaryl, hetarylCi-C6alkyl, aryloxy, hetaryloxy, and NR13R14;
R13 and R14 are independently selected from H, d-C8alkyl, C3-C1 Ocycloalkyl, aryl, hetaryl, aryld-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-Cealkylcarbonyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
R16 and R17 are independently selected from H, CrC8alkyl, C3-Ciocycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, d-C8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22;
R18 is selected from halo, OH, oxo, COOH, cyano d-C6alkyloxy, C3-Ci ocycloalkyloxy, aryloxy, hetaryloxy, hetarylthio and arylCi-C6alkyloxy; R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, d-C8alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendi- oxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy, NR23R24, me- thylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
R23 and R24 are independently selected from H, d-C8alkyl, and arylCi-C6alkyl;
m is selected from O, 1 , and 2;
n is selected from 1 and 2;
Y is selected from O and S;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
2. A compound of clause 1 wherein:
R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
R2 is d-dalkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substi- tuted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarboxy, arylcar- boxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each al- kyl and aryl/hetaryl group is substituted with 0-3 R18; Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano,
Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkyl or Ci-C4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
R5 is H;
R6 and R7 are independently selected from H and CrC4alkyl; and,
n is 2.
3. A compound of clause 1 wherein:
R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkyl, hetarylCrC4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCi-C4alkyl, and hetaryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C4alkyl, wherein each of the al- kyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20;
R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
R is selected from OH, d-C4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, d-C4alkyloxy, aryl, arylCi-C4alkyl, hetaryl, hetarylCi-C4alkyl, aryloxy, and hetary- loxy;
R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, Ci-C4alkyloxy, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
n is 2.
4. A compound of clause 1 wherein the compound is of formula Ia:
Figure imgf000141_0001
Ia.
5. A compound of clause 1 wherein the compound is of formula Ib:
Figure imgf000141_0002
Ib.
6. A compound of clause 1 wherein the compound is of formula Ic:
Figure imgf000142_0001
Ic.
7. A compound of clause 1 wherein the compound is of formula Id:
Figure imgf000142_0002
Id.
8. A compound of clause 1 wherein
R1 and R2, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCrC6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18.
9. A compound of clause 1 wherein:
Ring A is selected from:
Figure imgf000143_0001
Ring A is substituted with 0-2 R , and,
R is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, C(=O)R , and d-C6alkyloxy, wherein R is as defined above..
10. A compound of clause 1 wherein: Ring A is selected from:
Figure imgf000143_0002
Ring A is substituted with 0-2 R , and,
R is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and Ci-C6alkyloxy.
1 1 . A compound of clause 1 wherein: ring A is
Figure imgf000143_0003
Ring A is substituted with 0-2 R , and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
12. A compound of clause 1 wherein the compound is selected from the group:
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isobutyramide
Cyclopentanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
Cyclohexanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-amide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- benzamide
1 -Acetyl-piperidine-4-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
1 -Acetyl-piperidine-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
Cyclopentanecarboxylic acid ethyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i Joctane-θ- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
2,2-N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- propionamide
Tetrahydro-furan-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-4-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
Thiophene-2-carboxylic acid methyl-[4-(1 ^^-trimethyl-θ-aza-bicyclotS^.iloctane-θ- carbonyl)-benzyl]-amide
Furan-2-carboxylic acid methyl-[4-(1 jSjS-trimethyl-θ-aza-bicyclotS^.iloctane-θ- carbonyl)-benzyl]-amide
3-Chloro-4-(propane-2-sulfonyl)-thiophene-2-carboxylic acid methyl-[4-(1 ,3,3- trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-amide
6-Chloro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-nicotinamide δ-Methyl-isoxazole-S-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,3,N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- butyramide
3-Cyano-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
N-Methyl-2-phenoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- malonamic acid methyl ester
3-Methyl-but-2-enoic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
N-Methyl-2-phenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
1 -Trifluoromethyl-cyclobutanecarboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,5-Dimethoxy-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
4-Methanesulfonyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-Methyl-3-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
2,2-Difluoro-1 ,3-benzodioxole-4-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-6-morpholin-4-yl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-nicotinamide
N-Methyl-4-(2,2,2-trifluoro-acetyl)-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-benzamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isophthalamic acid 2,3-Dihydro-benzofuran-7-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3-Acetyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
1 ,1 ,3-Trimethyl-3-[4-(1 ,3,3-trimethyl-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- sulphonylurea
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
2,2,2-Trifluoro-ethanesulfonic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methylphenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-isopropyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Cyclopropyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Ethyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
3-Benzoyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea
3-Cyclohexyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea
3-(4-methy-phenyl)sulfonyl-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-
6-carbonyl)-benzyl]-urea
1 ,3-Dimethyl-3-phenyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- benzyl]-urea
3-(2,3-Dihydro-1 ,4-benzodioxin-2-ylmethyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(3-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, 3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea 3-(1 ,1 -Dioxo-tetrahydro-thiophen-3-yl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(tetrahydro-pyran-4-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]-octane-6- carbonyl)-benzyl]-urea
{1 ,3-Dimethyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-acetic acid methyl ester
1 -Methyl-3-(5-trif luoromethyl-1 ,3,4-thiadiazol-2-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
2-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-arbonyl)-benzyl]- ureidoj-benzoic acid methyl ester
3-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-benzoic acid ethyl ester
1 -Methyl-3-(3-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
3-(4-Benzyloxy-phenyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Acetyl-phenyl)-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-icyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Acetyl-phenyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Cyano-phenyl)-1 -methyl-1 -[4-(1 , 3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(2,2,4,4-tetrafluoro-4H-benzo-[1 ,3]dioxin-6-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methoxy-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-urea 1 -Methyl-3-[4-(2,2,2-trifluoro-acetyl)-cyclohexyl]-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -(4-Acetyl-phenyl)-1 ,3-dimethyl-3-[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Phenyl-3-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclopropyl}-urea
Piperidine-1 -carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]- amide
Morpholine-4-carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
1 ,3-Dimethyl-3-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-1 -phenyl-urea i -^-β-Aza-bicyclo-β^^nonane-S-carbonyO-benzyll-i jS-dimethyl-S-phenyl-urea
Piperidine-1 -carboxylic acid [4-(6-aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]- methyl-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]octane-3- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid [4-(6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ΛS-trimethyl-S-aza-bicycloβ^.il-octane-S- carbonyl)-benzyl]-amide
1 -[4-(6-Aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl-urea
1 ,3-Dimethyl-1 -phenyl-3-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carbonyl)- benzyl]-urea
Piperidine-1 -carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3- phenyl-urea
1 -[4-(3-Fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3-phenyl- urea Piperidine-1 -carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyridin-2-yl-ureidomethyl)-benzamide
^^-(S-Aza-bicyclotS^^lnonane-S-carbonyO-benzyll-i ^-dimethyl-S-pyridin^-yl-urea
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyridin-
2-yl-urea
Morpholine-4-carboxylic acid [4-(adamantan-2-ylcarbamoyl)-benzyl]-methyl-amide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-thiazol-2-yl-urea
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-carbonyl)-benzyl]-1 -thiazol-2- yl-urea
4-[3-(1 -Acetyl-piperidin-4-yl)-1 ,3-dimethyl-ureidomethyl]-N-adamantan-2-yl-benzamide
1 -(1 -Acetyl-piperidin-4-yl)-3-[4-(3-aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3- dimethyl-urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyrimidin-2-yl-ureidomethyl)-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyrimidin-2-yl- urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-thiazol-2-yl-ureidomethyl)-benzamide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-phenyl-ureidomethyl)-benzamide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3- pyrimidin-2-yl-urea
N-Adamantan-2-yl-4-[3-(4-hydroxy-cyclohexyl)-1 ,3-dimethyl-ureidomethyl]-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-hydroxy-cyclohexyl)-1 ,3- dimethyl-urea
1 -(4-Hydroxy-cyclohexyl)-1 ,3-dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-urea
1 -Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-imidazo- lidin-2-one
[4-(1 ,1 -Dioxo-isothiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- oct-6-yl)-methanone [4-(1 ,1 -Dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-bicyclo[3.2.1]oct-
6-yl)-methanone
[4-(5-Methyl-1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl- bicyclo[3.2.1]oct-6-yl)-methanone
(Octahydro-quinolin-1 -yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(4-Aza-tricyclo[4.3.1 .13 8]-undec-4-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)- phenyl]-methanone
(Octahydro-isoquinolin-2-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(3-Aza-bicyclo[3.2.2]non-3-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(6-Aza-bicyclo[3.2.1 ]oct-6-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
[4-(5-Benzyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]oct-6-yl)-methanone or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
13. The compound according to any of the clauses 1 -12, which is an agent useful for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial.
14. The compound according to clause 13, wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
15. The compound according to clause 13, wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 dia- betes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy. 16. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to any one of the clauses 1 -12 together with one ore more pharmaceutically acceptable carriers or excipients.
17. The pharmaceutical composition according to clause 16 which is suitable for oral, nasal, buccal, transdermal, pulmonal, or parenteral administration.
18. Use of a substituted amide, a prodrug thereof, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture or any tautomeric forms, wherein the substituted amide or a prodrug thereof is of formula I:
Figure imgf000151_0001
wherein: R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-;
R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCrC6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18; Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano, Ci-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl or d-C6alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R18;
R5 is selected from H, d-C6alkyl, C3-C6cycloalkyl, halo, OH, and cyano;
R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and trihalometh- oxy;
alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, Ci-C6alkyl, oxo, and d-C6alkyloxy;
R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, hetaryloxyd-C6alkyl, arylCi-CealkyloxyCi-Cealkyl, and hetarylCi-CealkyloxyCi-Cealkyl, wherein each of the al- kyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20;
R10 and R11 are independently selected from H, CrC8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ; alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, hydroxy, oxo, COOH, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCrC6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6al- kyl-carboxy, and hetaryld-C6alkylcarboxy;
R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, d-C8alkyloxy, aryl, arylCrC6alkyl, hetaryl, hetarylCrC6alkyl, aryloxy, hetaryloxy, and NR13R14;
R13 and R14 are independently selected from H, d-C8alkyl, C3-Ci ocycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-C6alkylcarbonyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
R16 and R17 are independently selected from H, CrC8alkyl, C3-Ciocycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, d-C8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22; R18 is selected from halo, OH, oxo, COOH, cyano d-C6alkyloxy, C3-Ci ocycloalkyloxy, ary- loxy, hetaryloxy, hetarylthio and arylCi-C6alkyloxy;
R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C8alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendi- oxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy, NR23R24, me- thylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
R23 and R24 are independently selected from H, d-C8alkyl, and arylCi-C6alkyl;
m is selected from O, 1 , and 2;
n is selected from 1 and 2;
Y is selected from O and S; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
19. The use according to clause 18 wherein:
R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-;
R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(0)m, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarboxy, arylcarboxy, hetarylcar- boxy, arylCi-C6alkylcarboxy, and hetaryld-Cealkylcarboxy, wherein each aryl/hetaryl group is substituted with 0-3 R18;
Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from 0 to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano, Ci-C6alkyloxy, Ci-C6alkyloxyCi-C6alkylene or d-C6alkylcarbonyl, wherein each al- kyl/alkylene group is substituted with 0-3 R18;
R5 is selected from H, CrC6alkyl, C3-C6cycloalkyl, halo, OH, and cyano;
R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and trihalometh- oxy;
alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, Ci-C6alkyl, oxo, and d-C6alkyloxy;
R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkylene, hetaryloxyCi-C6alkylene, arylCi-CealkyloxyCi-Cealkylene, and hetaryl-
Ci-C6alkyloxyCi-C6alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloal- kyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkylene, and arylCi-C6alkyloxyCi-C6alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20;
R10 and R11 are independently selected from H, Ci-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkylene, and hetarylCi-C6alkylene, wherein each of the alkyl/alkylene, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, hydroxy, oxo, COOH, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkylene, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-C6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkyl-carboxy, and hetarylCrC6alkylcarboxy;
R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, d-C8alkyloxy, aryl, arylCi-C6alkylene, hetaryl, hetarylCi-C6alkylene, aryloxy, hetaryloxy, and NR13R14;
R13 and R14 are independently selected from H, d-C8alkyl, C3-Ci ocycloalkyl, aryl, hetaryl, arylCi-C6alkylene, and hetarylCi-C6alkylene, wherein each of the alkyl/alkylene, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitro- gen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkylene, d-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-C6alkylcarbonyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl; R16 and R17 are independently selected from H, CrC8alkyl, C3-Ci0cycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, CrC8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22;
R18 is selected from halo, OH, oxo, and cyano;
R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, d-C8alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendi- oxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy, NR23R24, me- thylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy;
R23 and R24 are independently selected from H, d-C8alkyl, and arylCi-C6alkylene;
m is selected from O, 1 , and 2;
n is selected from 1 and 2; Y is selected from O and S;
20. The use according to clause 18 wherein:
R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
R2 is d-C4alkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 addi- tional heteroatoms selected from nitrogen, oxygen, and S(0)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarboxy, arylcar- boxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each al- kyl and aryl/hetaryl group is substituted with 0-3 R18; Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkyl or CrC4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
R5 is H;
R6 and R7 are independently selected from H and CrC4alkyl; and,
n is 2.
21 . The use according to clause 19 wherein:
R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
R2 is Ci-C4alkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substi- tuted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCrC6alkylene, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, Ci-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetaryl- Ci-C6alkylcarboxy, wherein each aryl/hetaryl group is substituted with 0-3 R18;
Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)n; Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkylene or Ci-C4alkylcarbonyl, wherein each al- kyl/alkylene group is substituted with 0-1 R18;
R5 is H;
R6 and R7 are independently selected from H and CrC4alkyl; and, n is 2.
22. The use according to clause 18 wherein:
R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCrC4alkyl, hetarylCrC4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCrC4alkyl, and hetaryloxyCrC4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20;
R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
R12 is selected from OH, Ci-C4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, Ci-C4alkyloxy, aryl, arylCi-C4alkyl, hetaryl, hetarylCi-C4alkyl, aryloxy, and hetary- loxy; R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, d-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, d-C4alkyloxy, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
n is 2.
23. The use according to clause 19 wherein:
R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCi-C4alkylene, hetaryl- Ci-C4alkylene, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyCi-C4alkylene, and hetaryloxyCi-C4alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCi-C4alkylene, hetarylCi-C4alkylene, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxy-
Ci-C4alkylene, wherein each of the alkyl/alkylene, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20;
R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and S(0)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
R12 is selected from OH, Ci-C4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, d-C4alkyloxy, aryl, arylCi-C4alkylene, hetaryl, hetarylCi-C4alkylene, aryloxy, and hetaryloxy;
R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, d-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, d-C4alkyloxy, aryl, hetaryl, arylCi-C4alkylene, hetarylCi-C4alkylene, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
n is 2.
24. The use according to clause 18 wherein the substituted amide or prodrug thereof is of formula Ia:
Figure imgf000161_0001
Ia.
25. The use according to clause 18 wherein the substituted amide or prodrug thereof is of formula Ib:
Figure imgf000161_0002
Ib.
26. The use according to clause 18 wherein the substituted amide or prodrug thereof is of formula Ic:
Figure imgf000161_0003
Ic.
27. The use according to clause 18 wherein the substituted amide or prodrug thereof is of formula Id:
Figure imgf000162_0001
Id.
28. The use according to clause 19 wherein the substituted amide or prodrug thereof is of formula Ie:
Figure imgf000162_0002
Ie
29. The use according to clause 18 wherein: R1 and R2, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-C10hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCrC6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18.
30. The use according to clause 19 wherein:
R1 and R2, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl,
C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkylene, hetarylCi-C6alkylene, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCi-C6alkyl-oxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarboxy, arylcarboxy, hetarylcar- boxy, arylCrC6alkylcarboxy, and hetaryld-Cealkylcarboxy, wherein each aryl/hetaryl group is substituted with 0-3 R18.
31 . The use according to anyone of the clauses 18-30 wherein: Ring A is selected from:
Figure imgf000163_0001
Ring A is substituted with 0-2 R25; and,
R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, C(=O)R12, and d-C6alkyloxy, wherein R is as defined above..
32. The use according to anyone of the clauses 18-30 wherein: Ring A is selected from:
Figure imgf000163_0002
Ring A is substituted with 0-2 R25; and,
R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
33. The use according to anyone of the clauses 18-30 wherein: Ring A is selected from:
Figure imgf000164_0001
ring A is substituted with 0-2 R25; and,
R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and Ci-C6alkyloxy.
34. The use according to clause 18 or 19 wherein the substituted amide or a prodrug thereof is of the selected from the group of clause 12.
35. The use according to any of the clauses 18-34 for the preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial.
36. The use according to clause 35, wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
37. The use according to clause 35, wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
38. The use according to any of the clauses 18-37 wherein the pharmaceutical composition is suitable for a route of administration selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
39. A method for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to any of clauses 1 -12. 40. The method according to clause 39, wherein the conditions, disorders, and diseases that are influenced by intracellular glucocorticoid levels.
41 . The method according to clause 39, wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
42. The method according to any one of clauses 40-41 , wherein the administering is via a route selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.

Claims

WHAT IS CLAIMED
1 . A compound of the formula I:
Figure imgf000166_0001
I wherein:
R1 is selected from H, R8(C=O)-, R9S(O)n-, R10R11NC(=Y)-, and R10R11NS(O)n-;
R2 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 3-12 membered saturated or partially saturated monocyclic or bicyclic ring consisting of the shown nitrogen, 2-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from d-C8alkyl, C3- Ciocycloalkyl, C3-Ci0hetcycloalkyl, C3-C6spirocycloalkyl, 3-6 membered spirohetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, -C(=NR16)NR17, OH, oxo, d-C6alkyloxy, arylCrC6alkyl-oxy, hetarylCi-C6alkyloxy, Ci-C6alkyloxyCi-C6alkyl, d-C6alkylcarboxy, aryl- carboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each alkyl and aryl/hetaryl group is substituted with 0-3 R18;
Ring A is a 5-12 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms and from O to 2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
Ring A is substituted with 0-3 groups selected from d-C8alkyl, halo, OH, oxo, cyano,
Ci-C6alkyloxy, Ci-CealkyloxyCi-Cealkyl or d-C6alkylcarbonyl, wherein each alkyl group is substituted with 0-3 R18;
R5 is selected from H, d-C6alkyl, C3-C6cycloalkyl, halo, OH, and cyano; R6 and R7 are independently selected from H, d-C6alkyl, F, trihalomethyl, and trihalometh- oxy;
alternatively, R6 and R7, together with the carbon atom to which they are attached, form a 3-8 membered saturated or partially saturated monocyclic ring consisting of the shown carbon atom, 2-5 additional carbon atoms, and 0-2 heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from halo, trihalomethyl, OH, Ci-C6alkyl, oxo, and Ci-C6alkyloxy;
R8 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCrC6alkyl, hetarylCrC6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, hetaryloxyCi-dalkyl, aryld-CealkyloxyCrCealkyl, and hetaryld-Cealkyloxyd-Cealkyl, wherein each of the al- kyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R19;
R9 is selected from d-C8alkyl, C2-C8alkenyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, C3-Ci0cycloalkyl, 3-10 membered hetcycloalkyl, aryloxyd-C6alkyl, and arylCi-CealkyloxyCi-Cealkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-3 R20;
R10 and R11 are independently selected from H, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, aryl, hetaryl, arylCi-C6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ;
alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen atom, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substituted with 0-3 groups selected from Ci-C8alkyl, aryl, hetaryl, aryld-C6alkyl, hetaryld-C6alkyl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, Ci-C6alkylcarbonyl, arylcarbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-C6alkylcarbonyl, d-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6al- kyl-carboxy, and hetarylCi-C6alkylcarboxy; R12 is selected from OH, d-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, d-C8alkyloxy, aryl, arylCi-C6alkyl, hetaryl, hetarylCi-C6alkyl, aryloxy, hetaryloxy, and NR13R14;
R13 and R14 are independently selected from H, CrC8alkyl, C3-Ci ocycloalkyl, aryl, hetaryl, arylCrC6alkyl, and hetarylCi-C6alkyl, wherein each of the alkyl/alkyl, cycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R22;
alternatively, R13 and R14, together with the nitrogen to which they are attached, form a 5-12 membered saturated or partially saturated monocyclic, bicyclic, or tricyclic ring consisting of the shown nitrogen, 4-10 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-3 groups selected from CrC8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarbonyl, aryl- carbonyl, hetarylcarbonyl, arylCi-C6alkylcarbonyl, hetarylCi-Cealkylcarbonyl, Ci-C6alkylcarboxy, arylcarboxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy;
R15 is selected from H, d-C6alkyl, and C3-C6cycloalkyl;
R16 and R17 are independently selected from H, Ci-C8alkyl, C3-Ci0cycloalkyl, halo, OH, cyano, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, d-C8alkyl, aryl, and hetaryl, wherein the alkyl and cycloalkyl groups are independently substituted with 0-3 R22;
R18 is selected from halo, OH, oxo, COOH, cyano d-C6alkyloxy, C3-Ci ocycloalkyloxy, aryloxy, hetaryloxy, hetarylthio and arylCi-C6alkyloxy;
R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, Ci-C8alkyl, C3-Ci ocycloalkyl, 3-10 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, methylendi- oxo, dihalo-methylenedioxo, C3-C6spirocycloalkyl, d-C6alkyloxy, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(O)nNR13R14, -N(R13)S(O)nR12, -N(R15)C(=Y)NR13R14, and -C(=NR16)NR17;
R22 is selected from H, OH, oxo, halo, cyano, nitro, d-C6alkyl, d-C6alkyloxy, NR23R24, me- thylendioxo, dihalomethylendioxo, trihalomethyl, and trihalomethyloxy; R23 and R24 are independently selected from H, d-C8alkyl, and arylCi-C6alkyl;
m is selected from 0, 1 , and 2;
n is selected from 1 and 2;
Y is selected from O and S; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
2. A compound according to claim 1 wherein:
R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
R2 is Ci-C4alkyl;
alternatively, R1 and R2, together with the nitrogen to which they are attached, form a 5-6 membered saturated ring consisting of the shown nitrogen, 2-4 carbon atoms, and 0-2 additional heteroatoms selected from nitrogen, oxygen, and S(O)n, wherein this ring is substi- tuted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, arylCi-C6alkyl, hetarylCi-C6alkyl, -C(=O)R12, -S(O)nR12, -S(=O)nNR13R14, -N(R13)S(O)nR12, OH, oxo, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, d-Cealkyloxyd-Cealkyl, d-C6alkylcarboxy, arylcar- boxy, hetarylcarboxy, arylCi-C6alkylcarboxy, and hetarylCi-C6alkylcarboxy, wherein each al- kyl and aryl/hetaryl group is substituted with 0-3 R18;
Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consisting of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)n;
Ring A is substituted with 0-3 groups selected from d-C4alkyl, halo, OH, oxo, cyano, d-C4alkyloxy, d-dalkyloxyd-dalkyl or d-C4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
R5 is H; R6 and R7 are independently selected from H and d-C4alkyl; and, n is 2.
3. A compound according to claim 1 wherein: R1 is selected from R8(C=O)-, R9S(O)2-, R10R11NC(=O)-, and R10R11NS(O)2-;
R2 is selected from H, d-C4alkyl and C3-C6cycloalkyl;
Ring A is an 8-1 1 membered saturated or partially saturated bicyclic or tricyclic ring consist- ing of the shown nitrogen, 5-10 carbon atoms and from 0 to 1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m;
Ring A is substituted with 0-3 groups selected from CrC4alkyl, halo, OH, oxo, cyano, Ci-C4alkyloxy, Ci-C4alkyloxyCi-C4alkyl or CrC4alkylcarbonyl, wherein each alkyl/alkyl group is substituted with 0-1 R18;
R5 is H;
R6 and R7 are independently selected from H and Ci-C4alkyl; and, n is 2.
4. A compound according to claim 1 wherein:
R8 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryloxyd-C4alkyl, and hetaryloxyCi-C4alkyl, wherein each of the alkyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R19;
R9 is selected from d-C6alkyl, C2-C6alkenyl, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, and aryloxyCi-C4alkyl, wherein each of the al- kyl/alkyl, alkenyl, aryl, hetaryl, cycloalkyl, and hetcycloalkyl groups are independently substituted with 0-2 R20;
R10 and R11 are independently selected from H, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, aryl, and hetaryl, wherein each of the cycloalkyl, hetcycloalkyl, aryl, and hetaryl groups are independently substituted with 0-3 R21 ; alternatively, R10 and R11, together with the nitrogen to which they are attached, form a 5-6 membered saturated or partially saturated monocyclic ring consisting of the shown nitrogen atom, 4-5 carbon atoms, and 0-1 additional heteroatoms selected from nitrogen, oxygen, and S(O)m, wherein this ring is substituted with 0-2 groups selected from d-C8alkyl, aryl, hetaryl, hydroxy, oxo, COOH, d-C6alkyloxy, arylCi-C6alkyloxy, hetarylCi-C6alkyloxy, and Ci-C6alkylcarbonyl ;
R12 is selected from OH, d-C4alkyl, C3-C6cycloalkyl, 3-10 membered hetcycloalkyl, triha- lomethyl, d-C4alkyloxy, aryl, arylCi-C4alkyl, hetaryl, hetarylCi-C4alkyl, aryloxy, and hetary- loxy;
R19, R20 and R21 are independently selected from H, halo, OH, oxo, cyano, d-C6alkyl, C3-C6cycloalkyl, 3-6 membered hetcycloalkyl, trihalomethyl, trihalomethyloxy, di- halo-methylenedioxo, Ci-C4alkyloxy, aryl, hetaryl, arylCi-C4alkyl, hetarylCi-C4alkyl, -C(=O)R12, -S(O)nR12, and -S(O)nNR13R14; and,
n is 2.
5. A compound according to claim 1 wherein the compound is of formula Ia:
Figure imgf000171_0001
Ia.
A compound according to claim 1 wherein the compound is of formula Ib:
Figure imgf000171_0002
Ib.
7. A compound according to claim 1 wherein the compound is of formula Ic:
Figure imgf000172_0001
Ic.
8. A compound according to claim 1 wherein the compound is of formula Id:
Figure imgf000172_0002
Id.
A compound according to claim 1 wherein the compound is of formula Ie:
Figure imgf000172_0003
Ie.
10. A compound according to claim 1 wherein: Ring A is selected from:
Figure imgf000172_0004
Ring A is substituted with 0-2 Fr5; and, R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, C(=O)R12, and d-C6alkyloxy, wherein R12 is as defined above..
1 1 . A compound according to claim 1 wherein: ring A is
Figure imgf000173_0001
Ring A is substituted with 0-2 R25; and,
R25 is selected from d-C8alkyl, halo, hydroxy, oxo, cyano, and d-C6alkyloxy.
12. A compound according to claim 1 wherein the compound is selected from the group: N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isobutyramide
Cyclopentanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
Cyclohexanecarboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i Joctane-θ- carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-amide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- benzamide i -Acetyl-piperidine^-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-amide i -Acetyl-piperidine-S-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-amide
Cyclopentanecarboxylic acid ethyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.i loctane-θ- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid methyl-[4-(1 ^^-trimethyl-θ-aza-bicyclotS^.iloctane-θ- carbonyl)-benzyl]-amide 2,2-N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- propionamide
Tetrahydro-furan-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-amide
N-Methyl-4-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
Thiophene-2-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iloctane-θ- carbonyl)-benzyl]-amide
Furan-2-carboxylic acid methyl-[4-(1 ^S-trimethyl-θ-aza-bicycloβ^.iJoctane-θ- carbonyl)-benzyl]-amide
3-Chloro-4-(propane-2-sulfonyl)-thiophene-2-carboxylic acid methyl-[4-(1 ,3,3- trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]-amide
6-Chloro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-nicotinamide δ-Methyl-isoxazole-S-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-amide
3,3,N-Trimethyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- butyramide
3-Cyano-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
N-Methyl-2-phenoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- malonamic acid methyl ester
3-Methyl-but-2-enoic acid methyl-[4-(1 ^^-trimethyl-θ-aza-bicyclotS^.i loctane-θ- carbonyl)-benzyl]-amide
N-Methyl-2-phenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-acetamide
1 -Trifluoromethyl-cyclobutanecarboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
3,5-Dimethoxy-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
4-Methanesulfonyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-Methyl-3-trifluoromethoxy-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
2,2-Difluoro-1 ,3-benzodioxole-4-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-amide
N-Methyl-6-morpholin-4-yl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-nicotinamide
N-Methyl-4-(2,2,2-trifluoro-acetyl)-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6- carbonyl)-benzyl]-benzamide
N-[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-benzamide
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- isophthalamic acid
2,3-Dihydro-benzofuran-7-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-benzyl]-amide
3-Acetyl-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-benzamide
1 ,1 ,3-Trimethyl-3-[4-(1 ,3,3-trimethyl-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]- sulphonylurea
N-Methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
2,2,2-Trifluoro-ethanesulfonic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-amide
N-Methylphenyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-isopropyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Cyclopropyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
N-Ethyl-trifluoro-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- methanesulfonamide
Trifluoro-N-methyl-N-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-methanesulfonamide
3-Benzoyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)- benzyl]-urea 3-Cyclohexyl-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- benzyl]-urea
3-(4-methy-phenyl)sulfonyl-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-
6-carbonyl)-benzyl]-urea
1 ,3-Dimethyl-3-phenyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- benzyl]-urea
3-(2,3-Dihydro-1 ,4-benzodioxin-2-ylmethyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(3-Methoxy-benzyl)-1 -methyl-1 -[4-(1 , 3, 3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(1 ,1 -Dioxo-tetrahydro-thiophen-3-yl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(tetrahydro-pyran-4-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]-octane-6- carbonyl)-benzyl]-urea
{1 ,3-Dimethyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-acetic acid methyl ester
1 -Methyl-3-(5-trif luoromethyl-1 ,3,4-thiadiazol-2-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
2-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-arbonyl)-benzyl]- ureidoj-benzoic acid methyl ester
3-{3-Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6-carbonyl)-benzyl]- ureidoj-benzoic acid ethyl ester
1 -Methyl-3-(3-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-ethylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]-octane-
6-carbonyl)-benzyl]-urea
3-(4-Benzyloxy-phenyl)-1 -methyl-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methylsulfanyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-
[3.2.1]octane-6-carbonyl)-benzyl]-urea
3-(4-Acetyl-phenyl)-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-icyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
3-(3-Acetyl-phenyl)-1 -methyl-1 -[4-(1 , 3, 3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea 3-(3-Cyano-phenyl)-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methyl-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]- octane-6-carbonyl)-benzyl]-urea
3-(4-Methoxy-benzyl)-1 -methyl-1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Methyl-3-(2,2,4,4-tetrafluoro-4H-benzo-[1 ,3]dioxin-6-yl)-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-(4-trifluoro-methoxy-phenyl)-1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- octane-6-carbonyl)-benzyl]-urea
1 -Methyl-3-[4-(2,2,2-trifluoro-acetyl)-cyclohexyl]-1 -[4-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-urea
1 -(4-Acetyl-phenyl)-1 ,3-dimethyl-3-[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-urea
1 -Phenyl-3-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclopropyl}-urea
Piperidine-1 -carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-amide
Piperidine-1 -carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]- amide
Morpholine-4-carboxylic acid [4-(3-aza-bicyclo-[3.2.2]nonane-3-carbonyl)-benzyl]- methyl-amide
1 ,3-Dimethyl-3-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-1 -phenyl-urea i -^-β-Aza-bicyclo-β^^nonane-S-carbonyO-benzyll-i jS-dimethyl-S-phenyl-urea
Piperidine-1 -carboxylic acid [4-(6-aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]- methyl-amide
Piperidine-1 -carboxylic acid methyl-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]octane-3- carbonyl)-benzyl]-amide
Morpholine-4-carboxylic acid [4-(6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-benzyl]- methyl-amide
Morpholine-4-carboxylic acid methyl-[4-(1 jδjδ-trimethyl-S-aza-bicyclotS^.il-octane-S- carbonyl)-benzyl]-amide
1 -[4-(6-Aza-bicyclo-[3.2.1 ]octane-6-carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl-urea 1 ,3-Dimethyl-1 -phenyl-3-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carbonyl)- benzyl]-urea
Piperidine-1 -carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)- benzyl]-methyl-amide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3- phenyl-urea
1 -[4-(3-Fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-di-methyl-3-phenyl- urea
Piperidine-1 -carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)- benzyl]-methyl-amide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyridin-2-yl-ureidomethyl)-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyridin-2-yl-urea
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyridin-
2-yl-urea
Morpholine-4-carboxylic acid [4-(adamantan-2-ylcarbamoyl)-benzyl]-methyl-amide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-thiazol-2-yl-urea
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-carbonyl)-benzyl]-1 -thiazol-2- yl-urea
4-[3-(1 -Acetyl-piperidin-4-yl)-1 ,3-dimethyl-ureidomethyl]-N-adamantan-2-yl-benzamide
1 -(1 -Acetyl-piperidin-4-yl)-3-[4-(3-aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3- dimethyl-urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyrimidin-2-yl-ureidomethyl)-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-1 ,3-dimethyl-3-pyrimidin-2-yl- urea
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-thiazol-2-yl-ureidomethyl)-benzamide
N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-phenyl-ureidomethyl)-benzamide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3- pyrimidin-2-yl-urea
N-Adamantan-2-yl-4-[3-(4-hydroxy-cyclohexyl)-1 ,3-dimethyl-ureidomethyl]-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-hydroxy-cyclohexyl)-1 ,3- dimethyl-urea
1 -(4-Hydroxy-cyclohexyl)-1 ,3-dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-urea
1 -Methyl-3-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-benzyl]-imidazo- lidin-2-one
[4-(1 ,1 -Dioxo-isothiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]- oct-6-yl)-methanone
[4-(1 ,1 -Dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-bicyclo[3.2.1]oct- 6-yl)-methanone
[4-(5-Methyl-1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl- bicyclo[3.2.1]oct-6-yl)-methanone
(Octahydro-quinolin-1 -yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(4-Aza-tricyclo[4.3.1 .13 8]-undec-4-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)- phenyl]-methanone
(Octahydro-isoquinolin-2-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(3-Aza-bicyclo[3.2.2]non-3-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
(6-Aza-bicyclo[3.2.1 ]oct-6-yl)-[4-(1 ,1 -dioxo-1 ,2,5-thiadiazolidin-2-ylmethyl)-phenyl]- methanone
[4-(5-Benzyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-(1 ,3,3-trimethyl-6-aza- bicyclo[3.2.1]oct-6-yl)-methanone or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
13. A compound according to claim 1 wherein the compound is selected from the group:
[4-(1 -Amino-cyclopropyl)-phenyl]-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]oct-6-yl)- methanone
Piperidine-3-carboxylic acid methyl-[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-benzyl]-amide N-Methyl-N-[4-(1 ,3,3-tri-methyl-6-aza-bicyclo[3.2.1]-octane-6-carbonyl)-benzyl]- butyramide
N-Methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide
N-[4-(3-Aza-bicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-N-methyl-benzamide
3-Cyano-N-methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide
N-[4-(3-Azabicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-3-cyano-N-methyl-benzamide
3-Fluoro-N-methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide
N-[4-(3-Aza-bicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-3-fluoro-N-methyl-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-3-fluoro-N-methyl-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-N-methyl-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-3-cyano-N-methyl-benzamide
Piperidine-1 -carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
Morpholine-4-carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
N-[4-(Octahydro-quinoline-1 -carbonyl)-benzyl]-benzamide
N-[4-(3-Azabicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-N-methyl-benzamide
4-[(Benzoyl-methyl-amino)-methyl]-N-(3-hydroxy-adamantan-1 -yl)-benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-3-cyano-N-methyl-benzamide
4-[(3-Cyano-benzoyl-methyl-amino)-methyl]-N-(3-hydroxy-adamantan-1 -yl)- benzamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-3-fluoro-N-methyl-benzamide
4-[(3-Fluoro-benzoyl-methyl-amino)-methyl]-N-(3-hydroxy-adamantan-1 -yl)-benzamide
1 -Acetyl-piperidine^-carboxylic acid methyl-[4-(octahydro-quinoline-1 -carbonyl)- benzyl]-amide
N-[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl-benzamide
3-Fluoro-N-methyl-N-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]octane-3-carbonyl)- benzyl]-benzamide
3-Fluoro-N-[4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
N-Methyl-N-[4-(1,8,8-trimethyl-3-aza-bicyclo[3.2.1]-octane-3-carbonyl)-benzyl]- benzamide
N-[4-(6-Aza-bicyclo[3.2.1]-octane-6-carbonyl)-benzyl]-benzamide
N-[4-(1,8,8-Trimethyl-3-aza-bicyclo[3.2.1]octane-3-carbonyl)-benzyl]-benzamide N-[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-benzamide
1 -Acetyl-piperidine^-carboxylic acid [4-(azepane-1 -carbonyl)-benzyl]-methyl-amide
4-(Benzoylamino-methyl)-N-(3-hydroxy-adamantan-1 -yl)-benzamide
3-Cyano-N-methyl-N-[4-(1 ,8,8-trimethyl-3-aza-bi-cyclo[3.2.1 ]octane-3-car-bonyl)- benzyl]-benzamide
3-Cyano-N-[4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
3-Fluoro-N-[4-(3-fluoro-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
4-(3-Fluoro-benzoylamino-methyl)-N-methly-N-(3-fluoro-adamantan-1 -yl)-benzamide
4-(3-Cyano-benzoylamino-methyl)-N-methly-N-(3-fluoro-adamantan-1 -yl)-benzamide
1 -Acetyl-piperidine-4-carboxylic acid methyl-[4-(1 ,8,8-trimethyl-3-aza-bicyclo[3.2.1 ]- octane-3-carbonyl)-benzyl]-amide
N-[4-(3-Fluoro-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl-benzamide
4-[(Benzoyl-methyl-amino)-methyl]-N-(3-fluoro-adamantan-1 -yl)-benzamide
3-Cyano-N-[4-(3-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl- benzamide
4-(Benzoylamino-methyl)-N-(3-fluoro-adamantan-1 -yl)-benzamide
1 -Acetyl-piperidine^-carboxylic acid [4-(3-aza-bicyclo[3.2.2]nonane-3-carbonyl)- benzyl]-methyl-amide
N-[4-(3-Fluoro-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-benzamide
4-(3-Cyano-benzoylamino-methyl)-N-(adamantan-2-yl)-benzamide
4-(3-Fluoro-benzoylamino-methyl)-N-(adamantan-2-yl)-benzamide
N-[4-(4-Azatricyclo-[4.3.1 .1 *3,8*]undecane-4-carbonyl)-benzyl]-3-fluoro-N-methyl- benzamide
N-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo-propyl}- benzamide
N-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo-propyl}- acetamide
4-Methanesulfonyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)- phenyl]-cyclo-propyl}-benzamide
N-Methyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclo-propyl}-benzamide
N-Methyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclo-propylj-acetamide
4-Methanesulfonyl-N-methyl-N-{1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]octane-6- carbonyl)-phenyl]-cyclo-propyl}-benzamide
N-[4-(Azepane-1 -carbonyl)-benzyl]-N-methyl-methane-sulfonamide
N-[4-(3-Aza-bicyclo[3.2.2]-nonane-3-carbonyl)-benzyl]-N-methyl-methane-sulfonamide
N-Methyl-N-[4-(1 ,8,8-tri-methyl-3-aza-bicyclo[3.2.1]-octane-3-carbonyl)-benzyl]- methane-sulfonamide
N-[4-(6-Aza-bicyclo[3.2.1 ]-octane-6-carbonyl)-benzyl]-N-methyl-methane-sulfonamide
N-[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-N-methyl- methanesulfonamide
N-Methyl-N-[4-(octahydro-quinoline-1 -carbonyl)-benzyl]-methanesulfon-amide
N-(3-Hydroxy-adamantan-1 -yl)-4-[(methanesulfonyl-methyl-amino)-methyl]-benzamide
N-(3-Fluoro-adamantan-1 -yl)-4-[(methanesulfonyl-methyl-amino)-methyl]-benzamide
N-[4-(3-Fluoro-8-aza-bicyclo[3.2.1]octane-8-carbonyl)-benzyl]-N-methyl-methane- sulfonamide
N-Adamantan-2-yl-4-[(methanesulfonyl-methyl-amino)-methyl]-benzamide
N-(4-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo- propylsulfamoyl}-phenyl)-acetamide
4-Chloro-N-{1 -[4-(1 ,3,3-tri-methyl-6-aza-bicyclo-[3.2.1]octane-6-carbonyl)-phenyl]- cyclo-propylj-benzene-sulfonamide
1 -Methyl-1 H-imidazole-4-sulfonic acid {1 -[4-(1 ,3,3-trimethyl-6-aza-bicyclo-[3.2.1 ]- octane-6-carbonyl)-phenyl]-cyclopropyl}-amide
N-{1 -[4-(1 ,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]-cyclo-propyl}- ethanesulfonamide
1 -[4-(Azepane-1 -carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl-urea
Piperidine-1 -carboxylic acid [4-(3-hydroxy-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide
Morpholine-4-carboxylic acid [4-(3-hydroxy-adamantan-1 -yl-carbamoyl)-benzyl]- methyl-amide
4-(1 ,3-Dimethyl-3-phenyl-ureidomethyl)-N-(3-hydroxy-adamantan-1 -yl)-benzamide
Piperidine-1 -carboxylic acid [4-(3-fluoro-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide Morpholine-4-carboxylic acid [4-(3-fluoro-adamantan-1 -yl-carbamoyl)-benzyl]-methyl- amide
4-(1 ,3-Dimethyl-3-phenyl-ureidomethyl)-N-(3-fluoro-adamantan-1 -yl)-benzamide N-Adamantan-2-yl-4-(1 ,3-dimethyl-3-pyridin-2-yl-ureidomethyl)-benzamide 1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-carbonyl)-benzyl]-1 -pyridin-2- yl-urea
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-thiazol- 2-yl-urea
1 -(1 -Acetyl-piperidin-4-yl)-1 ,3-dimethyl-3-[4-(2-oxa-5-aza-icyclo[2.2.1 ]heptane-5- carbonyl)-benzyl]-urea
1 -(1 -Acetyl-piperidin-4-yl)-3-[4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]-octane-8-carbonyl)- benzyl]-1 ,3-dimethyl-urea
1 ,3-Dimethyl-3-[4-(2-oxa-5-aza-bicyclo[2.2.1 ]heptane-5-arbonyl)-benzyl]-1 -pyrimidin- 2-yl-urea
Morpholine-4-carboxylic acid [4-(4-aza-tricyclo[4.3.1 .1 *3,8*]-undecane-4-carbonyl)- benzyl]-methyl-amide
1 -[4-(3-Hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-3-(4-hydroxy- cyclohexyl)-1 ,3-dimethyl-urea
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-fluoro-cyclohexyl)-1 ,3- dimethyl-urea
N-Adamantan-2-yl-4-[3-(1 -cyclopropyl-piperidin-4-yl)-1 ,3-dimethyl-ureidomethyl]- benzamide
1 -[4-(3-Methoxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]-1 ,3-dimethyl-3-phenyl- urea
N-Adamantan-2-yl-4-[3-(4-fluoro-phenyl)-2-oxo-imidazolidin-1 -ylmethyl]-benzamide
1 -[4-(3-Aza-bicyclo[3.2.2]nonane-3-carbonyl)-benzyl]-3-(4-fluoro-phenyl)-imidazolidin-
2-one
1 -(4-Fluoro-phenyl)-3-[4-(3-hydroxy-8-aza-bicyclo[3.2.1 ]octane-8-carbonyl)-benzyl]- imidazolidin-2-one
N-Adamantan-2-yl-4-(2-oxo-3-phenyl-imidazolidin-1 -ylmethyl)-benzamide
N-Adamantan-1 -yl-4-(1 ,1 -dioxo~[1 ,2,5]thiadiazolidin-2-ylmethyl) -benzamide N-Adamantan-2-yl-4-(1 ,1 -dioxo~[1 ,2,5]thiadiazolidin-2-ylmethyl) -benzamide (4-Azatricyclo[4.3.1 .1 *3,8*]-undec-4-yl)-[4-(1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)- phenyl]-methanone
Azepan-1 -yl-[4-(1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]-methanone
Azepan-1 -yl-[4-(5-methyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-phenyl]- methanone
N-Adamantan-1 -yl-4-(5-methoxymethyl-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)- benzamide
4-(1 ,1 -Dioxo-[1 ,2,5]thiadiazolidin-2-ylmethyl)-N-(3-hydroxy-adamantan-1 -yl)- benzamide
{5-[4-(Adamantan-1 -yl-carbamoyl)-benzyl]-1 ,1 -dioxo-[1 ,2,5]thiadiazolidin-2-yl}-acetic acid te/t-butyl ester or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
14. The compound according to any of the claims 1 -13, which is an agent useful for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial.
15. The compound according to claim 14, wherein the conditions, disorders, and diseases are influenced by intracellular glucocorticoid levels.
16. The compound according to claim 14 wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progression from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabe- tes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
17. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to any one of the claims 1 -13 together with one ore more pharmaceutically acceptable carriers or excipients.
18. The pharmaceutical composition according to claim 17, which is suitable for oral, nasal, buccal, transdermal, pulmonal, or parenteral administration.
19. The use of a compound according to any of claims 1 -13, for the preparation of a pharmaceutical composition for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial.
20. The use according to claim 19, wherein the conditions, disorders and diseases are influenced by intracellular glucocorticoid levels.
21 . The use according to claim 19, wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), the progression from IGT to type 2 diabetes, the progression of the metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
22. The use according to any of the claims 19-21 , wherein the pharmaceutical composition is suitable for a route of administration selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
23. A method for the treatment of conditions, disorders, or diseases wherein a modulation or an inhibition of the activity of 1 1 βHSD1 is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to any of claims 1 - 13.
24. The method according to claim 23, wherein the conditions, disorders, and diseases are influenced by intracellular glucocorticoid levels.
25. The method according to claim 23 wherein the conditions, disorders, or diseases are selected from metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), progres- sion from IGT to type 2 diabetes, progression of metabolic syndrome into type 2 diabetes, diabetic late complications, neurodegenerative and psychiatric disorders, and the adverse effects of glucocorticoid receptor agonist treatment or therapy.
26. The method according to any of claims 23-25 wherein the administering is via a route selected from oral, nasal, buccal, transdermal, pulmonal, and parenteral.
PCT/EP2006/068015 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides WO2007051810A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06819214A EP1948190A2 (en) 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides
AU2006310518A AU2006310518A1 (en) 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides
US12/092,230 US20090124598A1 (en) 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides
EA200801243A EA200801243A1 (en) 2005-11-01 2006-11-01 PHARMACEUTICAL APPLICATION OF SUBSTITUTED AMIDES
JP2008537121A JP2009514818A (en) 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides
CA002627306A CA2627306A1 (en) 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides
IL191035A IL191035A0 (en) 2005-11-01 2008-04-27 Pharmaceutical use of substituted amides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05110228 2005-11-01
EP05110228.3 2005-11-01
EP06116808.4 2006-07-07
EP06116808 2006-07-07

Publications (2)

Publication Number Publication Date
WO2007051810A2 true WO2007051810A2 (en) 2007-05-10
WO2007051810A3 WO2007051810A3 (en) 2008-01-24

Family

ID=37946770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/068015 WO2007051810A2 (en) 2005-11-01 2006-11-01 Pharmaceutical use of substituted amides

Country Status (9)

Country Link
US (1) US20090124598A1 (en)
EP (1) EP1948190A2 (en)
JP (1) JP2009514818A (en)
KR (1) KR20080076916A (en)
AU (1) AU2006310518A1 (en)
CA (1) CA2627306A1 (en)
EA (1) EA200801243A1 (en)
IL (1) IL191035A0 (en)
WO (1) WO2007051810A2 (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130898A1 (en) * 2006-05-01 2007-11-15 Incyte Corporation TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009100872A1 (en) * 2008-02-12 2009-08-20 Boehringer Ingelheim International Gmbh Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2243479A2 (en) 2009-04-20 2010-10-27 Abbott Laboratories Novel amide and amidine derivates and uses thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8497281B2 (en) 2009-11-06 2013-07-30 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
US8524894B2 (en) 2009-06-04 2013-09-03 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8673899B2 (en) 2008-05-01 2014-03-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8686149B2 (en) 2010-11-05 2014-04-01 Boehringer-Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
US8748444B2 (en) 2007-12-11 2014-06-10 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8754076B2 (en) 2008-07-25 2014-06-17 Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8765744B2 (en) 2010-06-25 2014-07-01 Boehringer Ingelheim International Gmbh Azaspirohexanones
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8829027B2 (en) 2008-10-23 2014-09-09 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US8846613B2 (en) 2010-11-02 2014-09-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US9079861B2 (en) 2007-11-07 2015-07-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2018172852A1 (en) * 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
JP2009513611A (en) * 2005-11-01 2009-04-02 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー Pharmaceutical use of substituted amides
US20100168083A1 (en) * 2006-03-21 2010-07-01 Soren Ebdrup Adamantane derivatives for the treatment of the metabolic syndrome
AU2007236049A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
EP2038255A2 (en) * 2006-06-16 2009-03-25 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted piperidine carboxamides
US8048908B2 (en) * 2006-07-13 2011-11-01 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
JP2010519242A (en) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー New compounds
JP2010519240A (en) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー N-adamantylbenzamide as an inhibitor of 11-beta-hydroxysteroid dehydrogenase
BRPI0806847A2 (en) 2007-02-23 2014-04-29 High Point Pharmaceuticals Llc N-ADAMANTIL BENZAMIDS AS 11-BETAHYDROXYESTEROID DEHYDROGENASE INHIBITORS
JP2010519239A (en) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー N-admantylbenzamide as an inhibitor of 11-beta-hydroxysteroid dehydrogenase
JP5486928B2 (en) 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8153798B2 (en) * 2007-03-09 2012-04-10 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
EP2141990A4 (en) * 2007-03-28 2011-07-06 High Point Pharmaceuticals Llc 11beta-hsd1 active compounds
CN101677562A (en) * 2007-04-11 2010-03-24 高点制药有限责任公司 Novel compounds
CA2685036A1 (en) * 2007-04-24 2008-11-06 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
MX2011005037A (en) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Adamantyl benzamide compounds.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
KR101332805B1 (en) * 2011-03-31 2013-11-27 한국화학연구원 Derivatives Having Adamantyl Group and Pharmaceutical Acceptable Salts Thereof
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
TW201408652A (en) * 2012-07-11 2014-03-01 Hoffmann La Roche Aryl sultam derivatives as RORc modulators
SG11201608710TA (en) * 2014-04-28 2016-11-29 Jiangsu Kanion Parmaceutical Co Ltd Anti-enterovirus 71 thiadiazolidine derivative
US10550097B2 (en) 2015-07-23 2020-02-04 Dsm Ip Assets B.V. Selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
HRP20230279T1 (en) 2016-03-22 2023-05-12 Helsinn Healthcare S.A. Benzenesulfonyl-asymmetric ureas and medical uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065351A1 (en) * 2003-01-24 2004-08-05 Novartis Ag Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2004089470A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
US3723442A (en) * 1970-12-31 1973-03-27 Yoshitomi Pharmaceutical 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes
US3784551A (en) * 1971-07-08 1974-01-08 Yoshitomi Pharmaceutical 2-oxo-1,4-dioxa-8-azaspiro (4.5) decanes and related compounds
US4350696A (en) * 1980-03-08 1982-09-21 Pfizer Inc. Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof
AU557300B2 (en) * 1982-03-16 1986-12-18 Farmitalia Carlo Erba S.P.A. Substituted 1h-pyrazolo(1,5-alpha)pyrimidines and processes for their preparation
FR2557110B1 (en) * 1983-12-23 1989-11-24 Sandoz Sa NOVEL CYCLIC AMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
FI864875A0 (en) * 1986-11-28 1986-11-28 Orion Yhtymae Oy NYA FARMAKOLOGISKT AKTIVA FOERENINGAR, DESSA INNEHAOLLANDE KOMPOSITIONER SAMT FOERFARANDE OCH MELLANPRODUKTER FOER ANVAENDNING VID FRAMSTAELLNING AV DESSA.
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5750532A (en) * 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
US5272167A (en) * 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8904174D0 (en) * 1989-02-23 1989-04-05 British Bio Technology Compounds
US5169850A (en) * 1990-01-22 1992-12-08 American Cyanamid Company N-(dialkylamino)methylene)-substituted pyrazolo(1,5-a)-pyrimidine-3-carboxamides and N-(dialkylamino)methylene-substituted-4,5-dihydropyrazolo-(1,5-a)-pyrimidine-3-carboxamides
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
US5591892A (en) * 1990-02-12 1997-01-07 Center For Innovative Technology Allosteric modifiers of hemoglobin
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5290803A (en) * 1990-02-12 1994-03-01 The Center Of Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5648375A (en) * 1990-02-12 1997-07-15 Virginia Commonwealth University Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5382680A (en) * 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
US5872282A (en) * 1990-12-07 1999-02-16 Virginia Commonwealth University Allosteric modifiers of hemoglobin
FR2677984B1 (en) * 1991-06-21 1994-02-25 Elf Sanofi N-SUBSTITUTED IMIDAZOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
AU676701B2 (en) * 1992-12-04 1997-03-20 Janssen Pharmaceutica N.V. Antiallergic triazolobenzazepine derivatives
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5395846A (en) * 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
FR2708608B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
PL181782B1 (en) * 1993-08-10 2001-09-28 Black James Foundation Ligands of gastrin and cck receptors
US5426105A (en) * 1993-09-24 1995-06-20 G.D. Searle & Co. Conformationally restricted angiotensin II antagonists
US5674879A (en) * 1993-09-24 1997-10-07 G.D. Searle & Co. Compositions including and methods of using conformationally restricted angiotensin II antagonist
TW279860B (en) * 1993-11-12 1996-07-01 Ciba Geigy Ag
GB9409150D0 (en) * 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
US5795907A (en) * 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
JPH10504525A (en) * 1994-05-27 1998-05-06 ジェイムズ・ブラック・ファウンデーション・リミテッド Gastrin and CCK antagonist
WO1997008135A1 (en) * 1995-08-30 1997-03-06 Bayer Aktiengesellschaft Acylaminosalicylic acid amides and their uses as pesticides
FR2741878B1 (en) * 1995-12-01 1998-01-09 Cird Galderma BIAROMATIC COMPOUNDS CARRYING AN ADAMANTYL ORTHO GROUP, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES THEREOF
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
DE69829048T2 (en) * 1997-04-22 2006-02-09 Euro-Celtique S.A. THE USE OF CARBOXYCLIC AND HETEROCYCLIC RESIDUES SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6521641B1 (en) * 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
US6541477B2 (en) * 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
US6448295B1 (en) * 1999-09-23 2002-09-10 G.D. Searle & Co. Use of substituted N-fused-phenyl-N-benzyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
AU2003250117B2 (en) * 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
ATE350374T1 (en) * 2002-11-07 2007-01-15 Merck & Co Inc PHENYLALANINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
CA2517166A1 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
KR20050115252A (en) * 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 Pyrazolo[1,5-a]pyrimidine derivatives
JP2006522747A (en) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ Pharmaceutical use of condensed 1,2,4-triazole
US7501405B2 (en) * 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
US20070270408A1 (en) * 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
US7700583B2 (en) * 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1670460B1 (en) * 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20060009918A1 (en) * 2004-07-08 2006-01-12 Sanku Mallik Methods and materials for enhancing the effects of protein modulators
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
EP2835367A1 (en) * 2005-01-05 2015-02-11 AbbVie Inc. Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
JP2009513611A (en) * 2005-11-01 2009-04-02 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー Pharmaceutical use of substituted amides
US20100168083A1 (en) * 2006-03-21 2010-07-01 Soren Ebdrup Adamantane derivatives for the treatment of the metabolic syndrome
AU2007236049A1 (en) * 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
JP2010519239A (en) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー N-admantylbenzamide as an inhibitor of 11-beta-hydroxysteroid dehydrogenase
JP2010519240A (en) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー N-adamantylbenzamide as an inhibitor of 11-beta-hydroxysteroid dehydrogenase
BRPI0806847A2 (en) * 2007-02-23 2014-04-29 High Point Pharmaceuticals Llc N-ADAMANTIL BENZAMIDS AS 11-BETAHYDROXYESTEROID DEHYDROGENASE INHIBITORS
US8153798B2 (en) * 2007-03-09 2012-04-10 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
EP2141990A4 (en) * 2007-03-28 2011-07-06 High Point Pharmaceuticals Llc 11beta-hsd1 active compounds
CN101677562A (en) * 2007-04-11 2010-03-24 高点制药有限责任公司 Novel compounds
CA2685036A1 (en) * 2007-04-24 2008-11-06 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065351A1 (en) * 2003-01-24 2004-08-05 Novartis Ag Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2004089470A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COPPOLA, GARY M. ET AL: "Perhydroquinolylbenzamides as Novel Inhibitors of 11.beta.-Hydroxysteroid Dehydrogenase Type 1" JOURNAL OF MEDICINAL CHEMISTRY , 48(21), 6696-6712 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002376625 *
FOTSCH C ET AL: "11[beta]-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases" EXPERT OPINION ON THERAPEUTIC PATENTS 2005 UNITED KINGDOM, vol. 15, no. 3, 2005, pages 289-303, XP002376609 ISSN: 1354-3776 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130898A1 (en) * 2006-05-01 2007-11-15 Incyte Corporation TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
US9079861B2 (en) 2007-11-07 2015-07-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8748444B2 (en) 2007-12-11 2014-06-10 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2009100872A1 (en) * 2008-02-12 2009-08-20 Boehringer Ingelheim International Gmbh Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
JP2011511817A (en) * 2008-02-12 2011-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzomorphane and related skeleton urea derivatives, medicaments containing such compounds and their use
US8673899B2 (en) 2008-05-01 2014-03-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US9073870B2 (en) 2008-05-13 2015-07-07 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8754076B2 (en) 2008-07-25 2014-06-17 Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8829027B2 (en) 2008-10-23 2014-09-09 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2243479A2 (en) 2009-04-20 2010-10-27 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8524894B2 (en) 2009-06-04 2013-09-03 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8822452B2 (en) 2009-06-04 2014-09-02 Laboratorios Salvat, S.A. Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US9663470B2 (en) 2009-11-06 2017-05-30 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US9328072B2 (en) 2009-11-06 2016-05-03 Vitae Pharmaceuticals, Inc. Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US8497281B2 (en) 2009-11-06 2013-07-30 Vitae Pharmaceuticals, Inc. Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US9090605B2 (en) 2010-06-16 2015-07-28 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
US8765744B2 (en) 2010-06-25 2014-07-01 Boehringer Ingelheim International Gmbh Azaspirohexanones
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
US8846613B2 (en) 2010-11-02 2014-09-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US8686149B2 (en) 2010-11-05 2014-04-01 Boehringer-Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US9120769B2 (en) 2010-11-05 2015-09-01 Boehringer-Ingelheim International Gmbh Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
US8975405B2 (en) 2011-08-17 2015-03-10 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018172852A1 (en) * 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same

Also Published As

Publication number Publication date
IL191035A0 (en) 2009-08-03
CA2627306A1 (en) 2007-05-10
EP1948190A2 (en) 2008-07-30
KR20080076916A (en) 2008-08-20
JP2009514818A (en) 2009-04-09
WO2007051810A3 (en) 2008-01-24
AU2006310518A1 (en) 2007-05-10
EA200801243A1 (en) 2008-10-30
US20090124598A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
EP1948190A2 (en) Pharmaceutical use of substituted amides
EP1615698B1 (en) New amide derivatives and pharmaceutical use thereof
US8153798B2 (en) Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
US7723323B2 (en) Pharmaceutical use of fused 1,2,4-triazoles
US7700583B2 (en) 11β-hydroxysteroid dehydrogenase type 1 active compounds
US8138342B2 (en) 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
US8053431B2 (en) Pharmaceutical use of substituted amides
WO2004089471A2 (en) NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20100009968A1 (en) 11beta-hydroxysteroid dehydrogenase type 1 active compounds
ES2343658T3 (en) ACTIVE COMPOUNDS OF 11BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1.
MX2008005322A (en) Pharmaceutical use of substituted amides
EP1785424A2 (en) Fused 1,2,4-triazoles and pharmaceutical uses thereof
ES2350834T3 (en) NEW AMIDA DERIVATIVES AND THEIR PHARMACEUTICAL USE.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12008500959

Country of ref document: PH

Ref document number: 2006310518

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 567661

Country of ref document: NZ

Ref document number: 2627306

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005322

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 191035

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2008537121

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006310518

Country of ref document: AU

Date of ref document: 20061101

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006310518

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006819214

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4550/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020087012901

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 08055583

Country of ref document: CO

Ref document number: 200801243

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200680050249.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06819214

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006819214

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12092230

Country of ref document: US

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0618130

Country of ref document: BR

Kind code of ref document: A2

Free format text: PEDIDO CONSIDERADO RETIRADO PELO NAO CUMPRIMENTO DE DETERMINACOES REFERENTES A ENTRADA NA FASE NACIONAL.